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I, Catherine Anne Welch, conﬁrm the work presented in this thesis is my own, except for the following collabo-
rations.
In 2009 to 2012 I was employed by the research department of Primary care and Population Health (PCPH)
as an research associate to work on the MRC funded project ‘Missing data imputation in clinical databases:
development of a longitudinal model for cardiovascular risk factors’ led by my supervisor Dr Irene Petersen.
The aim of the project was to develop, implement and evaluate multiple imputation algorithms for missing data,
which take into account the dynamic and longitudinal structure of large primary care databases.
The speciﬁc objectives of the project were to:
1. Describe the patterns and structure of missing data over time in The Health Improvement Network (THIN)
primary care database;
2. Develop an imputation algorithm to multiply impute the missing cardiovascular health indicators, taking
account of the speciﬁc features and timing of the data recording; and
3. Evaluate the results of imputation by comparison with distributions of relevant variables seen in external
research data and population surveys, and by application of imputed data in ongoing research projects.
The project was supported by a steering group including Irene Petersen, James Carpenter, Irwin Nazareth, Kate
Walters, Louise Marston, Richard Morris, Jonathan Bartlett and Ian White. The steering group provided overall
and individual feedback during the course of the project.
The results described in chapter 4 ‘Descriptive analysis of health indicator records in The Health Improvement
Network’ and section 6.1 ‘Imputing missing data in THIN’, were part of the research project described above.
Nevalainen and colleagues proposed the two-fold fully conditional speciﬁcation (FCS) algorithm, published in
Statics in Medicine in 2009[1]. I requested the original SAS code from the authors and I wrote a Stata program
to perform multiple imputation using the two-fold FCS algorithm. As described in the thesis, I further developed
the two-fold FCS algorithm for imputing longitudinal electronic health records. The Stata journal published3
details of the program in 2014[2] and it is public available from the Statistical Software Components archive
(http://ideas.repec.org/s/boc/bocode.html).
Work I completed speciﬁcally for this PhD includes the simulation studies described in chapter 5 ‘Developing
and evaluating the two-fold FCS algorithm’, the ﬁrst substantial study to evaluate the two-fold FCS algorithm
and assess bias and precision in different settings. Some of this work was published in Statistics in Medicine in
2014[3] and, likewise, work in section 4.4 describing a new approach to deal with outliers in data with repeated
measurements within patients (Published in Pharmacoepidemiology and Drug safety in 2011[4]). Finally, I
applied the two-fold FCS in a substantive analysis of THIN to examine the characteristics of patients with type 2
diabetes who had a greater than average total cholesterol reduction after initiating statin treatment (section 6.2).
For this study I wrote the protocol and designed this study from scratch.Abstract
Longitudinal electronic health records are a valuable resource for research because they contain information on
many patients over long follow-up periods. Missing data commonly occur in these data because it was collected
for clinical and not research purposes. Analysing data with missing values can potentially bias estimates and
standard errors resulting in invalid inferences.
Multiple imputation, commonly used in research to impute missing values, is increasingly regarded as the stan-
dard method for handling missing data in medical research because of its practicality and ﬂexibility under the
assumption the data is missing at random (MAR). Until now, few imputation approaches are sufﬁciently ﬂexible
to account for the longitudinal and dynamic structure of electronic health records. However, the two-fold fully
conditional speciﬁcation (FCS) algorithm was proposed to impute missing values in longitudinal data, but this
methods was not currently validated in the complex setting of longitudinal electronic health records.
I propose to adapt, evaluate and implement the two-fold FCS algorithm to impute missing data from large primary
care database. To achieve this, ﬁrst I investigate the extent and patterns of missing data in a longitudinal clinical
database for health indicators associated with cardiovascular disease risk to determine if the MAR assumption is
plausible. Additionally, I develop methods to identify and remove outliers, which can potentially bias imputa-
tions, from data with repeated measurements before imputation.
Next, I adapt and develop the two-fold FCS multiple imputation algorithm to impute missing values in longi-
tudinal clinical data for health indicators associated with cardiovascular disease risk and I validate the two-fold
FCS algorithm to assess bias and precision through challenging simulation studies. I develop a new software
programme which implements this adapted version of the two-fold FCS algorithm to impute missing values in
longitudinal data.
Finally, I apply the two-fold FCS algorithm in THIN to (i) model cardiovascular disease risk and (ii) understand
factors associated with greater total cholesterol reduction in patients with type II diabetes.Acknowledgements
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Introduction
In healthcare research, we cannot answer important questions using either randomised controlled trials or stand-
alone observational studies. For example, to monitor doctor prescribing behaviour, to study rare diseases (requires
recruiting many patients) or to investigate disease risk, develop risk prediction models and investigate the long
term effects of certain treatments (requires a long follow-up time). In these scenarios, electronic health records of
routinely collected clinical information are a valuable resource for epidemiological investigations and health care
research. Studies involving electronic health records address some of these questions, for example evaluating
antidepressant prescribing in pregnant women and children[5, 6], the large patient numbers allowed research
on rare conditions such as severe mental illness[7] and the long follow-up time allowed development of risk
prediction models for cardiovascular disease[8, 9, 10]. Despite the potential advantages of analysing electronic
health records, pressing methodological challenges remain, such as missing data. For example, studies on car-
diovascular risks require regular, recorded health indicators (such as weight, height, blood pressure and smoking
status) to achieve reliable inferences from statistical analyses but substantial missing data may bias the results if
not handled appropriately.
An important, widely used example of electronic clinical health records is The Health Improvement Network
(THIN)[11] primary care database. Primary care databases contain data on patient characteristics (such as age,
sex, socioeconomic status), diagnoses, prescriptions and health indicators captured through routine consultations
with a general practitioner (GP) or nurse. THIN includes electronic patient records for more than 11 million
patients registered with more than 500 General Practices across the United Kingdom (UK), some collecting data
since the early 1990s. GPs record each patient consultation from when patients register with the practice to the
time they leave, providing a longitudinal record of health data (mean follow-up time is 6.7 years)[11]. Inevitably,
information is recorded intermittently (non-monotone) in primary care databases due to irregular times between
consultations and only recording information relevant to the clinical question at the consultation.
The National Health Service (NHS) introduced legislation to encourage GPs to monitor patient health indicators
in primary care. New Patient Health Checks were introduced as part of the NHS Department of Health (DoH)
Regulations in 1992[12], aimed to improve quality of practice by linking pay to performance. This legislation
encouraged GPs to record health indicators for all newly registered patients. Despite the introduction of this18 Chapter 1. Introduction
legislation, previous research showed nearly 40% of patients did not have blood pressure or weight measured
in the ﬁrst registration year[13]. Since 2004, patients diagnosed with speciﬁc chronic conditions or diseases
are monitored at regular intervals as a part of National Health Service (NHS) care delivery plan for UK general
practice (Quality Outcome Framework, QOF)[14]. Therefore, patients with previous cardiovascular events, or at
risk of these, are much more likely to have several, regular measurements of health indicators recorded compared
to patients without these diseases. However, limited information exists on the structure and extent of missing data
in primary care records, where the procedure and motivation for recording health indicators varies over time.
Historically, ‘ad–hoc’ methods were commonly used for handling missing data[15]. These methods include
complete records analysis, simple mean imputation methods, last observation carried forward, and creating an
extra category for missing values. In a complete records analysis, only patients with complete data on all variables
are included in the analysis. However, this method is only generally valid if the patients with complete data are
representative of all patients, i.e. missing completely at random (MCAR). This assumption is usually implausible
in primary care data because clinicians often perform more tests or record more data for high disease risk patients.
Therefore, patients excluded from the analysis due to missing data may be systematically different from those
included. Although easy to apply, complete records analysis and other ‘ad–hoc’ methods, such as last observation
carried forward (the last observed response replaces the following missing response) and missing data category
(creating an extra category for the missing observations) may bias estimates and standard errors. Therefore, these
methods can result in misleading conclusions, because they do not appropriately consider the data structure or
reasons data are missing and make implausible assumptions about the missing data[16, 17].
An alternative approach for handling missing data is multiple imputation (MI)[18], increasingly regarded as the
standard method for handling missing data in medical research because of its practicality and ﬂexibility[19]. MI
creates multiple imputed datasets. In each, missing values are imputed from the conditional distribution given the
observed values using an imputation model. The originally intended analysis is applied to each imputed dataset
and the results combined using Rubin’s rules[18]. When the imputation model is correctly speciﬁed and the
missing at random (MAR) assumption is plausible, MI gives unbiased estimates and standard errors, leading to
valid conclusions [20].
The original implementation of MI used a joint multivariate normal imputation model [18]. However, this ap-
proach is rarely suitable for imputing missing data in longitudinal, electronic, health records. Usually the joint
multivariate normal imputation model is difﬁcult to deﬁne or does not exist with ordered variables, and also
inappropriate for binary and unordered categorical variables[21]. In this situation, fully conditional speciﬁcation
(FCS)[22] is a ﬂexible alternative, which speciﬁes a separate imputation model for each variable with missing
data conditional on all other covariates. Until now, very few imputation approaches are sufﬁciently ﬂexible to
account for the longitudinal and dynamic structure of electronic health records. Biased estimates and standard er-
rors can arise if the imputation model is incorrectly speciﬁed[19, 23] when imputing longitudinal patient records
where patients enter and leave the database at different times. In longitudinal electronic health records where19
measurements are recorded at different times, health indicator measurements may be aggregated into time blocks
(e.g. one month or one year blocks) and treated as distinct variables at each time block. One approach is to use
FCS to impute missing data at each time block separately conditional on other measurements recorded in the
same time block. However, correlations between health indicators measurements at different time blocks will not
exist in the imputed data. A second approach is to impute simultaneously all health indicators at all time blocks.
This approach may converge with a few time blocks. However, in electronic health records with many health
indicators and time blocks, this may potentially cause convergence problems due to co-linearity and over-ﬁtting
because of high correlations between repeated measurements of the same health indicator recorded at different
time blocks. For example, co-linearity may occur if patients have the same smoking status records for many time
blocks. Both the ﬁrst approach, imputing each time block separately, and the second approach, including all time
blocks in the imputation model, do not consider temporal ordering of the variables. The second approach does
not exploit the potential simpliﬁcations achieved by considering the temporal ordering of the variables.
To address the issues described above, Nevalainen et al.[1] proposed a new MI approach, the two-fold FCS al-
gorithm, to impute missing values in longitudinal data with an intermittent (non-monotone) missingness pattern.
The two-fold FCS algorithm visits each time block sequentially. Within each time block, a MI procedure is
followed to impute conditional on observed measurements and current imputations of missing values at the same
time block and the adjacent time blocks. When all time blocks are imputed, one among-time iteration is com-
plete. Within-time iterations and among-time iterations are repeated until estimates and standard errors become
stable (i.e. converged). When completed, imputed datasets are generated for statistical analysis. Conditioning on
measurements at adjacent time blocks takes into account the temporal ordering of the variables, while potentially
accurately estimating correlations in the imputed data and avoiding convergence problems. Nevalainen et al.
validated this algorithm using data simulated from a case-control study with measurements collected at three time
blocks and up to 40% missing values. However, it is not known how well it will perform in the more complex
setting of longitudinal, electronic health records with longer follow-up time, dynamic entry and exit from the
database and more missing data.
The aims of this thesis are to (a) explore the extent of the missing health indicator data in THIN and consider
removing outlier values from the data; (b) investigate potential reasons why the data are missing; (c) determine
if MI is valid (i.e. the MAR assumption is plausible); (d) develop and evaluate the two-fold FCS algorithm
to impute missing data in longitudinal, clinical databases, including producing a software package to apply the
two-fold FCS algorithm, and (e) compare to standard methods (such as complete records analysis) for handling
missing data in THIN.Chapter 2
Aims and objectives
The overall aim of this PhD is to adapt and evaluate the two-fold fully conditional speciﬁcation algorithm and
implement it to impute missing data from large primary care database to account for the longitudinal and dynamic
structures of these data.
The speciﬁc objectives are to:
1. investigate the extent and patterns of missing data in a longitudinal clinical database for health indicators
associated with risk of cardiovascular disease;
2. develop methods to identify and remove outliers before imputation;
3. adapt and develop the two-fold FCS multiple imputation algorithm to impute missing values in longitudinal
clinical data for variables associated with cardiovascular disease;
4. validate the two-fold FCS algorithm through challenging simulation studies; and
5. apply the two-fold FCS algorithm in THIN to (i) model risk for cardiovascular disease and (ii) understand
factors associated with greater total cholesterol reduction in patients with type II diabetes.
2.1 Outline of the thesis
The plan for the thesis is as follows:
In the following chapter, I describe primary care databases, and speciﬁcally THIN, explain the reasons health
indicators recording in primary care databases change over time and discuss the difﬁculties which arise when
data are missing.
In section 3.2 I outline missing data theory, including the different missingness mechanisms and simple ‘ad–hoc’
methods routinely used for handling missing data. ‘Ad–hoc’ methods can lead to biased results because assump-
tions they require for valid inference are implausible.
An alternative method, multiple imputation (MI), is preferred to ‘ad–hoc’ methods because it gives unbiased
results and reduces the uncertainly due to missing data under more general, plausible assumptions about the2.1. Outline of the thesis 21
missingness mechanism. In section 3.3, I describe MI, discuss the issues when applying MI to longitudinal
clinical databases and introduce the two-fold FCS algorithm.
I describe the data included in this thesis in section 4.1. To justify using MI, I need to understand the structure
and extent of missing data and, because I focus on longitudinal data, how this changes over time. In section
4.2, I investigate how recording changed by age and sex and, in section 4.3, over time. Outliers can potentially
bias imputations so, before using MI, I remove outliers using a new method I developed to identify outliers in
longitudinal clinical data, described in section 4.4.
Initially, I evaluate the two-fold FCS algorithm using simulated data to assess bias in different settings, described
in section 5.1. In section 5.2, a second simulation study evaluates the appropriate approach using the two-fold
FCS algorithm to impute missing total cholesterol measurements.
I implement the two-fold FCS algorithm, based on ﬁndings from the previous chapters, to impute missing values
in THIN data and compare to other imputation methods, described in section 6.1.
Section 6.2 describes another study investigating total cholesterol reduction after initiating statin treatment for
patients diagnosed with type 2 diabetes in THIN, using the two-fold FCS algorithm to impute missing values.
The discussion, chapter 7, outlines the ﬁndings in this thesis, implications of this study, the potential for applying
this method to impute missing values in similar longitudinal, clinical databases and possible future work.Chapter 3
Background
In this thesis, I investigate methods for handling missing data in longitudinal, clinical data, using a primary
care database. Therefore, in this chapter, I introduce primary care databases, describe how recording of health
indicators in primary care databases changes over time and explain the difﬁculties of analysing databases with
missing data.
To understand the missing data structure, in this chapter I outline missing data theory including different miss-
ingness mechanisms. I describe simple ‘ad–hoc’ methods routinely used for handling missing data and their
limitations and discuss handling missing data using the more suitable multiple imputation method. However,
limitations can arise when applying multiple imputation to longitudinal data. I discuss these limitations and
introduce the two-fold fully conditional speciﬁcation algorithm, which I evaluate later in the thesis, as a possible
alternative to standard multiple imputation approaches to impute missing data in longitudinal databases.
3.1 Primary care databases and missing data issues
In this section, I describe The Health Improvement Network (THIN) primary care database, explain the reasons
for missing data and why health indicator recording changed over time.
3.1.1 Primary care databases
In the UK, several electronic databases exist which contain data collected from each patient consultation with a
General Practitioner (GP) or other health care staff in the primary care setting. Patient information is collected
at irregular times from the point of registration with the practice to the time they leave the practice, providing a
longitudinal health record. The three largest databases in the United Kingdom (UK) are The Health Improve-
ment Network (THIN)[11], the Clinical Practice Research Datalink (CPRD) (formally General Practice Research
Database)[24] and QRESEARCH[25]. Available data included patient characteristics (for example, age and sex),
medical records (symptoms and diagnoses), prescription information, referral to specialists, laboratory results,
some lifestyle characteristics (for example, smoking status and alcohol consumption) and other health indicator
measurements taken in the GPs practice (for example weight, systolic blood pressure and total cholesterol).3.1. Primary care databases and missing data issues 23
3.1.2 The Health Improvement Network
For this PhD project, I analysed data from The Health Improvement Network (THIN) database, a large, longi-
tudinal, clinical primary care database widely used in epidemiological research[11]. General practices joined
the THIN Quality Data recording scheme, administered by Cegedim Strategic Data (CSD), and collected data
using the Vision practice management software. Medical events were coded using the hierarchical Read system
of coding[26] and prescriptions were coded using multilex encrypted ID codes from the UK Prescription Pricing
Authority and classiﬁed by chapter in the British National Formulary (BNF)[27]. Information on area deprivation
was available as quintiles of Townsend scores[28] of deprivation, based on the patients electoral ward from the
2001 Population Census (http://www.statistics.gov.uk/census2001/census2001.asp).
The patient data within these practices were approximately representative of the UK population[29]. All data
collected were anonymised at source before leaving the GP system and continually updated. In January 2014,
THIN contained records from over 11 million patients enrolled to 562 practices, including 6.2% of the UK pop-
ulation. The database was created in 2003, but data for some practices dates back to the early 1990s. Recording
of both consultations and prescriptions were similar to national consultation and prescription statistics[30, 31].
The data provider, CSD, obtained overall ethical approval to use THIN in scientiﬁc research from the South East
Medical Research Ethics Committee (MREC/03/01/073). The ‘Missing data imputation in clinical databases:
development of a longitudinal model for cardiovascular risk factors’ project received scientiﬁc approval from the
scientiﬁc review committee (SRC)
3.1.3 Data recorded in primary care
One major limitation when analysing primary care data is the substantial missing data because, although the
databases were designed for research, the data were collected for clinical management. Data collected for re-
search purposes, such as a clinical trial or cohort study, are more likely to be recorded at regular intervals during
follow-up compared to data collected for clinical management. However, in primary care, recording is intermit-
tent (see section 3.2.2). Hence, patient information is primarily recorded as required to diagnose or monitor a
condition or disease when the patient attends a GP consultation. A missing value suggests (i) the patient did
not consult with a GP, (ii) the patient consulted with a GP but the value was not measured, or (iii) the patient
consulted, the value was measured but not recorded. However, the data are not missing because the GP requested
certain information which the patient did not provide. Therefore, the missing data may not technically be ‘miss-
ing’ because it was usually not intended to be recorded. For the purpose of this study, we assumed the true values
would have been observed if the GP requested them for all patients so we could investigate existing methods for
handling missing data.
3.1.4 Improving recording in primary care
Over the past 20 years, the National Health Service (NHS) implemented some initiatives to encourage GPs to
regularly record health indicators, which included height, weight, systolic blood pressure measurements, smoking
status and alcohol consumption. In 1990, the NHS Department of Health (DoH) contract between GPs and the24 Chapter 3. Background
government was introduced[32]. The contracts aimed to improve quality of practice by linking pay to perfor-
mance. In 1992, the NHS DoH contract included New Patient Health Checks[12] to encouraged GPs to record
health indicators for all newly registered patients. These incentives stopped when the DoH introduced a new
contract in 2004. However, many practices continued to perform new patient health checks as they often provide
useful baseline information and an opportunity for GPs to identify any patient health problems. Marston et al.[13]
investigated health indicator recording in newly registered patients from 2004 to 2006 in THIN and found, despite
improved recording, nearly 40% of newly registered patients with missing health indicators records in the ﬁrst
registration year[13].
The revised 2004 DoH contract introduced the Quality Outcomes Framework (QOF)[14]. Under the scheme,
practices received points for good quality of care, shown by recording health indicators required to monitor
speciﬁc diseases. For example, GPs are required to record blood pressure measurements, total cholesterol mea-
surements and smoking status every 15 months for patients diagnosed with coronary heart disease (CHD). It is
in the practices interest to gain as many points as possible, not only for ﬁnancial reward but also to achieve good
patient management. Therefore, health indicators associated with risk of the diseases speciﬁed by QOF were
recorded more frequently after introducing this legislation[13, 8].3.2. Missing Data Theory 25
3.2 Missing Data Theory
In this section, I introduce missing data mechanisms and discuss ‘ad–hoc’ methods, frequently used in practice
for handling missing data, and their limitations.
3.2.1 Issues which arise from missing data
Missing data potentially biases statistical analyses, resulting in misleading conclusions[33]. Before considering
an approach for handling missing data, ﬁrst I consider different missingness mechanisms, which describe the
missingness pattern in the data. Later in the thesis, I investigate which missingness mechanisms I can assume
exist in the data and apply the appropriate approach for handling missing data, under this assumption, to achieving
unbiased statistical analysis.
3.2.2 Missing data mechanisms
Below I describe different non-responses which exist in epidemiological and medical data and give examples
from primary care data[34]:
 patient non-response - only very limited information known about a patient. For example, if a patient
recently registered with a practice, we know address, date of birth and sex, but the patient did not consult
so no health indicator measurements were recorded.
 item non-response - incomplete patient data. For example, the patients weight and blood pressure were
recorded at regular time intervals, but not total cholesterol measurements.
 wave non-response - speciﬁc to longitudinal studies and occur when (whether by design or not) patients
moved into and out of the study over time. This does not apply directly to primary care because data
were not collected at ﬁxed time points. However, usually patients did not consult for a period of time, so
no information was recorded for them until they attended a consultation. Also called intermittent (non-
monotone) missingness.
 attrition - again speciﬁc to longitudinal studies, refers to patients who dropped out and never returned.
Attrition occurred in primary care when a patient either died or transferred out of a practice. After this
time, no further information was collected. We cannot always distinguish patient attrition from wave non-
respondents until death or the patient consults. Also some patients may no longer attend the practice for
consultations, but are still registered. Attrition, also called monotone missing, commonly occurs in clinical
trial data[15].
From the examples described for each non-response type, all of them were observed in THIN. We should also
consider the process which introduced the missing data, or ‘missingness mechanism’. To explore this fur-
ther, consider a regression setting where Y denotes the outcome of interest, X denotes the covariate variables
with missing values and R = 1 when X observed and 0 if missing. Below, I describe the three missingness
mechanisms[17, 15, 18, 33]:26 Chapter 3. Background
1. Missing completely at random (MCAR): the reasons for missing data do not depend on the observed or
the missing values. For example, if a letter from the hospital with blood test results are lost, the chances
this random event occurs is the same for all patients regardless of patient characteristics or outcome. The
average outcome effect is the same among those with and without missing data.
More formally, under MCAR, the chance R = 1 given X;Y - using the notation fR[RjX;Y ] - does not
depend on X or Y , so fR[RjX;Y ] = fR[R]. Therefore, the distribution of X given Y does not depend on
R. Using the deﬁnition of conditional probability:
fR[XjY ;R] = fR[X;Y ;R]=fR[Y ;R]
= (fR[R]fR[X;Y ])=(fR[R]fR[Y ]) (because of the MCAR assumption)
= fR[XjY ] (3.1)
If this assumption is plausible, analysing observed data achieves unbiased but less precise estimates because
patients with missing data are excluded from the analysis. The observed data may suggest a plausible
MCAR mechanism, because none of the variables appear associated with data being missing, but we cannot
deﬁnitely conclude a MCAR mechanism from just the observed data. However, we can prove the MCAR
mechanism is implausible. For example, blood pressure values are not MCAR if recorded more often in
men than women.
2. Missing at random (MAR): the reasons for missing data depend on the observed values but not the missing
values. Or, we consider data MCAR conditional on the observed groups (i.e. observations within the same
groups with the same probability of X missing). Within these groups, we can obtain marginal estimates
from the observed data and average across the groups to achieve unbiased results.
For example, blood pressure is missing for some patients, but recorded more frequently for female patients
compared to male patients. Therefore, the probability of missing blood pressure is different for female and
male patients. In this situation, blood pressure is MCAR conditional on sex. Other variables, for example
age, may also determine blood pressure being recorded. Therefore, we can condition on several variables
to ensure a MCAR missingness mechanism data within each strata.
A similar argument gives the conditional probability (3.1) deﬁned above if we assume a MAR missingness
mechanism because R = 1 does not depend on X once we condition on Y , so fR[RjY ;X] = fR[RjY ].
Therefore, if we assume data MCAR or MAR, the distribution of variables with missing values conditional
on the fully observed variables is the same for all patients.
3. Missing not at random (MNAR): The reasons for missing data depend on the underlying missing data
values even after conditioning on the observed data. For example, systolic blood pressure is recorded more
frequently for patients with a high systolic blood pressure.
MNAR is the most difﬁcult mechanism to achieve unbiased estimates and standard errors (SE), because
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inferences, we require additional information or assumptions to describe the relationship between the prob-
ability of missing data and its missing value, not available from the observed data.
In other words, the conditional probability (Equation 3.1) deﬁned above does not hold if a plausible MNAR
missingness mechanism exists. R = 1 depends on both X and Y so the distribution of fR[XjY ] is different
if X is observed or not (i.e. whether R = 1 or not). Therefore, handling data with a MNAR missingness
mechanism is complex, as we either need to know exactly how R depends on X;Y or exactly how fR[XjY ]
differs according to R.
The different ‘missingness mechanisms’ are assumptions about the data to justify applying a speciﬁc imputation
approach for handling missing data, and not a property of the data[19]. We can make plausible assumptions
regarding the ‘missingness mechanism’ based on prior knowledge of the data, not just from the observed data, to
provide additional evidence for a speciﬁc mechanism[34].
In real life, ‘missingness mechanisms’ are a continuum between MAR and MNAR. The three categories of miss-
ingness are not mutually exclusive, all can occur in datasets like THIN. MCAR, pure MAR, and pure MNAR do
not exist because the pure form requires almost universally untenable assumptions. All missingness is MNAR to
an extent (i.e., not purely MAR). We need to understand the reasons why data are missing and which assumptions
are plausible before performing analyses on datasets with missing data. However, rather than focusing on whether
the assumptions are violated, instead we should consider if the violation is big enough to matter to a practical
extent[35].
Of the three missingness mechanisms, MAR provides a reasonable primary working assumption for an analysis
of data with missing values. It assumes the distribution of partially observed variables given the fully observed
variables is the same for all individuals. Given a sufﬁciently large dataset with many covariates like THIN, this
seems a plausible starting point to impute missing values in THIN.
3.2.3 ‘Ad–hoc’ methods for handling missing data
Various, commonly used ‘ad–hoc’ methods exist for handling missing data, discussed below[15, 16, 17]:
1. Complete records analysis: we only include patients with complete data for all variables in the analysis.
A popular method for handling missing values because standard statistical software automatically excludes
missing data and performs complete records analysis.
Under a MCAR missingness mechanism assumption, this method achieves unbiased estimates, but we
always reduce precision because we exclude records. However, the MCAR assumption is rarely plausible,
but sometimes justiﬁed in its simplicity if it introduces minimal bias and precision reduction. Although, if
missing data are MNAR, even a small proportion of missing data may bias estimates and SE.
We can achieve unbiased complete records analysis if the explanatory variables missing values are not
missing conditional on the outcome given the covariates[33, 36, 37], discussed in more detail in section
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2. Last observation carried forward (LOCF): the last observed response replaces the following missing re-
sponse. This method handles loss to follow-up. LOCF is often applied to longitudinal clinical trial data,
but also used in cohort studies.
A single value replaces each missing response for either outcome or exposure variables, used as an esti-
mate of a distribution. The subsequent analysis gives imputed responses the same status as actual observed
responses which underestimates the SE. A LOCF analysis is equivalent to analysing the last measured re-
sponses. One study suggests regression coefﬁcients are not just biased under LOCF but test of treatment
effect may suffer from greatly inﬂated Type I error rates (null hypothesis is accepted when it is false) and
conﬁdence intervals may have a far from the nominal coverage probability[38]. LOCF is based on strong
and often implausible assumptions about the data, such as the status of patients is unchanged. However,
patients who leave the study are possibly different from those that stay. Also, if loss to follow-up is infor-
mative, LOCF is biased[39].
3. Missing category method: creating an extra category for the missing observations. Dissimilar classes can
be grouped into one category which is not meaningful and the results are difﬁcult to interpret and possibly
biased[40]. In multivariate analysis, it is difﬁcult to explain the relationship between a missing indicator
category and other variables. To illustrate the drawbacks of the missing category method, we generated
different systolic blood pressure distributions for patients with each smoking status category (Figure 3.1
- left). We randomly selected 30% and changed the smoking status to missing. If we group together all
patients missing smoking status into a ‘missing’ category, the systolic blood pressure distribution in this
category is not similar to any one of the smoking status categories because it includes patients from all three
categories (Figure 3.1 - right). This ‘missing’ category is difﬁcult to interpret because the measurements
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Figure 3.1: Distribution of systolic blood pressure measurements for each smoking status with missing data
category
4. Marginal mean imputation: missing values imputed with the average of the observed values for that vari-
able. This method is difﬁcult to apply to categorical variable where the ‘average category’ has no meaning,
like sex. This method ignores all the other variables in the dataset, reducing the variation in the data. Also,3.2. Missing Data Theory 29
imputing missing data to the same value will underestimate the marginal SE and reduce the association
between variables. To illustrate the drawbacks of the marginal mean imputation method, we generated
systolic blood pressure distribution for patients (Figure 3.2 - left) and changed 30% of systolic blood pres-
sure values to missing. Next, we replaced the missing values with the mean of the original systolic blood
pressure distribution. Now this distribution spikes at the mean (Figure 3.2 - right), unlike the original dis-
tribution. Even though the mean systolic blood pressure stays the same for both distributions, but the SE
reduces from 0.06 to 0.05 because of this spike at the mean. 020406080100120140160Frequency126127128129130131132133134Systolic blood pressure
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Figure 3.2: Distribution of systolic blood pressure measurements before and after marginal mean imputation
5. Conditional mean imputation: we ﬁt a regression model to the complete data to obtain unbiased mean
estimators under the MAR assumption. Even though this method is an improvement over marginal mean
imputation, it still underestimates SE and gives the impression of too precise estimates because it treats the
imputed values as ‘true’ values.
6. Hot deck imputation: the data is divided into subgroups and missing values are selected with replacement
from the observed measurements (donor values) in the same subgroup. The hot deck literally refers to the
deck of matching computer cards for the donors available for a missing value (i.e. this is a non-parametric
method)[15]. Potential difﬁculties arise when deciding how to form appropriate donor groups. Even if we
select valid donor ‘decks’ and achieve unbiased estimates, we will underestimate the SE because we treat
the donor values as ‘true’ values[20].
Some of the ‘ad–hoc’ methods achieve unbiased estimates if the appropriate assumptions are plausible but
they do not correctly account for the uncertainty due to the missing data and will underestimate the SE, po-
tentially leading to a Type I error[41]. Except for complete records analysis which overestimates the SE. We
can adjust the SE, but the conditions for applying these adjustments are restrictive[15]. Frequently, ‘ad–hoc’
methods are applied and data is analysed before considering if the underlying assumptions are plausible, but we
should ﬁrst make assumptions about the data before performing the appropriate analysis under those assumptions.30 Chapter 3. Background
3.2.3.1 Maximum likelihood
Alternatively, we can consider the non-‘ad–hoc’ maximum likelihood (ML) approach for handling missing data.
With or without missing data, we ﬁrst construct the likelihood function. To calculate the ML estimates, we ﬁnd
the parameter values which make the likelihood function as large as possible and integrate the likelihood function
over the variables with missing data, obtaining the marginal probability of observing the observed variables[42].
Estimates obtained through maximum likelihood are asymptotically unbiased if missing data are MAR and the
model is speciﬁed correctly[43]. We can obtain SEs directly because a by-product of the maximisation is a nu-
merical approximation to the matrix of second derivatives at the maximum, i.e the SEs. ML can obtain estimates
and SEs for a linear regression of Y on binary X when X has missing values.
Sometimes we cannot calculate the ﬁrst or second derivatives of the log likelihood, for example when the analysis
includes many covariates or non-monotone missing data (and no direct way to incorporate auxiliary variables). In
this situation, a useful alternative is the expectation maximisation (EM) algorithm, an iterative procedure which
uses ML to obtain a mean vector and covariance matrix, so does not require the ﬁrst or second derivatives of the
log likelihood. The EM algorithm relates the ML estimation of a parameter  from the log-likelihood of  given
the observed values to the ML estimation based on the complete-data log-likelihood[15].
Expectation: conditional expectation (i.e. mean) of the missing data given the observed and current estimated
parameters are found and missing values are replaced with the expectation.
Maximisation: perform ML estimation of  as if there were no missing data.
The disadvantages of the EM algorithm are:
1. difﬁcult to produce general code;
2. it can be slow to converge, especially with many missing values, many covariates or non-monotone missing
data;
3. difﬁcult to obtain SE directly; and
4. the maximisation step is complex (i.e. has no closed form).
Alternatively, instead of the EM algorithm, we can use full information maximum likelihood (FIML), a parameter
estimation method which appropriately incorporates missing data. It directly maximizes the likelihood for the
speciﬁed analysis model rather than doing the two steps like the EM algorithm, giving estimates and SEs[42].
Applications which use FIML, such as structural equation modelling, allow models to include auxiliary or latent
variables[44], which can improve accuracy and precision of estimates. However, FIML may not be computa-
tionally feasible when analysing databases like THIN because, with many observations and time points, these
complex models may not converge.3.3. Multiple Imputation 31
3.3 Multiple Imputation
The previous section described missing data theory and some frequently used ‘ad–hoc’ methods for handling
missing data. In this section, I describe multiple imputation (MI) and explain why this approach is more suitable
than ‘ad–hoc’ methods. I emphasise the limitations of applying MI to longitudinal clinical databases. Finally,
I describe a new approach, two-fold fully conditional speciﬁcation MI algorithm, and explain why this method
may be more suitable for handling missing data in longitudinal clinical databases compared to other imputation
approaches.
3.3.1 Introduction to multiple imputation
The key step in MI is to ﬁt our model of interest to the data to obtain unbiased, precise estimates. To achieve this,
we must correctly estimate the distribution of the variables with missing values conditional on the observed data
and account for the uncertainty due to the missing data (rather than estimating the exact values of the missing
data, which we can never know).
We can use MI to create multiple imputed datasets: say we have a model of interest and a dataset we wish to ﬁt
this model to, but some values of explanatory variables in the model are missing. First, we specify the imputation
model (different from the model of interest). MI imputes the data by selecting draws from the predictive distri-
bution of the missing data given the observed values. Each imputed dataset is ‘complete’. We obtain unbiased
estimates and SEs when we ﬁt the model of interest to each imputed dataset and correctly combine the results,
provided: (i) the MAR assumption is plausible and (ii) the model of interest and in the imputation model are
congenial (i.e. the imputation models conditional distribution is the same as the model of interests predictive
distribution)[20].
To implement MI, we need a model for the partially observed variables given the fully observed (i.e. the imputa-
tion model). We can either achieve this directly, using a joint model, or approximate this process indirectly using
asequenceofconditionalmodels, calledfullyconditionalspeciﬁcation, whichIdescribeinmoredetailbelow[15].
The direct approach proceeds as follows; ﬁt a joint, multivariate normal distribution to the data conditional on
observed variables in the imputation model, draw random values from the joint conditional distribution and
replace the missing values with these draws (imputed) values.
We adapted the following technical justiﬁcation from Rubin’s Multiple Imputation for Non-response in Surveys,
1987[18] and applied the theory to a clinical data setting.
Y refers to outcome variables j = 1;:::;p. These variables are fully observed for all N patients in the data:
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where Yi is a row vector for patient i with p fully observed covariates. X refers to k = 1;:::;q covariates,
or predictors of the outcome (e.g. age, weight, blood pressure, etc.), with missing values recorded for all i =
1;:::;N patients in the database
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where Xi is a row vector for the ith patient and q covariates with missing values.
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is the response indicator for observed or missing values where Ri is a row vector for patient i and q covariates
with missing values. Rij is binary and Rij = 1 indicates an observed value in X for variable j recorded for
patient i and Rij = 0 indicates a missing value for X.
3.3.2 Bayesian inference
Q=Q(Y,X) is an estimation of a function of Y and X. With scalar Xi, a common quantity of interest is the
population mean  X =
PN
1 Xi=N.
Let obs = [(i;j)jRi;j = 1], where i = 1;:::;N refers to patient i in the database and j = 1;:::;p
refers to variable j, such that Xobs indicates the observed measurements of X in the database. Therefore,
mis = [(i;j)jRi;j = 0] such that Xmis indicates the missing measurements of X in the database.
A Bayesian inference for Q(Y;X) follows from its posterior distribution. Its conditional predictive distribu-
tion given the observed values (Y;Xobs) is calculated under speciﬁed models. The posterior distribution is
Pr(QjY;Xobs). As Q(Y;X) is a function of the observed values (Y;Xobs) and missing values in Xmis, the
posterior distribution of Q is calculated from the observed values and the posterior distribution of Xmis:
Pr(QjY;Xobs) =
Z
Pr(Q;XmisjY;Xobs)dXmis: (3.2)
General expressions for the posterior distribution of Xmis are less complex than those for Q because they do not
involve the integration in equation (3.2). Therefore, we consider the posterior distribution of Xmis instead of Q.
The posterior distribution of Q is obtained from (3.2), often evaluated directly. If we can assume the missing data
are MAR, we do not condition on R when drawing Xmis.
3.3.3 Maximum likelihood v.s Bayesian
The frequentist theory of maximum likelihood (ML) assumes large samples. If this assumption is implausible,
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of prior. However, inferences with small samples are more sensitive to the choice of prior distribution than
inferences with large samples. When prior information is available, better inferences can result from formally
incorporating this information. When prior knowledge is limited the Bayesian approach with disperse priors often
gives better frequentist inferences than large-sample approximations. For complex problems involving missing
data, the Bayesian approach is attractive as it provides answers in situations where no exact frequentist solutions
are available. The Bayesian answer, once derived, can be evaluated from a frequentist perspective. MI is based
on Bayesian principles and in general MI under a realistic model has excellent frequentist properties[15].
3.3.4 Fully conditional speciﬁcation (FCS)
Toperformimputationweneedajointmultivariatenormalmodelforthevariableswithmissingvaluesconditional
on the variables with no missing values. This model has parameter  say. We can estimate , under the MAR
assumption, and impute the missing values, taking full account of the uncertainty due to the missing data. In
many cases, full joint multivariate normal model is difﬁcult to deﬁne or is not multivariate normally distributed,
i.e. not congenial with the model of interest. These problems arise for the following reasons[21]:
 More than one variable is imputed;
 The predictor has missing values;
 Co-linearity occurs, especially with many variables and few observations;
 Rows or columns are ordered, e.g. longitudinal data;
 Different variables types (e.g. binary, unordered categorical, ordered categorical, continuous), so the appli-
cation of theoretically convenient models, such as the multivariate normal, are theoretically inappropriate;
or
 The relationship between the predictors is complex, e.g. non-linear, or subject to censoring.
Fully conditional speciﬁcation (FCS), or chained equations, is a computationally convenient, indirect approach
which approximates the joint multivariate normal model. This method implicitly imputes missing values using
a series of conditional regression models[21], under a plausible MAR assumption and assuming the joint multi-
variate normal distribution exists, known as compatibility of the conditionals[20].
If the joint distribution assumed by FCS exists, this process is a Gibbs’ sampler[45], an example of a ‘Markov
Chain Monte Carlo’ (MCMC) algorithm[15]. The Gibbs’ sampler generates a draw from the distribution
P(x1;:::;xp) of a set of p random variables x1;:::;xp when draws from the joint distribution are more difﬁcult
to compute compared to draws from conditional distributions p(xjjx1;:::;xj i;xj+1;;xp);j = 1;:::;p. Initial
values are chosen and new values sequentially selected from the conditional distribution. Under quite general
conditions the sequence of iterates converges to a draw from the joint distribution of X1;:::;Xp.
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1. For each variable in the imputation model in turn, ﬁlls in missing values with randomly chosen observed
values.
2. Discards the ‘ﬁlled-in’ values in the ﬁrst variable and speciﬁes a regression model for this variable condi-
tional on other variables in the imputation model and replaces the missing values with random draws from
the conditional distribution.
3. step 2 is repeated for each variable in turn and completes one ‘cycle’ once each variable is imputed.
4. step 3 is repeated cycles until estimates and standard errors become stable (i.e.convergence).
FCS is a ﬂexible alternative MI approach when we cannot specify a convenient and realistic joint distribution[45]
and requires less iterations compared to the joint model approach[21]. Despite a lack of theoretical justiﬁcation,
simulation studies showed this method works acceptably well[46]. Investigations of direct vs. indirect imputa-
tion found we can expect similar results from both[47]. However, recent work by Liu et al. deﬁned sufﬁcient
conditions (including compatibility of the conditionals) under which, as the sample size tends to inﬁnity, the
stationary distribution of the Markov chain generated by the chained equations algorithm (assuming that this
stationary distribution exists and the chain converges to it) converges to the posterior predictive distribution of the
missing data implied by a joint Bayesian model[48]. Hughes et al. and Liu et al. both proved a ‘non-informative
margins’ condition, which guarantees the imputed values obtained using chained equations (at convergence) are
drawn from the posterior predictive distribution of the missing data implied by a Bayesian joint model if, together
with the compatibility of conditionals (and assuming that the Markov chain generated by the chained equations
converges to a stationary distribution), the joint prior distribution factorises into independent priors[48, 49].
3.3.5 Summary of Repeated Imputations
Analysing a single imputed dataset treats the imputed values as ‘true’ values, and without adjustments it cannot
reﬂect variability under the imputation model. However, when the imputation model repeatedly draws imputa-
tions, we can combine the multiple complete data inferences to form one inference and increase the efﬁciency of
the estimate over that obtained from a single dataset and properly reﬂect uncertainty due to missing data[15, 50].
This method to correctly combine multiple inferences, called Rubin’s Rules[18], proceeds as follows:
If Q is the quantity of interest in the study, generally a k-dimensional row vector, X the database mean and  X the
population mean. If all data are observed, inferences for Q follow the distribution:
(Q   ^ Q)  N(0;U) (3.3)
where ^ Q is a statistic estimating Q, U is a statistic estimating the variance (k k covariance matrix) of (Q  ^ Q),
and N(0;U) is the k-variate normal distribution with mean 0 and variance U. Q is a 1-1 function of the quantity
of interest making the normal approximation reasonable.
We draw M sets of repeated imputations and construct m complete data sets, where ^ Q?1;:::; ^ Q?M and
^ U?1;:::; ^ U?M are the values of the statistics, ^ Q and U for each imputed datasets.3.3. Multiple Imputation 35
The ^ Q and U statistics provide the mean and variance of Q given (Y;Xobs;R). We combine the M repeated
estimates and associated variances for Q as follows:
 QM =
M X
m=1
^ Q?m
M
(3.4)
be the average of the M estimates,
 UM =
M X
m=1
^ U?m
M
(3.5)
be the average of the M variances, and
BM =
M X
m=1
( ^ Q?m    QM)
M   1
(3.6)
be the variance between (among) the M estimates, where the superscript t indicates transpose when Q is a vector.
The quantity
TM =  UM + (1 + M 1)BM (3.7)
is the total variance of (Q    QM).
Rubin[18] deﬁned an imputation procedure with m = 1 as ‘proper’ (properly reﬂecting uncertainty due to the
missing data) for the set of complete data statistics ( ^ Q;U) when we satisfy the following conditions:
1.  Q1  N( ^ Q;U)
2. B1  B where B is the variance of  Q1
3.  U1  U
4. B is stable under repeated sampling
Interval estimates and signiﬁcance levels for scalar Q are formed using a t reference distribution with
v = (M   1)(1 + r
 1
M )2 (3.8)
degrees of freedom, where rM is the relative increase in variance due to missing data:
rM = (1 + M 1)
BM
 UM
: (3.9)
A 100(1   )% interval estimate of Q is
 QM  tv(=2)T
1=2
M ; (3.10)
where tv(=2) is the upper 100=2 percentage point of the student t distribution on v degrees of freedom (e.g. if
v = 1 and 1    = 0:95, tv(=2) = 1:96). With inﬁnite imputations m = 1, the total variance reduces to the36 Chapter 3. Background
sum of the two variance components and the conﬁdence interval is based on a normal distribution v = 1[50].
Also, the signiﬁcance level associated with the null values Q0 is
Prob

F1;v > (Q0    QM)2=TM
	
(3.11)
where F1;v is an F random variable on one and v degrees of freedom. The fraction of missing information about
Q is:
M =
rM + 2=(v + 3)
rM + 1

Bm
 Um + Bm
:
(3.12)
3.3.6 Specifying the imputation model
The MI procedure includes certain variables in the imputation model to fully account for uncertainty in predicting
the missing values and create appropriate variability in the multiple imputed data[18]. Most importantly, all
variables in the model of interest, including the outcome variable[51], must be included in the imputation model.
It may appear circular to condition imputations on the outcome when the ﬁnal objective is to regress the outcome
on the full set of covariates: however, imputing draws from the conditional distribution of the missing covariates
given the observed covariates and the outcome yields consistent estimates of the regression coefﬁcients[15]. If
the outcome variable is excluded from the imputation model, relationships with this variable may not exist in the
imputed data because the imputations are generated assuming the variables are independent of the outcome[35].
In addition to the variables in the model of interest, we can obtain more precise estimates by including additional
variables in the imputation model, known as auxiliary variables[17]. If we only include variables from the model
of interest in the imputation model, the standard errors from analysing the imputed data are consistent with the
same analysis using the complete records. MI cannot add any additional information compared to the observed
records.
We can include auxiliary variables either predictive of the missing values and/or the probability of values being
missing in the imputation model[20]. When MI ﬁts a regression model to the variable with missing values
conditional on other variables in the imputation model, only auxiliary variables predictive of the missing values
will affect the draws from the conditional predictive distribution, not auxiliary variables only predictive of the
probability of the values being missing[20]. Therefore, as far as computationally feasible, we should include as
many auxiliary variables predictive of the missing values as possible[36]. However, including auxiliary variables
predictive of the missing values but not the probability of those values being missing will improve efﬁciency, but
not address bias[52]. We also want to include auxiliary variables predictive of the probability of values being
missing because this will increase the plausibility of the MAR assumption and reduce bias[52]. Therefore, we
should also include auxiliary variables predictive of both the missing values and the probability of values being
missing to obtain unbiased estimates and SEs from statistical analysis of the imputed data[52]. Over-ﬁtting
(including redundant predictors) may reduce the precision of the ﬁnal estimates to some extent but should not
increase bias because imputations are Bayesian, so it may be preferable to over- rather than under-ﬁt in the3.3. Multiple Imputation 37
imputation model[46], but a lack of correlation between the variables can bias the results towards the null[53].
However, MI tends to be forgiving when the model of interest and the imputation model are not congenial[50].
Schafer et a. recommended the imputation model should be rich enough to preserve the associations and re-
lationships among variables in the model of interest and ensure compatibility[50]. van Buuren et al.[21] early
work investigated FCS using a simulation study and found FCS produced essentially unbiased estimates with
appropriate coverage when using incompatible models. However, more recent work by Seaman et al.[54] found
FCS imputation model needs to be compatible, if the model of interest had non-linear or interaction relationships,
to achieve unbiased estimates and SEs. To ensure compatibility, we can impute passively: impute the main effect
and passively calculate the non-linear or interaction term. This method ignores the non-linear relationship or
interaction when imputing other variables with missing data. A second method is to impute the non-linear or
interaction term as ‘just another variable’ in the imputation model, and is the recommended method for linear
regression with quadratic or interaction effect[54]. Another method, substantive model compatible FCS, uses
rejection sampling to explicitly specify the imputation model for each variable with missing data[55]. When data
were MAR, substantive model compatibility FCS gave less biased estimates compared to including the term as
‘just another variable’[55].
Another consideration is when ratio variables are included in the model of interest. A recent study recommended
entering the log–transformed ratio terms separately into the imputation model[56]. Entering them without the
log-transformation can bias the results in some situations by imputing some very large or very small values
outside the range of acceptable values, including negative values. Using a log transformation ensured imputed
values were positive[56].
If using a model of interest, such as a generalized linear model, the outcome variable should be consistent in the
imputation model[46]. If the model of interest is a time-to-event model, we include the length of time each patient
is at risk and an event indicator in the imputation model. For a Cox model, White et al.[57] investigated differ-
ent functions of the time-to-event variable and demonstrated that the Nelson-Aalen estimator for the cumulative
hazardfunction andtheevent indicatorincludedtogether intheimputation modelprovidedthe leastbiasedresults.
3.3.7 MI vs complete records analysis
A complete records analysis relies on unrealistic missing data assumptions (MCAR) and can biased estimates and
reduce power, as explained in section 3.2.3. In most situations, the MAR assumption required for MI is a better
approximation to reality than either the MCAR assumption[15] or assuming missingness is independent of the
response given the covariates, as explained in the following paragraph. MI improves efﬁciency as well as reducing
bias compared with complete records analysis[58]. However, due to the added complexity, MI analysis is more
susceptible tohuman error (i.e. specifying an incompatibleimputation model) than completerecords analysis[19].
One study investigated the bias incurred for complete records and MI for different missingness mechanisms[37].38 Chapter 3. Background
MI appeared superior to complete records across a wider range of settings[37]. MI was more robust to different
missing data mechanisms compared to complete records in the bivariate case, though not in the univariate case.
When the data was MCAR, MI was more efﬁcient than complete records for estimating the coefﬁcient of an
incomplete variable X if X was strongly associated with outcome[37]. The complete records analysis was
unbiased provided that missingness is unrelated to the outcome variable, given the covariates[37]. Therefore, we
introduced bias in the complete records analysis if a covariate associated with missingness was excluded from the
model of interest[37].
It is informative to perform both MI and complete records analysis. It bridges the gap between current and future
practice[59] and reassuring if the results are similar. Although, where complete records and MI analyses give
different results, it is important to try and understand why[19]. We should also consider subject-matter context to
assess carefully whether MCAR, MAR, and/or other missing data mechanisms (in particular missing conditional
on X) are plausible, and therefore whether complete records analysis or MI are valid. If it is plausible that both
are valid, then MI is preferred because of its greater efﬁciency. If the missing data mechanism seems to ﬁt neither
approach perfectly, further investigations are required to understand the results from two approaches. While MI
is more robust to departures from assumptions, it is not guaranteed and reporting ﬁndings obtained from data
with substantial missingness in covariates should be appropriately cautious[37].
When data are missing for reasons beyond the control of investigators, the MAR assumption may not hold.
Sometimes it is not possible to relax the MAR assumption in any meaningful way without replacing it with
other equally untestable assumptions. However, in this situation, Schafer et al. recommends using principled
methodslikeMI thatassumeMARanywaybecause theywilltendtoperform betterthan‘ad–hoc’procedures[50].
3.3.8 How studies using primary care data handle missing data
In this section, I evaluate how recently published studies using primary care data report and handle missing data.
Other papers[19, 60, 61, 62] report ﬁndings from systematic reviews exploring how studies handle missing data,
but not in a primary care data context.
To keep this review contemporary I selected all papers from the last two years (from the period January 2011 to
June 2013) using primary care data and reported how they handled missing data. However, this is a descriptive
review rather than systematic or comprehensive review. A limitation of this is that I may not include all relevant
studies. However, the studies I selected are typical of those using primary care data, which gives an idea of
current practice.
I found 10 recently published papers which use primary care data I describe how these papers handle missing
data issues (Table 3.1) to show the problems with commonly used methods.3.3. Multiple Imputation 39
T
a
b
l
e
3
.
1
:
S
u
m
m
a
r
y
o
f
h
o
w
1
0
p
a
p
e
r
s
p
u
b
l
i
s
h
e
d
f
r
o
m
J
a
n
u
a
r
y
2
0
1
1
t
o
J
u
n
e
2
0
1
3
u
s
i
n
g
p
r
i
m
a
r
y
c
a
r
e
d
a
t
a
h
a
n
d
l
e
m
i
s
s
i
n
g
d
a
t
a
P
a
p
e
r
D
e
s
c
r
i
p
t
i
o
n
M
i
s
s
i
n
g
d
a
t
a
H
o
w
m
i
s
s
i
n
g
d
a
t
a
w
e
r
e
h
a
n
d
l
e
d
C
u
r
r
i
e
e
t
a
l
.
2
0
1
3
[
6
3
]
P
a
t
i
e
n
t
s
w
i
t
h
t
y
p
e
I
d
i
a
b
e
t
e
s
i
n
T
H
I
N
N
o
t
r
e
p
o
r
t
e
d
C
o
m
p
l
e
t
e
r
e
c
o
r
d
s
O
s
e
e
t
a
l
.
2
0
1
2
[
6
4
]
P
r
i
m
a
r
y
c
a
r
e
d
a
t
a
f
o
r
p
a
t
i
e
n
t
s
w
i
t
h
c
o
r
o
n
a
r
y
h
e
a
r
t
d
i
s
e
a
s
e
f
r
o
m
8
E
u
r
o
p
e
a
n
c
o
u
n
t
r
i
e
s
8
4
9
p
a
t
i
e
n
t
s
o
u
t
o
f
3
,
5
0
5
w
i
t
h
m
i
s
s
-
i
n
g
d
a
t
a
C
o
m
p
l
e
t
e
r
e
c
o
r
d
s
H
i
r
s
t
e
t
a
l
.
2
0
1
2
[
6
5
]
P
a
t
i
e
n
t
s
w
i
t
h
p
r
o
s
t
a
t
e
c
a
n
c
e
r
i
n
G
P
R
D
N
o
t
r
e
p
o
r
t
e
d
C
o
m
p
l
e
t
e
r
e
c
o
r
d
s
C
u
r
r
i
e
e
t
a
l
.
2
0
1
2
[
6
6
]
P
a
t
i
e
n
t
s
w
i
t
h
t
y
p
e
I
I
d
i
a
b
e
t
e
s
i
n
T
H
I
N
N
o
t
r
e
p
o
r
t
e
d
C
o
m
p
l
e
t
e
r
e
c
o
r
d
s
C
o
l
l
i
n
s
e
t
a
l
.
2
0
1
2
[
6
7
]
P
a
t
i
e
n
t
s
w
i
t
h
m
o
d
e
r
a
t
e
t
o
s
e
v
e
r
e
k
i
d
n
e
y
d
i
s
e
a
s
e
e
n
d
-
s
t
a
g
e
K
i
d
n
e
y
d
i
s
e
a
s
e
i
n
T
H
I
N
R
e
p
o
r
t
e
d
m
i
s
s
i
n
g
d
a
t
a
f
o
r
k
e
y
v
a
r
i
-
a
b
l
e
s
,
a
p
p
r
o
x
i
m
a
t
e
l
y
8
5
%
o
f
p
a
-
t
i
e
n
t
s
m
i
s
s
i
n
g
f
o
r
s
e
r
u
m
c
r
e
a
t
i
n
i
n
e
I
m
p
u
t
e
d
m
i
s
s
i
n
g
s
m
o
k
i
n
g
s
t
a
t
u
s
,
a
m
o
u
n
t
o
f
c
i
g
a
r
e
t
t
e
s
s
m
o
k
e
d
,
s
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
,
B
M
I
a
n
d
s
e
r
u
m
c
r
e
a
-
t
i
n
i
n
e
u
s
i
n
g
m
u
l
t
i
p
l
e
i
m
p
u
t
a
t
i
o
n
K
h
a
n
e
t
a
l
.
2
0
1
1
[
6
8
]
D
a
t
a
o
n
p
a
t
i
e
n
t
s
w
i
t
h
b
r
e
a
s
t
,
c
o
l
o
r
e
c
t
a
l
a
n
d
p
r
o
s
t
a
t
e
c
a
n
c
e
r
N
o
t
e
x
p
l
i
c
i
t
l
y
r
e
p
o
r
t
e
d
b
u
t
c
a
n
c
a
l
-
c
u
l
a
t
e
d
t
h
e
m
f
r
o
m
g
i
v
e
n
i
n
f
o
r
m
a
-
t
i
o
n
R
e
p
e
a
t
e
d
a
n
a
l
y
s
i
s
u
s
i
n
g
c
o
m
p
l
e
t
e
r
e
c
o
r
d
s
,
m
u
l
t
i
p
l
e
i
m
-
p
u
t
a
t
i
o
n
a
n
d
m
i
s
s
i
n
g
i
n
d
i
c
a
t
o
r
c
a
t
e
g
o
r
y
.
A
l
l
g
a
v
e
s
i
m
i
l
a
r
r
e
s
u
l
t
s
s
o
o
n
l
y
r
e
p
o
r
t
c
o
m
p
l
e
t
e
r
e
c
o
r
d
s
V
i
n
o
g
r
a
d
o
v
a
e
t
a
l
.
2
0
1
1
[
6
9
]
P
a
t
i
e
n
t
s
w
i
t
h
p
n
e
u
m
o
n
i
a
p
r
e
s
c
r
i
b
e
d
s
t
a
t
i
n
s
i
n
Q
R
E
S
E
A
R
C
H
M
i
s
s
i
n
g
T
o
w
n
s
e
n
d
d
e
p
r
i
v
a
t
i
o
n
s
c
o
r
e
,
B
M
I
a
n
d
s
m
o
k
i
n
g
s
t
a
t
u
s
R
e
p
e
a
t
e
d
a
n
a
l
y
s
i
s
u
s
i
n
g
c
o
m
p
l
e
t
e
r
e
c
o
r
d
s
a
n
d
m
i
s
s
i
n
g
d
a
t
a
c
a
t
e
g
o
r
y
.
B
o
t
h
g
a
v
e
s
i
m
i
l
a
r
r
e
s
u
l
t
s
s
o
r
e
p
o
r
t
e
d
o
n
l
y
m
i
s
s
i
n
g
d
a
t
a
c
a
t
e
g
o
r
y
M
i
l
l
e
r
e
t
a
l
.
2
0
1
1
[
7
0
]
P
a
t
i
e
n
t
s
w
i
t
h
c
h
r
o
n
i
c
o
b
s
t
r
u
c
t
i
v
e
p
u
l
m
o
n
a
r
y
d
i
s
-
e
a
s
e
i
n
G
P
R
D
M
i
s
s
i
n
g
B
M
I
a
n
d
/
o
r
s
m
o
k
i
n
g
s
t
a
t
u
s
N
o
t
e
x
p
l
i
c
i
t
l
y
e
x
p
l
a
i
n
e
d
,
b
u
t
s
t
u
d
y
a
p
p
e
a
r
s
t
o
u
s
e
m
i
s
s
i
n
g
d
a
t
a
c
a
t
e
g
o
r
y
V
i
n
o
g
r
a
d
o
v
a
e
t
a
l
.
2
0
1
1
[
7
1
]
P
a
t
i
e
n
t
s
w
i
t
h
c
a
n
c
e
r
p
r
e
s
c
r
i
b
e
d
s
t
a
t
i
n
s
i
n
Q
R
E
-
S
E
A
R
C
H
M
i
s
s
i
n
g
T
o
w
n
s
e
n
d
d
e
p
r
i
v
a
t
i
o
n
s
c
o
r
e
,
B
M
I
a
n
d
s
m
o
k
i
n
g
s
t
a
t
u
s
U
s
e
d
m
u
l
t
i
p
l
e
i
m
p
u
t
a
t
i
o
n
,
c
o
m
p
l
e
t
e
r
e
c
o
r
d
s
a
n
a
l
y
s
i
s
a
n
d
m
i
s
s
i
n
g
d
a
t
a
c
a
t
e
g
o
r
y
.
A
l
l
g
a
v
e
s
i
m
i
l
a
r
r
e
s
u
l
t
s
s
o
r
e
p
o
r
t
e
d
r
e
s
u
l
t
s
f
r
o
m
m
u
l
t
i
p
l
e
i
m
p
u
t
a
t
i
o
n
S
u
i
s
s
a
e
t
a
l
.
2
0
1
1
[
7
2
]
W
o
m
e
n
w
i
t
h
t
y
p
e
I
I
d
i
a
b
e
t
e
s
t
r
e
a
t
e
d
w
i
t
h
i
n
s
u
l
i
n
i
n
G
P
R
D
N
o
t
r
e
p
o
r
t
e
d
U
s
e
d
c
o
m
p
l
e
t
e
r
e
c
o
r
d
s
a
t
b
a
s
e
l
i
n
e
,
m
i
s
s
i
n
g
d
a
t
a
c
a
t
e
g
o
r
y
d
u
r
i
n
g
f
o
l
l
o
w
u
p40 Chapter 3. Background
None of these studies explained if the necessary assumptions for each method for handling missing data were
plausible, or how using these methods can potentially bias the results. Next, I discuss the studies that considered
missing data in more detail.
Some papers attempted to justify the chosen method for handling missing data. For example, the aim of Ose
et al.[64] study was to identify factors associated with health-related quality of life (HRQol, the discrepancy
between actual and desired functional capacity) in primary care at practice and patient-level in patients with coro-
nary heart disease. They used a multilevel analysis to identify associations with 14 potential explanatory variables
and HRQof at patient and practice level. The authors excluded patients missing any explanatory variables. The
authors did not report how many values were missing for each variable, but they did report that the HRQol was
similar between those patients included and excluded from the analysis, which suggests the patients included in
the complete records analysis were representative of the population.
Hirst et al. reduced the missing data by selecting a time period with more complete recording[65]. The aim
of the study was to develop a method to more accurately identify castration resistant prostate cancer patients
using primary care data. They investigated the incidence and prevalence of selected comorbidities before and
after castration resistant prostate cancer. First, they performed a complete records analysis, next they stratiﬁed
the analysis to before and after the introduction of QOF as a sensitivity analysis (see section 3.1.4). The authors
reported the results were more ‘reliable’ (precise) when analysing data recorded after the introduction of QOF
due to more complete recording.
Three studies compared different methods for handling missing data. Collins et al.[67] validated a risk prediction
model, the QKidney score, for patients in a primary care database and evaluated its discrimination and calibra-
tion. Initially, they performed multiple imputation. One variable, serum creatinine is important for predicting
kidney disease but, as this variable had substantial missing data, the authors created two scores, with and without
serum creatinine. They explained multiple imputation and the imputation model used, but they only use variables
from the model of interest in the imputation model. As discussed earlier, if no additional auxiliary variables are
included in the imputation model the standard errors are consistent with a complete records analysis. Also, data
were extracted for each patient over many years and it is not clear if they imputed missing values over time or just
at one time point. Collins et al. compared the MI results to a complete records analysis and they found the same
results for the model without serum creatinine but different results for the model with serum creatinine. They
suggested it was due to a possible MNAR mechanism but did not explain why.
Khan et al.[68] investigated the burden of health outcomes associated with treatment of British long-term cancer
survivors by ﬁnding the incidence of treatment associated health outcomes using a Cox proportional hazards
model. The authors found similar results for complete records, multiple imputation and missing indicator cate-
gory, so chose to report the complete records analysis. As explained earlier, it is preferable to report the results
from MI because it is more efﬁcient compared to a complete records analysis and the assumptions for MI are3.3. Multiple Imputation 41
more plausible compared to a complete records analysis. However, the authors did not explain MI, whether
the MAR assumption is plausible or the imputation model used. If, like Collins et al., they excluded auxiliary
variables from the imputation model, this could explain why the results following MI are similar to a complete
records analysis.
Vinogradova et al.[69] investigated pneumoinia risk in patients prescribed statins using logistic regression anal-
ysis, handling missing data using missing data category. The authors justify this method because the results
using a missing data category were the same as a complete records analysis. Both these methods require strong,
untestable assumptions, therefore, both methods showing the same results does not necessarily prove either
method is correct. Both methods may be incorrect and could yield the similar (incorrect) results.
In a different study, Vinogradova et al.[71] also investigated cancer risk in patients prescribed statins and per-
formed a logistic regression analysis, imputing missing data using MI. However, the authors did not explain MI,
if the MAR assumption is plausible or describe the imputation model used so it is not possible to determine
if MI was implemented correctly. The authors did compare the results to complete records analysis and found
similar results, but did not report the complete records analysis results. The authors used missing data category
as a sensitivity analysis, which also gave similar results. Again, MI and complete records analysis possibly gave
similar results because the authors possibly did not include auxiliary variables in the imputation model.
This small review of studies using primary care data with missing values suggest that most of the studies do not
fully consider the implications of missing data or how the methods used could affect the results. These studies
also did not consider if the method for handling missing data is appropriate for longitudinal clinical data. The
MI methods I investigate in this thesis could be used as an appropriate method for handling missing data in
longitudinal clinical data: the studies reviewed in this section could use these methods to impute missing values
to obtain unbiased results under a plausible MAR assumption.42 Chapter 3. Background
3.3.9 Problems with imputation in longitudinal clinical database
For the reasons discussed in the earlier section 3.3.4 (i.e. longitudinal data), we chose not to use a joint multivari-
ate normal distribution to impute missing values in THIN. Therefore, we investigated using FCS.
Say the longitudinal database consisted of i = 1;:::;n independent subjects with v = 1;:::;p variables and data
collected at j = 1;:::;q equally spaced time points. Let X = (X1;:::;Xq) denote the vector-valued random
variable consisting of the q repeated measurements of the p explanatory variables Xj = (Xj1;:::;Xjp) and Xobs
and Xmis denote the observed and the missing elements in X, respectively. Lastly, let Y denote the vector of
outcome variables. To apply MI, we used a suitable imputation model:
f(XmisjXobs;Y;) (3.13)
where  was a parameter describing the association between the Xs. We assumed a missing at random (MAR)
missingness mechanism so the model (3.13) does not condition on the missingness pattern.
We considered correctly applying MI, and speciﬁcally FCS, to data with repeated measurements to account for the
longitudinal and dynamic structure of the data. One approach was to impute missing values by ﬁtting MI models
separately to each time point. Using FCS, a series of (v = 1;:::;p) conditional density models were deﬁned at
time j.
f(Xmis
jv jX
j1;:::;X
j(v 1);X
j(v+1);:::;X
jp;Y;jv)f(Xmis
jv jX
j; v;Y )
(3.14)
where X refers to the observed and current imputed values of X.
If we imputed missing values from a large, dynamic longitudinal database with intermittent missingness[46] and
a long mean follow-up time like THIN, the correlations between measurements recorded at different times may
be distorted in the imputed data. Therefore, we wanted to impute each time point conditional on information at
other time points. Another option was to impute conditional on past and future observations at j = 1;:::;q time
points.
If we included measurements of variables recorded at each time point as separate variables into the imputation
model, imputations became computationally intensive and increased the possibility of co-linearity due to over-
ﬁtting because, in large, dynamic database with many variables, each imputation model had (p 1)+(q 1)p
potential covariates. Also, this imputation model is potentially difﬁcult to specify correctly because of the large
number of variables and time points:
f(Xmis
jv jX
1;:::;X
j 1;X
j; v;X
j+1;:::;X
q;Y ) (3.15)
3.3.10 Description of two-fold fully conditional speciﬁcation (FCS) algorithm
Nevalainen et al.[1] proposed an alternative method as a compromise between 3.14 and 3.15. The two-fold FCS
algorithm addresses the computational issue by restricting the imputation to a narrow time window. This method3.3. Multiple Imputation 43
 
Figure 1: The vertical lines represent the timelines of N patients in THIN. Patients enter (horizontal bar at the top of the line) and leave 
THIN at different times. A circle at the end of the timeline indicates the patient was transferred out of the practice, a cross indicates 
the patient died.  
The two-fold fully conditional specification (FCS) algorithm cycles through each time point t, selecting a small window of time points 
before and after t (blue box). Missing values at time t are drawn from the conditional distribution given observed values at time t, t+1 
and t-1. This is repeated a number of specified times, known as within-time iterations. Once these iterations are complete the 
algorithm moves on to the next time point until it has imputed at all time points. This is one among-time iteration. The number of 
iterations are also specified, so they will be repeated until assumed convergence. 
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Figure 3.3: Illustration of the two-fold fully conditional speciﬁcation (FCS) algorithm imputing simulated data.
The vertical lines represent the time-lines of N patients in THIN. Patients enter (horizontal bar at the top of the
line) and leave THIN at different times. A circle at the end of the time-line indicates the patient was transferred
out of the practice, a cross indicates the patient died.
is an approximation to the ‘full’ imputation model given by equation 3.15. The two-fold FCS algorithm proceeds
in two stages:
1. Within-time iterations: at time j. Xmis
jv is imputed conditional on
X
j 1;X
j; v;X
j+1
and the outcome Y . Observed and previously imputed values adjacent to time j are predictors in the
imputation model and not imputed at this stage. We specify bw within-time iterations and one within-time
iteration applies the FCS algorithm to all p variables at time point j (Figure 3.3).
2. Among-time iterations: The within-time iteration is repeated sequentially for all time points. When values
were imputed at all times, an among-time iteration is complete. We specify ba among-time iterations.
Among-time iterations are required to ensure inter-correlation among repeatedly measured variables are
maintained in the imputed data (Figure 3.3).
Restricting the imputation models to a small time window reduces computational problems due to over ﬁtting,
but may still consider the longitudinal and dynamic structure because the imputation model conditions on mea-
surements at adjacent time points. However, the two-fold FCS algorithm assumes conditional independence,
i.e. measurements outside of the time window are independent given that we are conditioning on measurements
closer in time. The two-fold FCS algorithm also takes advantage of the intermittent missingness pattern because
the imputation models condition on not only observed measurements before the time point of interest but also
after the time point of interest.
The previous implementation of the two-fold FCS algorithm imputed time-dependent variables only and all
subjects entered and exited the study at the same time points with only 3 time points[1]. For this PhD study we
implemented a more ﬂexible two-fold FCS algorithm which imputes time-independent variables, increase the44 Chapter 3. Background
time window width and imputes missing data for subjects with different entry and exit time points. We assumed
compatibility of conditionals (i.e. we can assume an underlying joint multivariate model exists) when using the
two-fold FCS algorithm to impute missing values in longitudinal clinical data, and we attempted to correctly
specify imputation models, to ensure congeniality. Under these assumptions, the analysis of data imputed using
the two-fold FCS algorithm obtains unbiased estimates and unbiased SEs calculated using Rubin’s rules[73].
3.3.11 Summary
In this chapter, I described the theory required to understand the results of the analysis in the following thesis
chapters. I discussed the THIN data used in this thesis, particularly the issues raised by missing data. I discussed
the concepts of missing data theory, including the limitations of frequently used ‘ad–hoc’ methods for imputation
and why MI is a preferred imputation method. I described MI and I discussed issues that arise when imputing
longitudinal data using existing approaches and I introduced the two-fold FCS algorithm and explained how this
approach may overcome the limitations of the other approaches. Next, chapter 4 reports a descriptive analysis
of health indicator recording in THIN so I can understand when and why values are missing and if the MAR
assumption is plausible, which justiﬁes using MI to impute missing values.Chapter 4
Descriptive analysis of health indicator recording
in The Health Improvement Network
Up to this point, this thesis focused on analysing data from primary care, such as The Health Improvement
Network (THIN), and in particular the issues raised by missing data. I discussed how Rubin’s missingness
mechanism taxonomy applies in this context and described commonly used ‘ad–hoc’ methods, which are only
valid when implausible assumptions about the missing data are true. I described multiple imputation (MI), which
is valid under more plausible assumptions about the missing data compared to the ‘ad–hoc’ methods. I explained
why certain MI approaches are not suitable to impute missing data in primary care databases and how the two-
fold fully conditional speciﬁcation (FCS) algorithm has potential to impute missing data in longitudinal, clinical
database but not yet validated in this setting. Before I investigate using the two-fold FCS algorithm to impute
missing data in THIN, I explore the extent and patterns of missing data in THIN for health indicators (such as
weight, systolic blood pressure and total cholesterol) associated with risk of cardiovascular disease (CVD) to
understand if the missing at random (MAR) assumption is plausible, and if it holds at all times of health indicator
recording. In this chapter, I ﬁrst describe the data extracted from THIN, and a few other data sources from the
Health Survey for England, used in this thesis. Secondly, I describe how health indicator recording for patients
varies by age and sex. Next, I describe how health indicator recording changed over time and in particular how
National Health Service (NHS) legislation inﬂuenced changes in health indicator recording. These investigations
allow me to evaluate the plausibility of the MAR assumption for health indicators recorded in THIN and how this
changes over time. Incorrectly recorded values (i.e. outliers), which can adversely inﬂuence imputations, are a
common occurrence in primary care data. Therefore, in my ﬁnal investigation before using MI, I introduce a new
method to identify and exclude outliers in longitudinal data.
4.1 THIN data included in this study
Many general practices became computerised in the 1990s to manage patient information more effectively,
starting with Vamp software before gradually changing to Vision software after 1995 (Figure 4.1). However,
practice mortality was inaccurate during the time immediately after changing to new software, which raised a few
data quality issues because practice mortality rate is derived from mortality data. The inaccurate mortality rates46 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
occurred because practices excluded patients from the transfer to Vision if they died before practices changed
to Vision. Therefore, the mortality rate was artiﬁcially reduced when practices changed to Vision software, and
increased over time as patients who transferred to Vision died. One study examined the mortality recording in
these practices and derived a marker, the Acceptable Mortality Recording (AMR) date, to indicate when practices
recorded a mortality rate similar to national statistics[74]. Analysing data recorded before the AMR date biases
mortality estimates because the patients mortality rate did not represent the general UK population.
Another issue which arose from practices becoming computerised was inaccurate data recording because some
practices still used paper records at the same time as electronic records. Horsfall et al. examined this issue and
derived a marker, the Acceptable Computer Usage (ACU) date, to indicate the earliest date when the average
annual recording rate included at least one medical record, one additional health data (AHD) record and two
prescription records per patient[75]. Horsfall et al. showed that the ACU date in combination with the AMR date
produced incidence of disease and prescribing trends consistent with external data sources[75]. Also, using only
the ACU date did not capture sudden peaks in mortality recording due to data updates or conversions, resulting
in periods of low mortality included in the analysis. Therefore, I included patient records in this study after the
latest of the AMR date and ACU date.050100150200250300350400450500550Number of practices1 Jan 19851 Jan 19901 Jan 19951 Jan 20001 Jan 20051 Jan 2010ComputerisationVisionAMRACU
Figure 4.1: Cumulative distribution of dates when practices became computerised (computerisation), changed to
Vision software, records showed acceptable mortality rate (AMR) and acceptable computer usage (ACU) of 553
practices included in THIN version 1201
Practices record postcodes in the patient records and the data provider Cegedim Strategic Data (CSD) link
correctly entered postcodes to area level information, known as postcode variable indicator (PVI) data, which
includes Townsend deprivation score quintile[28]. The Townsend deprivation score quintiles were derived using
2001 census data. In total, 16 practices stopped contributing data to THIN before the PVI data were generated
in 2006. As PVI data were not recorded for patients in these practices, I excluded them from this study. I also
excluded an additional 4% of practices because less than 80% of patients had a Townsend deprivation score
recorded, which occurred if the patients postcode was not a valid postcode in 2001.4.2. Recording of health indicators in THIN by age and sex 47
In summary, to form the cohort for analysis in this thesis, I selected data for each patient from the latest of i) AMR
date, (ii) ACU date, (iii) registration date (the date the patient registered to the practice) or (iv) 1 January 1995. I
followed patients up and censored them at the earliest of (i) death, (ii) the patient transfers out of the practice or
(iii)the practiceisno longercontributing datatoTHIN (i.e. theymay havechosento useadifferent dataprovider).
I included patients permanently registered to a practice (in contrast to ‘temporary’ registration status, the ‘per-
manent’ registration status implies the patient does not intend to leave the practice and the patients registration
status is expected to continue indeﬁnitely) any time from 1 January 1995 to 31 December 2012, with all relevant
dates complete and in a logical order and not missing date of birth, sex or Townsend deprivation score quintile. I
included patient information recorded when patients were aged between 18 and 100 years.
THIN is updated once a year, so I included the latest data available at the time I performed each analysis, which
explains the different patient numbers and date ranges included in the different analyses.
I developed extensive Stata code to extract and manage the data before analysis, which is available on request.
4.1.1 Other data sources
For comparative purposes I used the Health Survey for England (HSE). The HSE is a series of annual surveys
designed to measure health and health-related behaviours in adults and children in England and is considered
nationally representative. Approximately 15,000 adults were included in each survey. I extracted data from three
surveys in different calendar years, 1998[76], 2006[77] and 2008[78].
4.2 Recording of health indicators in THIN by age and sex
In this section, to understand the reasons GPs record health indicators, ﬁnd differences in health indicator record-
ing and evaluate the extent of the missing data, I describe health indicator recording by age and sex.
4.2.1 Methods
I included THIN data described in section 4.1 in this analysis from 1 January 1999 to 31st December 2011. I
censored patients at 5 years after their last consultation if they did not consult for at least 5 years.
I extracted the annual recording of routine health indicators (height, weight, systolic blood pressure and total
cholesterol) if patients had at least one measurement recorded during each calendar year. I calculated the annual
recording per 100 person years and per 100 consultations. A consultation occurred if the patient visited the
practice and consulted with a doctor or nurse. Health indicators were recorded when patients attend a consul-
tation, so fewer health indicators recorded per 100 person years might be explained by patients attending fewer
consultations, which I can determine by also reporting health indicator recording per 100 consultations. However,48 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
many consultations do not record these health indicators.
4.2.2 Results
In total, 5,374,834 patients to 504 practices were included in the analysis. The height measurement annual record-
ing per 100 person years peaked at age 20-25 years and again at age 75-80 years with a rapid decrease after this
peak (Figure 4.2). The peak at age 20-25 years was approximately double for female patients compared to male
patients, but was the same for both at age 75-80 years (Figure 4.2). The height measurement annual recording
per 100 consultations decreased as age increased after the peak at age 20-25 years (Figure 4.2). The peak at age
20-25 years was apparent for height measurements per 100 person years and per 100 consultations, but the peak
at age 75-80 year for height measurements per 100 person years was no longer apparent for height measurements
per 100 consultations (Figure 4.2). Male patients had slightly more height measurement annual recording per
100 consultations compared to female patients in the younger ages groups, but this difference reduced as age
increased (Figure 4.2).
The weight measurement annual recording per 100 person years were recorded more frequently by age and sex
compared to height measurements (Figure 4.2). The weight measurement annual recording per 100 consultations
also peaked for female patients at age 20-25 years, same as height measurements, but constantly increased for
male patients up to age 75 years (Figure 4.2). After age 75 years, the weight measurement annual recording per
100 consultations decreased as age increased for both male and female patients (Figure 4.2).
The systolic blood pressure measurement annual recording was greater than for height and weight (Figure 4.2).
The highest peak in systolic blood pressure measurement annual recording per 100 person years for female
patients occurred at age 20-25 years, but no peak at this age for male patients (Figure 4.2). This peak for female
patients, but not male patients, aged 20-25 years was also apparent for the systolic blood pressure measurement
annual recording per 100 consultations (Figure 4.2).
The total cholesterol measurement annual recording per 100 person years was lowest for patients aged 18 years
and increased to a peak for patients aged approximately 70 years (Figure 4.2). Total cholesterol measurement
annual recording per 100 person years was very similar for male and female patients, but the total cholesterol
measurement annual recording per 100 consultations was higher for male patients compared to female patients
(Figure 4.2).
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Figure 4.2: Height, weight, systolic blood pressure and total cholesterol measurement annual recording for pa-
tients in THIN from 1999 to 2011 by age and sex, per 100 person years (left) and per 100 consultations (right)50 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
4.2.3 Discussion
In summary, the above ﬁndings showed that height, weight and systolic blood pressure measurement annual
recording per 100 person years was higher for younger female patients (aged less than 50 years) compared to
younger male patients. After age 75 years, annual recording per 100 person years was similar for male and
female patients, and decreased after this age. The total cholesterol measurement annual recording per 100 person
years was similar for male and female patients. However, male patients had a higher recording of height and total
cholesterol measurements per 100 consultations compared to female patients. The annual recording of weight
and systolic blood pressure measurements per 100 consultations was similar for male and female patients, except
recording was higher for female patients compared to male patients less than age 40 years. Next, I consider
possible reasons for these ﬁndings.
Patients may be less likely to have multiple height measurements recorded because adult patient’s heights are
unlikely to change over time. The decrease in height measurement recording as age increased may occur because
a height measurement was recorded for most patients at younger ages and this measurement was kept in the
patient record and referred to when the patient consulted with the GP at older ages. However, weight and systolic
blood pressure measurements can vary over time so, to monitor patients, GPs may record them more frequently
than height measurements. Bhaskaran et al. found a similar distribution of weight measurement recording, by
age and sex, in CPRD [79], with weight measurements recorded more frequently for female patients compared to
male patients and increased weight measurement recording up to age 75 years, which decreased after age 75 years.
Young female patients may of had more health indicator measurements recorded compared to young male pa-
tients because they consult more (Figure 4.3)[80]. Many female patients aged 20-25 years possibly consulted for
pregnancy or contraception related reasons, when height, weight and systolic blood pressure measurements were
measured.012345678Consultations per patient1830405060708090100Age (years)MaleFemale
Figure 4.3: Consultations per patient by age and sex
The increased consultation rates for all patients potentially explains the peak at age 75-80 years in height and4.2. Recording of health indicators in THIN by age and sex 51
weight measurement recording. As patients become older, disease risk increases and patients attend more con-
sultations that require the GPs to record these measurements. Also, retired patients, particularly retired men, may
be more likely to consult during retirement because they have more free time compared to before retirement.
However, the height and weight measurements annual incidence per 100 consultations still decreased slightly
as patients got older suggesting fewer height and weight measurements recorded as patients age increased after
accounting for the increased consultations. Adjusting for consultation did not explain the high systolic blood
pressure measurement recording at older ages (80+ years) because consultations per patient also decrease (Figure
4.3). Systolic blood pressure is an important health indicator for many diseases and easily measured in the GP
practice, so when patients were older with an increased disease risk, blood pressure may be measured more
frequently to monitor these patients.
Before age 70 years, total cholesterol measurement recording per 100 consultations was more frequent for male
patients compared to female patients which may be because male patients have a higher CVD risk, which total
cholesterol is an important health indicator for[10, 84]. Total cholesterol measurement recording per 100 consul-
tations decreased steeply after the peak at age 70 years for male and female patients, which was similar to the
ﬁndings for height and weight and the overall decrease in consultations per patients (Figure 4.3). This decline
was possibly a survival effect. Health indicator recording initially increases because the patients were older and
became sicker and required monitoring. The sickest patients that required the most monitoring died before the
healthier patients, who stayed alive and required fewer health indicators recorded. Another explanation is the
elderly may ﬁnd it more difﬁcult to visit the GP practice for a consultation, and some may be housebound. Alter-
natively, elderly patients may move to a nursing home and no longer visit their local GP or require a home visit,
which would exclude them from this analysis. Some elderly patients may transfer to the practice that provides
medical care for that nursing home, but that practice may not contribute data to THIN.
4.2.4 Summary
In this section, I described health indicator recording by age and sex for health indicators associated with CVD.
These results suggest missing health indicator values are not MCAR because health indicator recording varies by
age and sex.
In the next section, I describe health indicator recording over calender time to assess the plausibility of the MAR
assumption over the years of follow-up included in the data analysis.52 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
4.3 Longitudinal recording of health indicators in THIN
In the previous section, I described the differences between health indicator recording by age and sex for health
indicators associated with CVD. In this section, I describe health indicator recording over time in THIN. As
described in section 3.1.4, the Department of Health (DoH) introduced ‘new patient health checks’ in 1992, to
measure some health indicators for all patients when they register with a practice, and the Quality Outcomes
Framework (QOF) in 2004, to encourage GPs to monitor patients with QOF speciﬁed diseases by measuring
health indicators. I investigate how this legislation affected health indicator recording in THIN, assess the MAR
assumption plausibility and evaluate if it holds at all times of health indicator recording to justify using MI to
impute missing data.
4.3.1 Methods
For the purpose of this descriptive analysis, I identiﬁed four patient cohorts who’s registration year with a general
practice in THIN was 1995, 2000, 2005 or 2010. These patients were included in the analysis from the year of
registration until they transferred out of the practice, died or censored at 31 December 2011. For each patient,
I identiﬁed the date measurements were recorded for each of the following health indicators: height; weight;
smoking status (current/ex-smoker/non-smoker); systolic blood pressure; and total cholesterol. I performed the
following analysis for each health indicator and patient cohort:
 The proportion of male and female patients with at least one of each health indicator measurement recorded
each calendar year after registration.
 A Kaplan-Meier failure curve to investigate the time from registration to the ﬁrst of each health indicator
measurement for male and female patients.
 The proportion of male and female patients with at least one of each health indicator measurement recorded
each calendar year after registration by disease status.
The QOF guidance outlined the speciﬁc health indicators to monitor certain diseases, outlined in the following
section 4.3.2. I analysed each health indicator by the diseases the health indicators were monitored for. I used
QOF speciﬁed Read codes to identify a disease diagnosis (coronary heart disease (CHD, Appendix A); stroke or
transient ischaemic attack (stroke, Appendix B); diabetes (Appendix C); chronic obstruction pulmonary disease
(COPD, Appendix D) in patient records.
4.3.2 QOF guidance
QOF points were awarded to general practices for evidence of ongoing management of patients with speciﬁc
diseases.
First introduced in 2004, QOF (http://www.nhsemployers.org/PayAndContracts/
GeneralMedicalServicesContract/QOF/Pages/Rewarding-QOF.aspx)awardedpointsfor‘the
percentage of patients with a diabetes diagnosis whose notes recorded body mass index (BMI) in the previous4.3. Longitudinal recording of health indicators in THIN 53
15 months’. GPs monitored BMI for patients with a diabetes diagnosis, aiming to reduce weight in overweight
patients with a diabetes diagnosis and improve glycaemic control. Both height and weight measurements were
required to calculate BMI.
Also in the 2004 guidance, QOF awarded points for ‘the percentage of patients with CHD, stroke or diabetes
whose notes have a record of blood pressure in the previous 15 months’. GPs monitored systolic blood pressure
for patients with a coronary heart disease (CHD), stroke or diabetes diagnosis as it is important for these patients
to maintain a normal systolic blood pressure.
In 2006, a new QOF guidance awarded points for ‘the percentage of patients with CHD, stroke or diabetes who
have a record of total cholesterol in the previous 15 months’. QOF derived this guidance from evidence that lower
total cholesterol reduced vascular risk for patients diagnosed with CHD, stroke or diabetes (see website).
The 2004 QOF guidance awarded points for recording smoking status every 15 months for patients diag-
nosed with at least one of the following diseases: CHD, stroke, diabetes or COPD. This guideline ex-
cluded patients who never smoked. In 2008 (http://www.nhsemployers.org/PayAndContracts/
GeneralMedicalServicesContract/QOF/Pages/ChangesToQOF200809.aspx), QOF modiﬁed
this guidance to include a smoking status record for all patients diagnosed with these diseases, regardless of
previous smoking status.
4.3.3 Results
In total, 33,454 patients registered in 1995 and this increased to 188,847 in 2010 (Table 4.1). Patients were
younger in cohorts registered earlier. More female patients than male patients registered, and this percentage was
similar for each cohort (Table 4.1).
Table 4.1: Number, median and mean age at registration and sex distribution of newly registered patients in 1995,
2000, 2005 or 2010.
Cohort Number of Age (years) Sex, n (%)
patients median (IQR) Male Female
1995 33,454 31.4 (21.4, 45.9) 15,813 (47.3) 17,641 (52.7)
2000 113,047 31.5 (23.7, 44.3) 52,659 (46.6) 60,388 (53.4)
2005 193,963 31.9 (24.2, 44.1) 89,885 (46.3) 104,078 (53.7)
2010 188,847 32.3 (24.8, 45.4) 86,719 (45.9) 102,128 (54.1)
IQR: interquartile range54 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
4.3.3.1 Percentage of patients with at least one measurement recorded
For height, weight, systolic blood pressure and smoking status, the percentage of patients in each cohort with
at least one measurement recorded was highest in the registration year (Figure 4.4), from 50% to 80%. This
percentage decreased to the lowest point in the years immediately after registration, and increased again to its
highest point in the year 2011; 10–15% for height measurements, 30–35% for weight measurements, 50–55% for
systolic blood pressure measurements and 45–55% for smoking status (Figure 4.4).
The percentage of female patients with at least one height, weight, systolic blood pressure and smoking status
measurement recorded was higher than male patients (Figure 4.4).
4.3.3.2 Time from registration to ﬁrst measurement
Most patients had at least one height and weight measurement recorded during follow-up; at least one height
measurement recorded for 80% of male patients and 85% of female patients and at least one weight measurement
recorded for 85% of male patients and 95% of female patients (Figure 4.5). During follow-up, at least one systolic
blood pressure measurement was recorded for almost all female patients and approximately 90% of male patients
(Figure 4.5).
For height, weight and smoking status recording, female patients in cohorts registered later had a ﬁrst record
slightly sooner after registration compared to female patients in cohorts registered earlier (Figure 4.5). This
difference between the cohorts was greatest for smoking status recording (Figure 4.5). Approximately 90% of
male patients and almost all female patients had at least one smoking status recorded during follow-up (Figure
4.5).4.3. Longitudinal recording of health indicators in THIN 55 020406080% of female patients
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Figure 4.4: Percentage of female patients (left) and male patients (right) in each cohort with at least one height,
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Figure 4.5: Time from registration to ﬁrst height, weight, systolic blood pressure or smoking status measurement
for female patients (left) and male patients (right) in each cohort.4.3. Longitudinal recording of health indicators in THIN 57
4.3.3.3 Percentage of patients with and without diseases identiﬁed by QOF that have at least
one measurement of the required health indicators
The percentage of patients with at least one height, weight, systolic blood pressure or smoking status measure-
ment recorded was higher for patients with diabetes compared to patients without diabetes (Figure 4.6). This
difference was greater in the later calendar years. I found similar results for at least one systolic blood pressure
measurement recorded for patients with CHD or stroke diagnosis (Appendix E). After the QOF guidelines were
introduced in 2004, approximately twice as many patients with diabetes had a smoking status recorded compared
to patients without diabetes (Figure 4.6). I found similar results for patients with at least one smoking status
measurement recorded and CHD, stroke and COPD diagnosis (Appendix E).
Generally, more female patients had at least one systolic blood pressure measurement or smoking status recorded
compared to male patients, but recording was very similar for male and female patients diagnosed with diabetes
(Figure 4.6), CHD, stroke or COPD (Appendix E).
4.3.3.4 Total cholesterol
Total cholesterol measurement recording was very different to the other health indicators. The percentage of
patients with at least one total cholesterol measurements was lowest in the registration year (Figure 4.7). The
percentage of patients with at least one total cholesterol measurement recorded increased during follow-up, and
was greater for patients in cohorts registered earlier (Figure 4.7).
In each cohort, I observed a longer time between registration and recording the ﬁrst cholesterol measurement
compared to other health indicators. For example, in the ﬁrst year of registration approximately 75% of patients
had a ﬁrst height, weight, systolic blood pressure or smoking status measurement record but approximately 15%
of patients had a total cholesterol measurement recorded (Figure 4.7).
The percentage of patients with diabetes and at least one total cholesterol measurement was substantially greater
than patients without diabetes (Figure 4.7). Total cholesterol recording increased steadily over time to approx-
imately 80% of patients with diabetes in 2011 compared to approximately 20% of patients without diabetes in
2011. I found similar results for patients with other diseases (CHD and stroke) (Appendix E).
Overall, total cholesterol recording was very similar for male and female patients.58 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network 0255075100% of female patients199519971999200120032005200720092011 Year measurement recordedHeight 0255075100% of male patients
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Figure 4.6: Percentage of female patients (left) and male patients (right) with and without diabetes in each cohort
with at least one height, weight, systolic blood pressure or smoking status measurement recorded each year during
follow-up.4.3. Longitudinal recording of health indicators in THIN 59 020406080% of female patients
1
9
9
5
1
9
9
7
1
9
9
9
2
0
0
1
2
0
0
3
2
0
0
5
2
0
0
7
2
0
0
9
2
0
1
1
Year measurement recorded
Total cholesterol
0
20
40
60
80
% of male patients
1
9
9
5
1
9
9
7
1
9
9
9
2
0
0
1
2
0
0
3
2
0
0
5
2
0
0
7
2
0
0
9
2
0
1
1
Year measurement recorded
Total cholesterol
0.00
0.25
0.50
0.75
1.00
Female patients
0
2
4
6
8
1
0
1
2
1
4
1
6
Y
e
a
r
s
 
f
r
o
m
 
r
e
g
i
s
t
r
a
t
i
o
n
 
t
o
 
f
i
r
s
t
 
m
e
a
s
u
r
e
m
e
n
t
Total cholesterol
0.00
0.25
0.50
0.75
1.00
Male patients
0
2
4
6
8
1
0
1
2
1
4
1
6
Y
e
a
r
s
 
f
r
o
m
 
r
e
g
i
s
t
r
a
t
i
o
n
 
t
o
 
f
i
r
s
t
 
m
e
a
s
u
r
e
m
e
n
t
Total cholesterol
0
25
50
75
100
% of female patients
1995
1997
1999
2001
2003
2005
2007
2009
2011
Year measurement recorded
Total cholesterol
0
25
50
75
100
% of male patients
1
9
9
5
1
9
9
7
1
9
9
9
2
0
0
1
2
0
0
3
2
0
0
5
2
0
0
7
2
0
0
9
2
0
1
1
Year measurement recorded
Total cholesterol
solid line - diabetes, dashed line - no diabetes
Registered 1995 Registered 2000 Registered 2005 Registered 2010
Figure 4.7: Percentage of female patients (left) and male patients (right) in each cohort with at least one total
cholesterol measurement recorded each year during follow-up (top), time from registration to ﬁrst total cholesterol
measurement for female patients in each cohort (middle) and percentage diabetic and non-diabetic patients in each
cohort with at least one total cholesterol measurement recorded each year during follow-up (bottom; solid line -
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4.3.4 Discussion
In summary, the above ﬁndings showed height, weight, systolic blood pressure and smoking status recording was
highest in the registration year, due to DoH introducing new patient health checks (discussed earlier in section
3.1.4). Height measurements mostly stay the same for patients after age 18 years, which explains why height
was less frequently measured, but weight, systolic blood pressure and smoking status can vary over time so GPs
repeatedly measured these health indicators to monitor patient health.
Overall, health indicator recording increased after DoH introduced the QOF guidance in 2004. Recording par-
ticularly increased for patients with QOF speciﬁed diseases. Therefore, many disease free patients had few
health indicator measurements recorded after the registration year. Bhaskaran et al. also observed similar weight
measurement recording in CPRD, with increased recording in more recent years and for patients with type II
diabetes compared to patients without type II diabetes[79].
Female patients consulted more than male patients[81, 82]. One study that investigated reasons why men and
women consult found psychiatric chronic illness and psychological distress were more strongly associated with
consultation in women than in men. Current somatic symptoms and cognitive factors (illness attitudes related to
illness behaviour and health anxiety) were more strongly associated with consultation in men than women, despite
women reporting more physical symptoms and negative illness attitudes overall[83]. Systolic blood pressure was
recorded more frequently for female patients compared to male patients, possibly because female patients visited
the GP for the contraceptive pill or pregnancy related consultations. During these consultations, GPs require a
blood pressure measurement.
Fewer patients had a total cholesterol measurement recorded compared to other health indicators. One explana-
tion is because a blood sample was required to measure total cholesterol, usually only taken if the GP suspects the
patient has a disease, indicated by a high BMI or high blood pressure, and requires total cholesterol measurement
to conﬁrm diagnosis. However, total cholesterol recording increased after the introduction of QOF in 2004 and
also after 1999 when statins (a lipid-modifying drug) became more commonly prescribed. Lipid-modifying drugs
lower total cholesterol so GPs measure and record total cholesterol for patients prescribed lipid-modifying drugs
to monitor total cholesterol reduction.
I found no differences in recording between sex for patients diagnosed with any one of the QOF speciﬁed condi-
tions discussed in this section.
From the analysis, I observed only a few patients had health indicators recorded in a given year and missing data
was dependent on age, sex and disease status. Therefore, the results from a complete records analysis in a given
year would probably be biased because the MCAR assumption is violated.
The MAR assumption is plausible in the registration year. Many patients had data recorded in this year, because4.3. Longitudinal recording of health indicators in THIN 61
of new patient health checks, which depended less on unobserved data, i.e. the MNAR assumption is unlikely.
However, MCAR is also unlikely because observing health indicators is conditional on registration status in each
year and, as I have shown in this section, newly registered patients were more likely to have health indicators
recorded. I can include registration status in the imputation model to increase the plausibility of the MAR as-
sumption.
The MAR assumption was less plausible in the years after registration because data was mainly recorded for
patients with a disease diagnosis. The MAR assumption can be made more plausible by including disease status
variables in the imputation model. Diseases status is probably predictive of both missingness and the underlying
missing values so, as explained in section 3.3.6, it is important to include these variables in the imputation model
to achieve unbiased estimates and SEs and to increase the MAR assumption plausibility. Therefore, when I
impute missing health indicator values in THIN in chapter 6, I will condition on disease status.
The MAR assumption was least plausible for total cholesterol measurements compared to other health indicators
because recorded measurements were probably abnormal so the MNAR assumption was more plausible (total
cholesterol recording more likely for patients with higher total cholesterol) than the MAR assumption. However,
as well as conditioning on disease status in the imputation model to make the MAR assumption more plausible, I
can also condition on lipid-modifying drugs which is also predictive of missing total cholesterol and the underly-
ing total cholesterol values.
Many patients had at least one recording of the health indicators described in this section during follow-up, sug-
gesting the best imputation approach exploits the longitudinal data, such as the two-fold FCS algorithm. These
measurements could be predictive of both missingness at future times (for example, patients with high weight
measurement recorded may be more likely to have future weight measurements recorded) and the underlying
missing values themselves (patients with a high weight measurement recorded may be more likely to have a high
weight measurement at other times) and, therefore, important to include these variables in the imputation model
to both improve the plausibility of the MAR assumption and increase the accuracy of the imputed values.
4.3.5 Summary
From the analysis in this section, I found health indicator recording changed over time and by disease status.
Therefore, I can increase the MAR plausibility of missing health indicators over time by including disease status
and lipid-modifying drugs for total cholesterol, as well as age, gender, in the imputation model. Also, the two-
fold FCS algorithm is potentially a suitable method because it can incorporate measurements at other times and
many patients had at least one health indicator measurement, except total cholesterol, recorded during follow-up.
Before I apply the two-fold FCS algorithm, I ﬁrst consider identifying and excluding outliers in THIN. The next
section described a new approach to identify outliers in data with repeated measurements, like THIN.62 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
4.4 Two stage method to remove outliers from longitudinal data
Any incorrectly recorded values may inﬂuence the imputation of the missing values and potentially bias the
associations between the variables and the imputed values drawn from the conditional distribution based on the
data. Therefore, I investigate removing incorrectly recorded values before imputation and retain extreme but
genuine values in the dataset to represent true variation in the population.
In this section, I compare a new method to identify outliers for health indicators repeatedly recorded in THIN
to existing methods. I illustrate the methods using height measurements. The results for other health indicators
(weight, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure and diastolic blood pres-
sure) are reported in Appendix F. I submitted these ﬁndings for publication and Pharmacoepidemiology and drug
safety published the manuscript describing this method in 2011[4] (Appendix G).
4.4.1 Introduction
THIN consist of repeated measurements of health indicators such as height, weight, blood pressure and choles-
terol for several million patients. Inevitably, some values for these health indicators were recorded incorrectly.
However, some extreme values were genuine because the database covers a large, diverse population. The chal-
lenge for researchers is to distinguish between incorrect records and those which represent true, but extreme
values.
Existing methods to identify outliers include removing values more extreme than the mean  a multiple of
the standard deviation[85]. Also, the Dixon Test[86] compares the most extreme value with the second most
extreme to identify outliers and is the recommended method to exclude outliers before using the data to deﬁne
a Reference Interval (RI) for laboratory tests using a sample of healthy individuals to calculate a suitable range.
Outliers potentially affect the calculation of this range. The Dixon Test was previously validated for use with
cross-sectional data, but not longitudinal data.
In longitudinal records, repeated measurements were recorded for individual patients so outliers occurred at two
levels: population level and individual level. Population level outliers were values substantially outside the range
of the distribution of measurements from the general population e.g. height measurements above 2.4 metres.
Individual level outliers were highly implausible values in the context of measurements collected over time for
each patient. E.g. an patient with height repeatedly measured as 1.8 metres was unlikely to suddenly shrink to
1.5 metres. However, 1.5 metres was a plausible measure for another patient. Therefore, existing methods did not
capture this incorrectly recorded value because they only detected population level outliers. Ignoring individual
level outliers potentially biases further analyses, such as calculation of an patient’s body mass index (BMI). For
example, if a patient weighed 60 kg and had a height of 1.8 metres, this patient’s body mass index (BMI) is 18.5
kgm 2; within the normal range. However, if height was incorrectly recorded as 1.5m, the BMI was 26.7 kgm 2;
the patient is overweight.4.4. Two stage method to remove outliers from longitudinal data 63
4.4.2 Methods
For comparative purposes, I chose to select a 10% random sample of practices from THIN. As THIN consisted
of many patients, the analysis of a subset of patients was more manageable. I included patients in the analysis if
they met the inclusion/exclusion criteria described in section 4.1. Patients aged 16 years and over were included
and data from the time period 1995 to 2009.
4.4.2.1 Population level outliers deﬁned using Health Survey for England
To identify potential population level outliers, I interrogated the Health Survey for England (HSE). I extracted
data from two surveys in different calendar years, 1998[76] and 2008[78], to capture changes in the distribution
of the health indicators in the general population over the study period.
I identiﬁed and removed potential population level outliers using three different approaches.
1. Application of acceptable ranges from external sources
I identiﬁed age and sex speciﬁc ranges from the HSE data. For each health indicator, I added/subtracted
10% to the most extreme values in HSE. Data in THIN were identiﬁed as outliers and changed to missing
if they were outside these age and sex speciﬁc ranges. For the purposes of this study, I assumed the
distribution of heights within sex and age range is approximately Gaussian. The 10% range was considered
conservative, to ensure I retained extreme but true measurements.
2. Standard deviation from mean
For each practice, I found the height measurements distribution and standard deviation. Any measurements
more extreme than the mean  3 times the standard deviation were identiﬁed as outliers and changed to
missing.
3. The Dixon Test
I applied The Dixon Test[86] to each practice included in the study. If the difference between the most
extreme (large or small) value and the next most extreme value divided by the range of values exceeds 1
3,
the extreme value in question was identiﬁed as an outlier[86].
4.4.2.2 Individual level outliers
After excluding population level outliers identiﬁed using HSE data, a series of multilevel linear regression models
with a patient speciﬁc random intercept and slope were ﬁtted to the remaining data to identify individual level
outliers for patients with at least two measurements recorded on different dates. I assumed patients with single
measurements were correct unless it was outside the ranges identiﬁed at population level. The following model
was ﬁtted to the height measurements adjusted for age and sex.
i = patient
j = date measurement was recorded
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xij = age of patient i when height measurement was recorded on j
zi = sex of patient i
yij =  + xxij + zzi + i + ij + ij
where i  N(0;2
) was the random intercept for patient i
and ij  N(0;2
) was the random slope for patient i and height measurement recorded on j
and ij  N(0;2
) was the random error for patient i and height measurement recorded on j.
This model allowed height to vary linearly with age, consistent with research identifying a small decrease in
height with age over the typical period of observation[87]. Allowing for this potential linear trend had little
computational or inferential cost. This model was desirable to identify outliers for measurements more likely to
vary over time, such as weight.
Random effects models take account of the variability within patients and the standardised residuals of the ran-
dom effects (observed value minus predicted value divided by the square root of the residual mean square) gauge
the distance the measurement was from the ﬁtted value predicted by the model. If the measurement was very
different from the mean of all the observations for that patient, they had a larger positive/negative standardised
level 1 residual. Measurements were identiﬁed as outliers and excluded if the standardised residuals were more
extreme than 10. The model was reﬁtted to the remaining data and outliers were identiﬁed again using the same
‘cut-off’. This process was repeated until no more outliers were identiﬁed.
Adjusting for age and sex took account of the different mean and variability between men and women. The
purpose of this approach was to identify and exclude measurements that fell outside the main bulk of the sex and
age speciﬁc distribution. To do this I identiﬁed outliers on the basis of the standardised level 1 residual, not the
level 2 (within patient) residual. I also investigated alternate standardised residuals 5 and 15 because the 10
‘cut-off’ was selected arbitrarily.
Due to the size of THIN, I analysed data from each practice separately and the results were combined. On
average, there were approximately 9,000 patients registered to each practice at any one time.
If a patient had two very different measurements, it was more difﬁcult to ascertain which point was erroneous.
The method described was unlikely to identify either measurement as an outlier because the line of best ﬁt was
in between these two points. Since I ﬁtted a multilevel model, the line of best ﬁt was not exactly in the middle of
both points, due to shrinkage, and the two points had different size standardised residuals. Therefore, I proceeded
as follows: if patients had two measurements and at least one standardised residual of these measurements was
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4.4.2.3 Validation of standardised residual ‘cut-off’ points
To validate the ‘cut-off of 10, two volunteers (a general practitioner and a statistician) were raters, blinded to po-
tential outlier status and asked independently to use professional judgement to determine if height measurements
plotted against age for 100 randomly selected patients were an extreme outlier, a possible outlier, a low possibility
outlier or not an outlier. I compared the raters’ judgement to the calculated standardised residuals, categoriesed
as follows prior to validation:
 No outlier: j standardised residual j< 2;
 Low possibility outlier: 2 j standardised residual j< 5;
 Possible outlier: 5 j standardised residual j< 10; and
 Extreme outlier: 10 j standardised residual j.
4.4.3 Results
In total, 43 practices were included in the analysis and 548,450 patients contributed data after they were 16 years
old. Of these patients, 315,944 had one or more height measurement available and 513,367 height measurements.
4.4.3.1 Population level outliers
 Application of acceptable ranges from external sources
Altogether, 1,550/513,367 (0.3%) measurements were outside the population level age and sex speciﬁc
ranges derived from HSE (Table 4.2). This included a number of data entry errors e.g. the record 176
meters was probably incorrectly entered in centimetres. After excluding population level outliers, the age
and sex speciﬁc minimum, maximum and mean measurements were similar to the HSE data.
 Standard deviation from mean
Excluding height measurements more extreme than 3 standard deviations from the mean identiﬁed
751/513,367 (0.1%) outliers. The range of retained measurements still included implausible values (0.01m
to 10.02m) after applying this method.
 The Dixon Test
The Dixon Test did not identify any outliers. In this scenario, The Dixon Test was insensitive.
4.4.3.2 Individual level outliers
After excluding population level outliers identiﬁed using boundaries derived from HSE data, I ﬁtted the random
effect model once and 75 measurements had corresponding standardised residuals more extreme than  10.
Thirteen measurements were the most extreme of two measurements when at least one measurement was more
extreme than  8. After ﬁtting the model twice more, I identiﬁed 93 measurements as individual level outliers,
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Table 4.2: Maximum + 10% and minimum -10% of height measurements found in Health Survey for England
(HSE) data from 1998 and 2008 by age and sex.
Age range Male Female
Min-10% Max+10% Min-10% Max+10%
16  and < 25 1.26 2.22 1.26 2.03
25  and < 35 1.37 2.23 1.27 2.06
35  and < 45 1.36 2.21 1.24 2.06
45  and < 55 1.35 2.18 1.22 2.02
55  and < 65 1.27 2.16 1.25 1.99
65  and < 75 1.33 2.10 1.26 1.96
75 + 1.32 2.08 1.11 1.97
Using a  5 ‘cut-off’, I identiﬁed 825 individual level outliers when I ﬁtted the random effects model once to the
data. However, this did not effect the range of values retained. A  15 ‘cut-off’ was less sensitive and I only
identiﬁed 9 individual level outliers after ﬁtting the random effect models 3 times.
In total, I identiﬁed 1,643 (0.3%) height measurements as outliers after application of both methods to identify
population level outliers and individual level outliers using a ‘cut off’ of  10 standardised residuals.
4.4.3.3 Validation
Using a sample of 100 patients with 40 extreme individual level outliers, one rater identiﬁed 30 (75.0%) of these
as extreme outliers and the other identiﬁed 32 (80.0%). The raters and the random effects model were consistent
(Table 4.3). Out of 310 measurements which were not extreme outliers, rater 1 identiﬁed 18 (5.8%) as extreme
outliers and rater 2 identiﬁed 27 (8.7%) as extreme outliers.
The measurements the raters classiﬁed as no outlier, low possibility outlier, possible outlier and extreme outlier
were in concordance with the standardised residuals calculated by the random effects model (Figure 4.8). How-
ever, they did not identify a number of extreme outliers.
4.4.4 Discussion
In this section, I examined methods to remove outliers from electronic health care records. Removing population
outliers based on sensible boundaries deﬁned by representative survey data was more efﬁcient compared to other
methods such as the Dixon Test and three times the standard deviation.
Historically, it was common practice to select an acceptable range of values based on a multiple of the standard
deviation. The earliest formulation of an outlier test criterion a rule of thumb, and involved ‘reject(ing) any
observation whose residual exceeds in magnitude ﬁve times the probable error’ (i.e. 3.37 times the standard4.4. Two stage method to remove outliers from longitudinal data 67
Table 4.3: Height measurements identiﬁed as outliers by the random effects model adjusted for age and sex and
the two raters.
Outlier Random effects model
No outlier Low possibility Possible Extreme
Total 150 95 65 40
Rater 1, No outlier 150 (100.0) 94 (99.0) 30 (48.4) 4 (10.0)
n (%) Low possibility 0 (0.0) 1 (1.0) 7 (11.3) 0 (0.0)
Possible 0 (0.0) 0 (0.0) 7 (11.3) 6 (15.0)
Extreme 0 (0.0) 0 (0.0) 18 (29.0) 30 (75.0)
Rater 2, No outlier 126 (84.0) 74 (77.9) 26 (41.9) 4 (10.0)
n (%) Low possibility 11 (7.3) 16 (16.8) 3 (4.8) 0 (0.0)
Possible 13 (8.7) 5 (5.3) 6 (9.7) 4 (10.0)
Extreme 0 (0.0) 0 (0.0) 27 (43.6) 32 (80.0)
deviation) because if the Gaussian law of error was truly satisﬁed, only about one observation in a thousand
was rejected, ‘and therefore little damage will be done in any case’[85]. For cross-sectional data, using ﬁxed
thresholds calculated as a multiple of the sample standard deviation was inadequate for identifying outliers. They
can inﬂate the estimated standard deviation so their presence was not detected[88]. Recent work has also showed
that outlier detection using ﬁxed multiples was inefﬁcient[89]. In addition, the proportion of measurements
identiﬁed as outliers was inﬂuenced by the size of the sample. This method had shortcomings with longitudinal
data because it did not identify implausible height measurements as outliers. A possible explanation for this
because THIN is clinical data, rather than research data, with more data entry errors.
Another method investigated was The Dixon Test. This method did not identify any outliers in THIN, maybe
because masking affected The Dixon Test, which occurs when the less extreme ones mask the aberrance of the
most extreme.
In addition to removing population outliers, I repeatedly ﬁtted a random effects model to longitudinal clinical data
to further identify a small number of individual level outliers. This two stage method may reassure longitudinal
data users that records were consistent within patients by identifying implausible changes between successive
observations.
Initially, the random effect model was ﬁtted to the data without removing population level outliers, but the method
had difﬁculties converging in some situations. However, after removal of population level outliers, the method
converged successfully as the most extreme values were no longer present to inﬂuence the random effects models.
If a patient had an extreme measurement recorded, in most cases this resulted in the GP taking further measure-68 Chapter 4. Descriptive analysis of health indicator recording in The Health Improvement Network
Figure 4.8: Distribution of standardised residuals for height measurements classiﬁed as no outlier, low possibility
outlier, possible outlier or extreme outlier by the two raters (negative standardised residuals were recoded to
positive)
ments, either to ascertain it was a true measurement or to monitor the patient. Extreme measurements were less
likely to be identiﬁed as outliers when repeatedly recorded. Therefore, this method accurately identiﬁes an outlier
in the situation where the measurement was very different to all the other measurements recorded for a patient.
With three or more measurements, assuming the majority were reasonably accurate, individual level outliers were
identiﬁed with minimum reference to the population distribution. I used population level information for only
two measurements to identify the most likely outlier.
As with all these methods to identify outliers, the ‘cut-off’ was an arbitrary choice and sometimes difﬁcult to
justify. The aim of this study was to attempt to identify the most likely outliers and retain the true but extreme
values. Therefore, even though the boundaries described in Table 4.2 were wide, the random effects models were
a ‘double check’ for the remaining values to identify individual level outliers.
A ‘cut-off’ point of standardised residuals more extreme than  5 identiﬁed more outliers each time the random
effects model was re-ﬁtted to the data compared to using  10 as a ‘cut-off’. However, using a ‘cut-off’ of 
5 could artiﬁcially reduce the variation too much. A ‘cut-off’ of  15 was too large as it did not identify some4.4. Two stage method to remove outliers from longitudinal data 69
impossible values as outliers. A small validation study was conducted to justify using  10 standardised residuals
as a suitable ‘cut-off’ point for height. Extreme outliers from the random effects model did not always agree with
the points selected by the raters. This result was not surprising as the rater’s judgement was compared against a
deﬁned set of rules. However, there was a good agreement shown as 75% and 80% of extreme individual level
outliers were identiﬁed by the raters.
The appropriate ‘cut-off’ choice might vary for other variables. A limitation of using height as an example was
limited variation within individual measurements. However, I used the two-step method to identify outliers for
other health indicators in THIN and I found excluding weight measurements with standardised residuals more
extreme than  10 excluded approximately the same number of outliers as for height.
In a similar process to this study, other studies used a combination of a deﬁned range (‘cut-off’ points) and iden-
tify any remaining outliers using an iterative re-weighting process as a robust estimator[90, 91]. These studies
didn’t use repeated measurement data.
The two stage outlier removal method was efﬁcient, low cost and computationally relatively easy to apply to
longitudinal data. Removing outliers increases users’ conﬁdence in the data. If very large samples of data were
used, a few outliers may have little impact on the analysis. However, many studies used a subset of primary care
databases and other electronic health records, e.g. comparing a group of patients with disease X against a group
of patients with disease Y. In these samples, outliers due to measurement error may substantially bias the results.
Regression dilution will occur if outliers were present in the data as they increase the variance of the covariate[92].
If no external source of data exists to compare against, use common sense as an alternative way to exclude the
most extreme, impossible population level measurements, e.g. exclude height measurements greater than 3m or
less than 1m. I applied this method to identify outliers in longitudinal data from THIN primary care database, but
it is easily adapted to identify outliers in other data sources with repeated measurements on individuals.
4.4.5 Summary
In this section, I described a method to identify outliers in data with repeated measurements. I identiﬁed and
removed these outliers before using multiple imputation so they do not incorrectly inﬂuence the ﬁt of the imputa-
tion model to the data.
In the following chapter, I will evaluate how well the two-fold FCS algorithm performs using a simulation study
to impute missing weight, systolic blood pressure, smoking status and total cholesterol measurements, using
methods informed by the ﬁndings in this chapter.Chapter 5
Developing and evaluating the two-fold fully
conditional speciﬁcation algorithm
In the previous chapter, I described health indicator recording in The Health Improvement Network (THIN) by
age, sex and over time and explained how the missing at random (MAR) assumption was plausible if I condition
on certain variables when imputing, which justiﬁes using multiple imputation (MI). As explained in section 3.3,
the two-fold fully conditional speciﬁcation (FCS) algorithm may be a suitable method to impute missing data in
longitudinal, clinical databases. However, before applying the two-fold FCS algorithm in THIN, in this chapter I
assess bias and precision using simulated data.
In the next section, I simulate health indicator variables to mimic the essential features of their distributions
in THIN. Then I change weight, systolic blood pressure and smoking status values to missing using a MCAR
missingness mechanism and compare the bias and precision of estimates from ﬁtting the model of interest to the
original simulated data, complete records analysis and data imputed using a ‘baseline MI’ (i.e. impute missing
values at one time point) and using the two-fold FCS algorithm. Simulation studies are advantageous because
they allow me to compare the imputed data to the original data to evaluate the two-fold FCS algorithm because the
original coefﬁcients are known from the data generation mechanism. Also, I can re-run the analysis with different
among-time iterations and window width to investigate how varying these parameters affects convergence.
In the last section of this chapter, I repeated the simulation process but include total cholesterol and lipid-
modifying drugs variables in the simulated data. As described in chapter 4, total cholesterol is recorded less
frequently compared to weight, systolic blood pressure and smoking status so I change more total cholesterol
values to missing compared to other health indicators. I ﬁnd the bias and precision of total cholesterol estimates
from ﬁtting the model of interest to the original simulated data and compare to different approaches to impute
missing total cholesterol values using the two-fold FCS algorithm.5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 71
5.1 Simulation study to evaluate the two-fold fully conditional speciﬁca-
tion algorithm
In this section, I evaluate the two-fold FCS algorithm, by comparing bias and precision, using a simulation study
to assess its potential for routine application to large primary care databases. I explore how biased and precision
varies with two key parameters: the among-time iterations and the time window width. I submitted part of this
work for publication as part of the project funded by the MRC and Statistics in Medicine published this article[3]
(Appendix H).
5.1.1 Methods
Later in this thesis, to impute THIN data, I stratify patients by practice and sex to allow relationships among
health indicators to vary by practice and sex and impute each strata separately to reduce the data included in
each imputation. But, before imputing THIN data, I evaluate the two-fold FCS algorithm using simulated data
which accurately reﬂected the planned THIN imputation in section 6.1. Speciﬁcally, I simulated data to mimic
an extracted THIN cohort to investigate the association between health indicators recorded at a baseline time
block and a future coronary heart disease (CHD) event. I generated samples of N = 5;000 male patients in each
simulated dataset. This sample size should have enough power to obtain meaningful results. Also, I chose to
impute male patients only because, in chapter 4, I showed the risk of CHD and health indicator recording varied
by sex. Also, as the statistical properties of the method should be similar across different linear relationships
between the variables, the results found from a simulation study based on males should apply to females. I used
the following steps to perform the simulation study:
1. simulated full data including complete observations for patients based on a cohort of patients extracted from
THIN;
2. ﬁtted the model of interest to the full data, recording parameter estimates and standard errors;
3. made observations missing completely at random (MCAR);
4. imputed missing data to create multiple imputed datasets, and
5. ﬁtted the model of interest to each imputed dataset, and combined the results using Rubin’s rules[18].
6. Recorded the imputation-based parameter estimates and standard errors.
I chose to use a MCAR mechanism instead of MAR mechanism, even though earlier in this thesis I showed the
MCAR assumption was not plausible, because the statistical properties (estimates and SE) will be similar. Also,
a MCAR mechanism allowed me to detect bias introduced by the imputation method and (if there is no bias) use
comparisons of SEs from full data, complete record and MI analysis to directly compare efﬁciency.
I repeated the process 1,000 times so I could estimate bias in the parameter estimates, compare the empirical
standard errors of the parameter estimates with the estimated standard errors and estimate the coverage of nominal72 Chapter 5. Developing and evaluating the two-fold FCS algorithm
95% conﬁdence intervals.
5.1.1.1 Data generation mechanisms
I built up simulated data for patients using a sequence of conditional steps, starting with the simulation of the
patients and their registration times. The probabilities for the algorithm were derived from a cohort of male
patients extracted from THIN, as described in section 5.1.1.3. For the simulation study, I created 1,000 simulated
datasets, each consisting of N = 5;000 male patients and 10 years of follow-up time from 2000–2009. For each
patient i, where i = 1;:::;N, and for each year (or time block) t from 2000 to 2009, indicated by t = 0;:::;9, I
simulated the following categorical and continuous health indicator and patient characteristic variables associated
with CHD risk: time of registration (1999 or before); smoking status; age at baseline; Townsend deprivation
score quintile (measurement of social deprivation); systolic blood pressure; weight and anti-hypertensive drug
treatment. I investigated two different data generation mechanisms:
Data generation mechanism I
For each patient i = 1;:::;N:
1. I marked patient i as registered with the general practice in 1999 with probability p1, and created binary
variable where regi = 1 denoted patients registered in 1999 and regi = 0 for patients registered before
1999;
2. I generated baseline age (i.e. age in 2000), denoted agei with values a = 1;:::;10, corresponding to
5-year age categories from 40 to 89, using probabilities q0;a for patients registered before 1999 (regi = 0)
and probabilities q1;a otherwise;
3. I generated smoking status (time-independent), denoted smokei, from a multinomial logistic model condi-
tional on age category in 2000:
logitfPr(smokei = b)g = smoke
0;b +
10 X
a=2
smoke
a;b [agei = a]
where b = 1 (non-smoker - reference category);2 (ex-smoker);3 (current smoker);
4. I generated social deprivation (Townsend deprivation score quintile, from 1 (least deprived) to 5 (most
deprived), denoted townsendi, from an ordinal logistic regression model conditional on registration (1999
or other), age category in 2000 and smoking status:5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 73
logitfPr(townsendi = c)g = town
0;c + town
1 [regi = 1] +
10 X
a=2
town
2;a [agei = a]
+
3 X
b=2
town
3;b [smokei = b]
where c = 1;:::;5, with reference category c = 1;
5. I generated continuous time-dependent systolic blood pressure and weight measurements, denoted
systolici and weighti respectively, for calendar years 2000 to 2009 (denoted t = 1;:::10).
For time block t:
systolici;t = 
sys
0;t + 
sys
1;t [regi = 1] +
10 X
a=2

sys
2;t;a[agei = a] +
3 X
b=2

sys
3;t;b[smokei = b]
+
5 X
c=2

sys
4;t;c[townsendi = c] +
t 1 X
l=0

sys
5;t;lsystolici;l +
t 1 X
l=0

sys
6;t;lweighti;l + 1;i;
and
weighti;t = 
weight
0;t + 
weight
1;t [regi = 1] +
10 X
a=1

weight
2;t;a [agei = a]
+
3 X
b=1

weight
3;t;b [smokei = b] +
5 X
c=1

weight
4;t;c [townsendi = c]
+
t X
l=0

weight
5;t;l systolici;l +
t 1 X
l=0

weight
6;t;l weighti;l + 2;i;
where 1;i
iid N(0;2
1) and 2;i
iid N(0;2
2):
6. I generated binary time-dependent anti-hypertensive drug treatment variables, denoted drugi;t for time
block t, from logistic regression models:
logitfPr(drugi;t = 1)g = 
drug
0;t + 
drug
1;t [regi = 1] +
10 X
a=2

drug
2;t;a[agei = a]
+
3 X
b=2

drug
3;t;b [smokei = b]
+
5 X
c=1

drug
4;t;c [townsendi = c]
+
drug
5;t systolici;t + 
drug
6;t weighti;t:
7. I generated a time to CHD event outcome Ti from an exponential distribution (with constant proportional
hazard) with log hazard equal to:
0 +
10 X
a=2
1;a[agei = a] +
3 X
b=2
2;b[smokei = b]
5 X
c=1
3;c[townsendi = c]
+5;1systolici;1 + 6;1weighti;1 + 7;1[drugi;1 = 1]74 Chapter 5. Developing and evaluating the two-fold FCS algorithm
5.1.1.2 Imputing smoking status
Apart from smoking status, all the health indicators investigated in chapter 4 were continuous variables, assumed
approximately normally distributed, even though many measurements are rounded to the nearest integer (Figures
5.1 and 5.2). However, smoking status is a categorical variable (with 3 categories; non-smoker, ex-smoker and
current smoker) so a normal distribution is inappropriate for imputing missing smoking status values. Addition-
ally, when choosing an appropriate approach to impute smoking status, I considered how smoking status changes
over time because observed values depend on previously recorded values. (For example, if a patient is recorded
as a current smoker, I did not want to impute the patient as a non-smoker at a future time point.) 02468101214Percent1.21.31.41.51.61.71.81.922.12.2Height (m)
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Figure 5.1: Distribution of height and weight measurements recorded at registration 02468101214Percent050100150200250Systolic blood pressure (mmHg)
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Figure 5.2: Distribution of systolic blood pressure and total cholesterol measurements recorded at registration
A few studies used MI to impute missing smoking status in primary care databases, but the authors did not com-
pare the results after imputation with population data so they may not be representative[9, 8, 93]. Some studies
dichotomised smoking status into ‘never’ and ‘ever’ smokers because of difﬁculties deﬁning ex-smokers, even
though this approach is subject to misclassiﬁcation and loses the richness of the variable[9, 8]. Marston et al.[13]
imputed missing health indicator values for newly registered patients in THIN and compared the results to the
data recorded in the Health Survey for England (HSE). This study found that the distribution of each continuous5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 75
health indicators in THIN was similar to the same variables in the HSE, but not smoking status (with 3 categories)
and recommended further investigation to determine the best approach to impute missing smoking status[13].
For this thesis, I investigated smoking status recording in detail to determine a suitable imputation approach.
Smoking status recording at registration improved since the introduction of new patient health checks[94] and
now regularly recorded for patients diagnosed with a QOF speciﬁed disease since the introduction of QOF[95] in
2004, but not regularly recorded for those without a QOF speciﬁed disease (discussed in section 4.3). However,
the QOF guidelines regarding smoking status recording changed since their introduction in 2004. Originally, GPs
were not required to record smoking status if the patients previous smoking status was non-smoker. This was
amended in 2008 so GPs were required to record smoking status for all patients diagnosed with CHD, stroke,
hypertension, diabetes, COPD, asthma, CKD or psychosis, regardless of previous smoking status. Therefore, the
reason and incentives for recording smoking status changed over time.
From discussing smoking habits with GPs, I discovered GPs recorded only a few smoking status records for
non-smokers during follow-up because they considered it unlikely that adult non-smokers would start smoking
so thought it unnecessary to update smoking status regularly for known non-smokers. However, ever smokers
may change smoking status so GPs update smoking status regularly for these patients; ex-smokers would start
smoking again and current smokers would stop smoking.
I investigated if smoking status recording in THIN ﬁtted these patterns. I extracted the data described in section
4.1 for this analysis, from 1 January 1995 to 31 December 2009 for patients aged between 18 and 100 years with
at least two years follow-up. I investigated smoking status recording each year and compared these percentages to
the HSE 2006 survey[77]. First, I calculated the percentage of patients in THIN with each smoking status per year.
Next, I changed the records such that patients who only ever had a non-smoker record were non-smokers at all
time points and recalculated the percentage with each smoking status (Figure 5.3). The recalculation increased the
percentage of non-smokers to 45-50% each year, slightly less than the percentage of non-smokers in HSE in 2006
(52%)[77], which provides additional support for the GPs’ hypothesis. Therefore, from these ﬁndings, before im-
puting smoking status, assuming patients who only ever had a non-smoker record were non-smokers at all times
points captures most of the non-smoker records and greatly reduces the missing data from 60%-90% to 40%-50%.
The percentage of ex-smokers and current smokers in HSE was respectively 26% and 22%. Since these per-
centages were much higher than those observed in THIN (Figure 5.3), I imputed the remaining missing smoking
status values to either ex-smoker or current smoker.
Data generation mechanism II
I used a second data generation mechanism, identical to the ﬁrst except for the way smoking status was generated
andconditionedon, toinvestigateifestimateswerelessbiasedifIimputedbasedontheﬁndingsinsection5.1.1.2.
Speciﬁcally, I used step 3 from Data generation mechanism I, as described previously, to generate smoking status76 Chapter 5. Developing and evaluating the two-fold FCS algorithm
Figure 5.3: Percentage of patients aged 40 years and over with each smoking status per year. The ﬁgure on the
left shows the distribution of smoking status records and patients missing smoking status in THIN from 1995 to
2009. The ﬁgure on the right shows the same distributions when patients who only ever had non-smoking records
are assumed to be non-smokers in all years.
in the ﬁrst time block (year 2000), smokei;0;. Patients who were non-smokers in that time block were marked
as non-smokers for the next time blocks of follow-up. For the remaining patients (smokers or ex-smokers) for
t = 1;:::;9 we generated
Pr(smokei;t = 2jsmokei;1 6= 1) =
8
<
:
s2;t 1 if smokei;t 1 = 2 and
s3;t 1 if smokei;t 1 = 3:
where b = 1 (non-smoker - reference category);2 (ex-smoker);3 (current smoker)
The remaining steps were the same as data generating mechanism I, except when I generated the values of the
other time-dependent variables at time block t, smoking status at time block t, smokei;t was conditioned on.
Townsend deprivation score quintile and the time to CHD were generated conditional on smoking status at time
block t = 0.
5.1.1.3 Estimating parameters for the data generation mechanism
I derived the parameter values (the ‘true’ data generation parameter values for the simulation) for each data
generation step in the algorithms given above, using appropriate regression, from a cohort of patients extracted
from THIN.
The cohort included 321,780 male patients, permanently registered to practices contributing to THIN, aged be-
tween 40 and 89 in the ﬁrst time block t = 0 without any CHD events before 1 January 2001. I extracted the
time of registration (dichotomised to either in 1999 or other if not in 1999), age in the ﬁrst time block t = 0 and
Townsend deprivation score quintile for these patients.
To ensure smoking status recording was complete in the ﬁrst time block, I identiﬁed all smoking status records5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 77
between the years 1995 and 2005. For patients without a record when t = 0, I replaced the missing value with the
smoking status recorded closest to t = 0. I assumed patients without a smoking status record between the years
1995 and 2005 were non-smokers in 2000. If patients recorded more than one smoking status in a time block, I
selected the highest risk category (i.e. smokers over ex-smokers) because the CHD risk for patients who change
from a current smoker to an ex-smoker within a time block (one year) was probably similar to patients who stay
a current smoker.
I extracted all weight and systolic blood pressure measurements, identiﬁed outliers[4] using methods described
in section 4.4, and replaced them with missing values. If patients recorded more than one weight measurement or
systolic blood pressure measurement per time block I selected one at random.
Patients received anti-hypertensive drug treatment during a time block if prescribed two or more of the following
drugs during the time block; angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockser
(ARB)-2, thiazide and related diuretics, calcium-channel blockers or beta-adrenoceptor blocking drugs.
Using a CHD diagnosis Read code list (Appendix I)[96], I identiﬁed all CHD diagnoses records between 1
January 2001 and 31 December 2009. I calculated the time to ﬁrst CHD diagnosis from 1 January 2001 for each
patient with one or more CHD read code.
5.1.1.4 Model of interest
I chose an exponential time-to-event model of interest to investigate the association between CHD events (after
the year 2000) with age category, smoking status, anti-hypertensive drug treatment, systolic blood pressure,
weight and Townsend deprivation score quintile recorded in 2000, the ﬁrst time block t = 0. I ﬁtted the expo-
nential model to the cohort of patients extracted from THIN to obtain the ‘true’ coefﬁcients (log hazard ratios)
associated with each explanatory variable (Table 5.1).
I generated a hazard function of CHD logi for patients i = 1;:::;N in each simulated dataset using the log
hazard ratios (column labelled ”THIN cohort” in Table 5.1) and the time-to-event Xi drawn from an exponential
distribution Xi  exp[i]. The cumulative distribution function of the random variable Xi follows a uniform
distribution, FX(Xi)  U[0;1]. Therefore, I generated the survival time Xi for each patient as follows:
1   e iXi  U
e iXi  U
 iXi  logU
Xi 
 logU
i
i = 1;:::;N78 Chapter 5. Developing and evaluating the two-fold FCS algorithm
where U was a value selected at random from the uniform distribution to generate event times[97]. Patients with
time-to-event less than 9 time blocks were not censored; those with a time-to event of greater than 9 time blocks
were censored at 9 time blocks. Approximately 10% of patients in the simulated dataset had a CHD event. All
other patients were censored after 9 time blocks; the end of follow-up. For the purpose of this study, transfer out
of the practice and death were ignored.
5.1.1.5 Missingness mechanism
I simulated datasets with no missing values for N = 5;000 patients with records from time blocks t = 0;:::;9. Of
the variables in the model of interest, age, Townsend deprivation score quintile and anti-hypertensive drug treat-
ment were fully observed. For the other variables, I deﬁned a missingness process (or alternatively observation
process) from observed recording in THIN (arising from GP consultations), but assuming a MCAR missingness
mechanism.
Initially, I considered changing 70% of values for each variable to missing at each time block. However, the
imputations did not converge because of the sparsely observed data. Instead, for each patient and time block, I
simulated a binary indicator ‘consulted’, with probability 0.3 of consultation, as approximately 30% of patients
attend a consultation each year, which allowed me to reproduce consultation rates in the simulated data (i.e. in-
formation recorded for patients who consulted and not recorded for patients who did not consult). Conditional on
‘consulted’ in a given time block, I (independently) changed weight, systolic blood pressure and smoking status
values to missing with probability 0.05. Under this mechanism, the expected years between weight observations
is 1=(0:3  0:95) = 3:5 years, consistent with missing data in electronic health records like THIN.
5.1.1.6 Imputation strategies
I created the Stata command, twofold, which implements an extended version of the two-fold FCS algorithm
to accommodate multiple imputation of longitudinal, clinical records in large datasets. The previous implemen-
tation in SAS was too inﬂexible for use in this context because it imputed time-dependent variables only, all
subjects entered and exited the study at the same time point and only validated using data with 3 time points. This
more ﬂexible implementation imputes time-independent variables, increases the time window width and imputes
missing data for subjects with different entry and exit time points. The Stata Journal published a paper describing
the twofold command (Appendix J)[2].
I investigated the following imputation approaches to impute missing data:
1. The FCS imputation model imputed missing values in all time blocks by entering measurements at each
time block as separate variables in the imputation model, the CHD event indicator and time-to-event. I refer
to this MI model as the ‘full imputation’ model, which used 10 cycles and 5 imputations.
2. The FCS imputation model imputed missing values in the baseline time block conditional only on other
measurements recorded in the same time block, the CHD event indicator and time-to-event. I refer to this5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 79
MI model as the ‘baseline imputation’ model, which used 10 cycles and 5 imputations.
3. The two-fold FCS algorithm[1] imputed the missing data in all time blocks using 5 imputations. I in-
vestigated a few different approaches. Firstly, I imputed using bw = 5 within-time iterations, ba = 20
among-time iterations and  = 1 time window. I compared the estimates and standard errors to the re-
sults following imputation with all combinations of among-time iterations ba = 3;10;30 and wider time
windows  = 2;3. I investigated two different approaches to impute missing smoking status:
 Method 1 - smoking status recorded in the baseline time block was imputed as a time-independent
variable.
 Method 2 - following the investigations in section 5.1.1.2, I imputed smoking status as time-dependent
variable recorded in each time block assuming patients were non-smokers in all time blocks if they
only had non-smoker status recorded. Next, I used the two-fold FCS algorithm to impute the re-
maining missing values in each time block to either ex-smokers or current smokers, which includes
imputing all patients with no smoking records at any time blocks to either ex-smokers or current
smokers.
After generating data using generation mechanism I and changing values to missing, I compared the bias and
precision of estimates from ﬁtting the model of interest to data imputed using all imputation approaches and
smoking status method 1. After generating data using generation mechanism II and changing values to missing, I
compared the bias and precision of estimates from ﬁtting the model of interest to data imputed using all imputa-
tion approaches and smoking status method 2.
5.1.1.7 Statistics used in the evaluation
After each simulation k = 1;:::;s, I ﬁtted the model of interest to the full data, complete records (with missing
values) or data imputed using MI. In each case, I used these results to derive parameter estimates and associated
standard errors.
Say ^ k denotes a parameter estimate and associated standard error ^ k. For , the true parameter value used in the
data generation mechanism, I calculated the following statistics:
1. From Rubin’s conditions for proper imputation in section 3.3.5, ^  is normally distributed with mean .
Therefore, we calculate bias as the average of the difference between these across the simulations:
1
s
s X
k=1
^ k   
2. Empirical variance:
1
s   1
s X
k=1
(^ k  b  )2
where the average imputed mean across simulations is given by:
 ^  =
1
s
s X
k=1
^ k80 Chapter 5. Developing and evaluating the two-fold FCS algorithm
3. Estimated variance:
 ^ 2 =
1
s
s X
k=1
^ 2
k
4. Z-score for bias:
Bias(^ ) =
^    
p
^ 2=s
used to calculate a p-value
5. Mean square error:
MSE(^ ) = V ar(^ ) + Bias(^ ;)2 =  ^ 2 + (^    )2
6. Conﬁdence interval coverage[52], i.e. the proportion of the s conﬁdence intervals
^ k  tk;0:975
q
^ 2
k
that include the true value, . k is the degrees of freedom calculated using Rubin’s Rules.
7. If Nc is the number of patients included in a complete records analysis with variance  ^ 2
c, the effective
number of records gained is:
Nc   ^ 2
c
 ^ 2
8. The fraction of missing information is deﬁned in section 3.3.5. A smaller the fraction of missing informa-
tion reported by a method suggests it recovers more information. If the results show that the fraction of
missing information (or the fraction of information lost due to missing data) was small, the estimates were
more precise (efﬁcient).
To assess if the imputations were unbiased, averaged imputed variance across simulations should approximately
equal the empirical variance, according to Rubin’s conditions for proper imputation in section 3.3.5: Draw wi;k 
s(;2) with i = 1;:::;n patients and k = 1;:::;s simulations
Calculate sample means
 w:;k =
1
n
wi;k
Get  w:;1;  w:;2;:::;  ws and these should follow s(; 
2
n )
Calculate:
s2
k =
1
n   1
(wi;k    w:;k)2
Sampling distribution of:
 w:;1   
q
s2
1
n
;:::;
 w:;s   
q
s2
s
n
 tn 1
s2
1;:::;s2
s 
22
n 1
n   1
So average across simulations to give the simulated variance:
1
s

s2
n
n
=
2
n
(5.1)5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 81
Alternatively, the Monte Carlo standard error is given by:
1
s
(  wi;k   )2 (5.2)
Over a large number of simulations (5.1) approximately equals (5.2)[18]. (5.1) was the estimate of (5.2) from the
data.
Further, I investigated correlations between weight measurements recorded in different time blocks and systolic
blood pressure measurements recorded in different time blocks from the data imputed using the two-fold FCS
algorithm to investigate if correlations between repeated measurements were maintained in the imputed data[98].
I compared the correlations after imputation to the correlations from the full simulated data. I investigated the
correlations with weight measurements in 2000 and correlations with weight measurements in 2005 because I
imputed missing values in time blocks from 2000 to 2009 and I wanted to investigate if different results were
found at the ﬁrst time block (when measurements were after 2000) compared to the middle (when measurements
were before and after 2005, so possibly more information was available to more accurately estimate correlations
compared to 2000).
5.1.2 Results
The ‘full imputation’ model, which included a variable for measurements at each time block, did not converge
on approximately 25% of datasets because repeated measurements of the same health indicator at different time
blocks included in the imputation model caused convergence problems. Therefore, it was not considered further.
The log hazard ratios from ﬁtting the time-to-event model to the full data were similar to the THIN cohort log
hazard ratios used to generate the data (Table 5.1).
The log hazard ratios from the complete records analysis were similar to the full data log hazard ratio estimates
(Table 5.1). However, the standard error (SE) and empirical SE from the complete records analysis were larger
than the standard deviations from the full data (Table 5.2). The relative % bias was small for most estimates from
the complete records analysis and the coverages were all close to 95% (Table 5.3), suggesting a negligible bias in
the estimates from the complete records analysis. Weight and systolic blood pressure had a larger relative % bias,
possibly artiﬁcially inﬂated because the weight and systolic blood pressure estimates were small relative to their
standard errors (Table 5.3). The p-value for Z score for bias was greater than 0.05 for all but one of the estimates,
age group 40-44. In summary, the estimates from a complete records analysis had a small bias and, although
larger than for the original full data, it is not more than we would expect by chance. However, I do not expect bias
from complete records analysis as data were made MCAR. The inﬂated SEs occur because of less power due to
the reduced sample size.82 Chapter 5. Developing and evaluating the two-fold FCS algorithm
Table 5.1: Log hazard ratios from ﬁtting an exponential model to predict risk of coronary heart disease to the
THIN cohort, full simulated data, complete records analysis after full simulated datasets were changed to miss-
ing, imputed data using baseline imputation and imputed data using the two-fold fully conditional speciﬁcation
algorithm Method 1 and Method 2 with 20 among-time iterations, 5 within-time iterations.
Variables THIN Full Complete Baseline Two-fold FCS
cohort data case imputation Method 1 Method 2
Townsend 1 Reference
deprivation 2 0.1520 0.1503 0.1425 0.1497 0.1498 0.1588
score 3 0.2377 0.2367 0.2431 0.2366 0.2366 0.2422
quintile 4 0.2433 0.2400 0.2279 0.2391 0.2401 0.2535
5 0.4034 0.4024 0.3935 0.4020 0.4023 0.4017
Weight (kg) 0.0019 0.0019 0.0015 0.0016 0.0019 0.0017
Systolic blood 0.0048 0.0049 0.0051 0.0048 0.0051 0.0053
pressure (mmHg)
Anti-hypertensive 0.2935 0.2868 0.2852 0.2897 0.2855 0.2915
drug treatment
Smoking Non- Reference
status smoker
Ex- 0.0679 0.0692 0.0633 0.0672 0.0579 0.0567
smoker
Current 0.2386 0.2385 0.2307 0.2342 0.2325 0.2261
smoker
Age group 40 - 44 -1.2820 -1.2872 -1.3167 -1.2869 -1.2880 -1.2890
(years) 45 - 49 -1.0632 -1.0652 -1.0892 -1.0655 -1.0662 -1.0623
50 - 54 -0.6402 -0.6392 -0.6467 -0.6398 -0.6408 -0.6330
55 - 59 -0.3589 -0.3597 -0.3700 -0.3598 -0.3605 -0.3536
60 - 64 -0.2485 -0.2473 -0.2545 -0.2480 -0.2481 -0.2423
65 - 69 -0.0396 -0.0416 -0.0470 -0.0418 -0.0409 -0.0348
70 - 74 Reference
75 - 79 0.1108 0.1039 0.1116 0.1043 0.1057 0.1129
80 + 0.1387 0.1421 0.1255 0.1383 0.1414 0.1368
Constant term -5.1993 -5.2297 -5.2550 -5.2098 -5.2552 -5.2833
Method 1: Only smoking status recorded in the baseline time block is included as a time-independent variable in
the imputation model
Method 2: Smoking status is a time-dependent variable in the imputation model5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 83
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The log hazard ratios from ﬁtting the time-to-event model to data imputed using the baseline imputation model
were similar to the estimates from the complete records analysis (Table 5.1). The relative % bias’s were smaller
for baseline imputation compared to complete records analysis, suggesting even less bias in the estimates (Ta-
ble 5.3). At the same time, the precision of estimates of the baseline imputation log hazard ratios improved
(smaller SEs) compared to the complete records analysis for fully observed variables but was similar for imputed
variables; weight, systolic blood pressure and smoking status (Table 5.2). For these variables, the empirical SE
increased slightly, so the SEs were too small compared to empirical SE and, therefore, the coverages for these
estimates were underestimated (Table 5.3). The relative % bias MSEs were smaller following baseline imputation
compared to the complete records analysis (Table 5.3), suggesting less unexplained information so the imputed
data explained more of the variation. Despite the improved SEs, none of the p-values for z-score were signiﬁcant
because of a concomitant reduction in bias.
The log hazard ratios from the analysis of data imputed using the two-fold FCS algorithm Method 1 with bw = 5,
ba = 20 and  = 1 were similar to the analysis of data imputed using baseline imputation (Table 5.1). However,
SEs and empirical SEs from analysing data imputed using the two-fold FCS algorithm Method 1 were all smaller,
and therefore more precise, compared to baseline imputation (Table 5.2). In particular, the continuous variables
with missing data (weight and systolic blood pressure) showed the most reduction in bias, giving coverages
closer to the nominal 95% coverage level (Table 5.4). However, the reduction in bias was not observed for the
categorical variable with missing data, smoking status. The estimates of SEs and empirical SEs for smoking
status were slightly smaller compared to analysing data imputed using baseline imputation (Table 5.2).
The results from analysing data imputed using the two-fold FCS algorithm when using Method 2 were similar to
Method 1, except the smoking status log hazard ratios were more precise (Table 5.2). The coverage of the coef-
ﬁcient estimates using Method 2 were closer to 95% and had smaller mean square errors compared to imputing
missing data using two-fold FCS algorithm Method 1 (Table 5.4). However, this gain in precision comes at an
acceptable price in detectable bias for smoking status.
Only a small effective number of records gained were required for the complete records analysis to achieve the
same precision as analysing data imputed using baseline imputation (Table 5.5). This increased signiﬁcantly
for the weight coefﬁcient when analysing of data imputed using the two-fold FCS algorithm Method 1, with
not as much of an increase for systolic blood pressure coefﬁcient. The effective number of records gained for
the smoking status coefﬁcients was similar for data imputed using baseline imputation and using the two-fold
FCS algorithm Method 1, when smoking status was time-independent. However, the effective number of records
gained increased for the smoking status coefﬁcients when analysing data imputed using the two-fold FCS algo-
rithm Method 2, when smoking status was time-dependent (Table 5.5).5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 87
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The fraction of missing information halves for the weight coefﬁcient when analysing data imputed using the
two-fold FCS algorithm compared to analysing data imputed using baseline imputation (Method 1 and 2). How-
ever, only when analysing data imputed using the two-fold FCS algorithm Method 2, when smoking status was
time-dependent, reduced the fraction of missing information for the smoking status coefﬁcients compared to
analysing data imputed using baseline imputation (Table 5.6). The fraction of missing information was similar
from analysing data imputed using any of the three imputation methods for the systolic blood pressure coefﬁcient .
After ﬁtting the model of interest to each dataset imputed using Method 1 with ba = 3;10;20 and 30 among-time
iterations and  = 1;2 and 3 window width, and keeping bw = 5 within-time iterations, I found the results had
similar bias and precision to the result described with  = 1 window width, ba = 20 among-time iterations and
bw = 5 within-time iterations.
Table 5.6: Fraction of missing information for each covariate with missing data in the imputed data
Variables Baseline Two-fold FCS
imputation (smoking time- (smoking time-
independent) dependent)
Weight 0.6490 0.3040 0.2882
Systolic blood pressure 0.6365 0.6065 0.6114
Smoking status Non-smoker
Ex-smoker 0.6317 0.6339 0.2803
Current smoker 0.6314 0.6227 0.33475.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 89
5.1.2.1 Correlations
From investigating the correlations between weight measurements at different time blocks, I found the two-fold
FCS algorithm with  = 1 time block window produced imputations which accurately estimated correlations
between weight measurements with 1 time block difference. However, the correlations were underestimated when
the time between the observations was greater than 1 time block (top graphs, Figure 5.4). Increasing the number
of among-time iterations resulted in correlations between all time blocks closer to the correlations in the full data.
The biggest improvement was from 3 to 10 among-time iterations, but less improvement from 10 to 20 iterations,
and less again from 20 to 30 iterations. For example, with 1 within-time iteration, the correlation between weight
in 2000 and weight in 2003 was 0.82 when 3 among-time iterations were used, but the correlation increased to
0.90 with 10 among-time iterations, which is closer to the correlation of 0.94 in the full data. However, with
20 among-time iterations the correlation was 0.92, so there was a 0.08 difference in correlations from 3 to 10
among-time iterations but only 0.04 difference in correlations from 10 to 20 among-time iterations. I found the
correlations in the middle of the follow-up time (i.e. correlations with weight measured in 2005) were closer to
the correlations from the full data compared to correlations at the beginning of follow-up (i.e. correlations with
weight measured in 2000) (Figure 5.4).
With a  = 2 time block window (i.e. imputation at time block t conditioned on measurements at time blocks
t   2, t   1, t + 1 and t + 2), correlations between weight measurements 1 or 2 years apart were accurately
estimated (middle graphs, Figure 5.4). With a  = 3 time block window, correlations were accurately estimated
when the difference was 1, 2 or 3 time blocks (bottom graphs, Figure 5.4). These results suggest correlations were
closer to the correlations from the full data if the number of time blocks between the measurements was less than
or equal to the width of the time block window. However, increasing the window width only gave correlations
closer to the correlations from the full data for correlations between nearby time blocks but increasing the number
of among-time iterations gave correlations closer to the full data for correlations between all time points.
When ba = 3 or ba = 10, the correlations between weight measurements were not close to the correlations from
the full data when  = 1 and increasing the window width gave correlations closer to the correlations from the
full data. This may suggest a lack of convergence with 3 or 10 among-time iterations and additional information
at other time blocks were required to get correlations closer to the correlations from the full data.
Increasing the number of among-time iterations did not achieve correlations much closer to the correlations from
the full data for correlations between repeated systolic blood pressure measurements, suggesting only a few
among-time iterations were required to give correlations close to the correlations from the full data for correlations
between systolic blood pressure measurements in data imputed using the two-fold FCS algorithm. However,
increasing the time window width used by the two-fold FCS algorithm gave correlations closer to the correlations
from the full data for correlations between repeated systolic blood pressure measurements when the speciﬁed time
block width was equal to or less than the difference between time blocks (Figure 5.5), the same as correlations
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Figure 5.4: Correlations between weight measurements in different time blocks found in the full simulated data
and imputed data using the two-fold FCS algorithm with 3, 10, 20 and 30 among-time iterations and 1 (top
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Figure 5.5: Correlations between systolic blood pressure measurements in different time blocks found in the full
simulated data and imputed data using the two-fold FCS algorithm with 3, 10, 20 and 30 among-time iterations
and 1 (top graphs), 2 (middle graphs) and 3 (bottom graphs) time block windows.92 Chapter 5. Developing and evaluating the two-fold FCS algorithm
5.1.3 Discussion
This simulation study showed that coefﬁcient estimates were less biased (closer to the ‘true’ coefﬁcient value)
and more precise (smaller standard errors), the effective number of records gained increased signiﬁcantly for the
weight coefﬁcient, with smaller increase for the systolic blood pressure coefﬁcient and the fraction of missing
information halves for the weight coefﬁcient from analysing data imputed using the two-fold FCS algorithm
compared to data imputed using baseline imputation. This suggests that the two-fold FCS algorithm recovers
more of the missing information than baseline imputation, even with 70% missing data in each time block. More
information was recovered for the weight variable, with higher correlations between repeated measurements,
compared to systolic blood pressure, with lower correlations between repeated measurements.
The bias, precision and number of effective records gained and fraction of missing information from analysing
data imputed using the two-fold FCS algorithm with time-independent smoking status were similar to analysing
data imputed using baseline imputation. When imputing time-dependent smoking status using the two-fold
FCS algorithm, the coefﬁcients of the subsequent analyses were more precise but the smoking status estimates
themselves were slightly more biased. The most likely explanation is the approach I used to impute smoking
status did not identify all of the non-smokers (because they never had a smoking status recorded, section 5.3)
and I may have incorrectly imputed them as either ex-smokers or current smokers. As non-smokers have a lower
risk of CVD, these misclassiﬁed patients caused the time-to-event model to underestimated the risk associated
with ex-smokers and current smokers. Also, the effective number of records gained doubled and the fraction of
missing information halved when analysing data imputed using the two-fold FCS algorithm when smoking status
was a time-dependent variable compared to a time-independent variable, so the two-fold FCS algorithm recovers
more information for time-dependent variables compared to time-independent.
For time-dependent variables, the two-fold FCS algorithm used the information in repeated measurements
recorded at different time blocks to inform imputation because they are correlated, but the baseline imputation
did not. This enabled the two-fold FCS algorithm to achieve less biased, more precise estimates with increased
effective number of records gained and smaller fraction of missing information compared to baseline imputation.
This was also true when imputing using the two-fold FCS algorithm with time-dependent smoking status com-
pared to time-independent smoking status.
The estimated correlations between weight measurements recorded in different time blocks were more accurate in
data imputed with more among-time iterations. However, correlations estimates between systolic blood pressure
measurements in different time blocks were not more accurate with more than 10 among-time iterations. In the
full simulated data, the correlations between systolic blood pressure measurements, ranging from 0.45 to 0.65,
were lower than the correlations between weight measurements, ranging from 0.95 to 0.98, suggesting accurate
correlation estimates were obtained if ‘true’ correlations were high. If variables had lower correlations between
repeated measurements, increasing the number of among-time iterations did not give more accurate correlation es-
timates because the imputed results can only gain a limited amount of information, implied by the low correlation.5.1. Simulation study to evaluate the two-fold fully conditional speciﬁcation algorithm 93
I increased the window width to include variables recorded at more time blocks in the imputation model. This
additional information allowed correlations in the imputed data to converge closer to the ‘true’ correlation for
repeated measurements within the speciﬁed time window width. This result suggests correlations at greater
distance than the window width are systematically underestimated. This can be remedied to a limited extent
by increasing the number of among-time iterations, as described in the previous paragraph, but this does not
eliminate the bias completely and unable to achieve correlations close to the ‘true’ correlation if the underlying
correlations are lower. In practice, therefore, we should consider a window width the same length as the distance
of the correlations we wish to accurately estimate.
5.1.4 Summary
In this section, I used a simulation study to understand and explore the properties of the two-fold FCS algorithm
in the context of THIN data, and how (i) the choice of two key parameters (window width and among time itera-
tions) and (ii) the method of imputing smoking (an example of a longitudinal categorical variable) affected bias
and precision. Overall, the results showed this method improved bias and precision of time-dependent variables
compared to baseline imputation. I investigated the effect of changing the among-time iterations and the window
width, which did not effect the bias or precision of the estimates, but more among-time iterations and wider
window width achieved correlations closer to the ‘true’ correlations in the imputed data. Later in the thesis, I
impute missing weight, systolic blood pressure and smoking status in THIN using the methods described in this
section.
Total cholesterol is another variable I want to include in the model of interest, but my earlier investigation found
substantially more missing values in THIN compared to weight, systolic blood pressure and smoking status, as
described in section 4. Imputing missing total cholesterol values requires a more detailed investigation so, in the
next section, I describe another simulation study to investigate different approaches to impute total cholesterol.94 Chapter 5. Developing and evaluating the two-fold FCS algorithm
5.2 Simulation study to evaluate imputation strategies for missing total
cholesterol
In additional to the health indicators described, I also wish to include total cholesterol in my coronary heart
disease (CHD) risk analysis because it strongly predicts CHD events. My investigation in section 4.3 found total
cholesterol was recorded most frequently in patients diagnosed with QOF speciﬁed diseases, including CHD.
But, in this section, my analysis includes predicting a future CHD event in undiagnosed patients with fewer total
cholesterol measurements recorded. Also, total cholesterol recording frequency increased for patients prescribed
lipid-modifying drugs, compared to patients not prescribed, so GPs can evaluate if the drug lowers total choles-
terol effectively.
In this section, I used another simulation study, with missingness patterns and substantial missing values similar
to those observed in THIN, to investigate different applications of the two-fold FCS algorithm to impute missing
total cholesterol measurements, attempting to optimise the available information.
5.2.1 Methods
To generate the data for this study, I ﬁrst simulated data using data generating mechanism II described in the
previous section, and also simulated variables for lipid-modifying drugs and total cholesterol.
GPs control abnormal cholesterol levels using lipid-modifying drugs. Using THIN data described in section
4.1, I ﬁtted two regression models to the total cholesterol values with age as the dependent variable, one for
patients prescribed lipid-modifying drugs and another for patients not prescribed lipid-modifying drugs. The
results found, for patients aged 40 years or more, total cholesterol measurements were higher for patients not
prescribed lipid-modifying drugs compared to patients prescribed lipid-modifying drugs and total cholesterol
decreases for both as age increased (Figure 5.6). These different distributions suggest I should simulate total
cholesterol measurements separately for patients prescribed lipid-modifying drugs and patients not prescribed
lipid-modifying drugs.
To simulate the data, I ﬁrst generated baseline age (i.e. age in 2000), denoted agei, with values a = 1;:::;7
corresponding to the age categories 40-44, 45-49, 50-54, 55-59, 60-64, 65-69 and 70-89.
5.2.1.1 Data generation mechanism
Initially, I simulated total cholesterol measurements separately for patients prescribed any lipid-modifying drugs
in the ﬁrst time block t = 0 and not prescribed any lipid-modifying drugs in the ﬁrst time block t = 0, but the
associations in the simulated data did not reﬂect those in the THIN cohort. The problem occurred because only a
few patients in the younger age groups were prescribed lipid-modifying drugs and develop CHD (for example, in
our sample of 321,831 patients, 9,365 were prescribed lipid-modifying drugs, 524 of these were in age group 40-
44 and, of these, 30 had a CHD event) so were not accurately simulated. Instead, I used the following alternative5.2. Simulation study to evaluate imputation strategies for missing total cholesterol 95
Figure 5.6: Distribution of mean total cholesterol (mmol l 1) by age, for patients prescribed lipid-modifying
drugs and not prescribed lipid-modifying drugs
data generating mechanism to generate lipid-modifying drugs and total cholesterol variables:
1. generated binary time-independent lipid-modifying drug treatment variables, denoted lipidi;t for time t =
1, from logistic regression models:
logit(P(lipidi;0 = 0)) = 
lipid
0;0 +
7 X
a=1

lipid
1;0;a[agei = a] +
3 X
b=1

lipid
2;0;b[smokei;0 = b]
+
5 X
c=1

lipid
3;0;ctownsendi + 
lipid
4;0 systolici;0
+
lipid
5;0 weighti;01 + 
lipid
6;0 antihypei;0 (5.3)
2. generated time-dependent total cholesterol measurements, denoted choli;t for calendar years (time blocks)
2000 to 2009 (denoted t = 0;:::9). For time block t for patients with lipidi;0 = 0:
choli;t = chol
0;t +
7 X
a=1
chol
1;t;a[agei = a] +
3 X
b=1
chol
2;t;b[smokei;t = b] +
5 X
c=1
chol
3;t;c[townsendi = c]
+chol
4;t systolici;t + chol
5;t weighti;t + chol
6;t choli;t 1 + 3;t (5.4)
where 3;i
iid N(0;2
3) The difference between the mean total cholesterol values for patients prescribed
lipid-modifying drugs and patients not prescribed lipid-modifying drugs was approximately 1 for patients
aged 60 years and over (Figure 5.6), so I assumed this difference was true for all ages and drew total
cholesterol measurements using the same coefﬁcients for patients with lipidi;0 = 0 and subtracted 1 from
these measurements.
5.2.1.2 Estimating parameters for the data generation mechanisms
Again, as in the previous section, I obtained associated parameters values from the same cohort of patients
recorded in THIN. The cohort consisted of male patients, permanently registered with 1 of the 500 general
practices contributing to THIN, aged between 40 and 89 in the ﬁrst time block t = 0 without any records of CHD96 Chapter 5. Developing and evaluating the two-fold FCS algorithm
events before 1 January 2001.
Weight, systolic blood pressure and total cholesterol outliers were identiﬁed using the method described
previously[4], in section 4.4, and replaced with missing values. Data for continuous variables were extracted
using the same methods described in section 5.1. I assumed patients received lipid-modifying drugs during the
whole time period if any lipid-regulating drug prescription was recorded during the ﬁrst time block.
Using a CHD diagnosis Read code list (Appendix I)[96], I identiﬁed all CHD diagnosis records between 1 Jan-
uary 2001 and 31 December 2009 and indicated patients with CHD if they had at least one CHD Read code. I
also calculated the time-to-event from 1 January 2001 to the ﬁrst CHD diagnosis date.
The cohort extracted from THIN had missing measurements of weight, systolic blood pressure, smoking status
and total cholesterol. I only included patients with complete measurements for all variables in a given time block
to estimate parameters in that time block. Again, smoking status was fully observed in the baseline time block,
so I estimated parameters using patients with complete measurements of weight, systolic blood pressure and total
cholesterol.
5.2.1.3 Model of interest
The model of interest was the same model described in the previous section 5.1, with the additional explanatory
variables lipid-modifying drugs and total cholesterol recorded in the ﬁrst time block t = 0.
5.2.1.4 Missingness mechanism
Missingness mechanism 1
After I simulated a completely observed dataset of 5,000 patients with records from 2000 to 2009, I next deﬁned a
missingness process (or alternatively observation process) for these simulated data from the observed recordings
in THIN (arising from GP consultations). For reasons discussed in section 5.1, I assumed a MCAR missingness
mechanism, so the remaining data were a random selection of the full records. Of the variables in the model,
age, Townsend deprivation score quintile, anti-hypertensive drug treatment and lipid-modifying drugs were fully
observed. Weight, systolic blood pressure, smoking status and total cholesterol missingness was conditional on
the patient consulting in the relevant time block. Therefore, for each patient and time block, I simulated a binary
indicator ‘consulted’, with probability 0.3, as approximately 30% of patients attend a consultation each year, of
consultation. Conditional on ‘consulted’ in a given time block, I (independently) changed weight, systolic blood
pressure, smoking status and total cholesterol values to missing with probability 0.05. Using this missingnes
mechanism, patients have 70% of missing values in for the time-dependent health indicators each year, which
approximately agrees with the descriptive analysis ﬁndings4.
The only difference between missingness mechanism 1 in this section compared to section 5.1 is total cholesterol
with missing values was included in this section.5.2. Simulation study to evaluate imputation strategies for missing total cholesterol 97
Missingness mechanism 2
The proportion of total cholesterol measurements recorded in THIN increased following the introduction of QOF,
as discussed in section 4.3. Therefore, for missingness mechanism 2, different proportions of total cholesterol
measurements were MCAR within each time block for patients who did consult using the following criteria so
the percentage missing decreases each time block from 97% in the ﬁrst time to 70% in the last time block:
Ui  U(0;1)
Total cholesterol is missing for patient i ifPr(choli;t) = Ui < (9   t)=10
if t = 0;:::;8
Pr(choli;9) = Ui < 0:01
(5.5)
5.2.1.5 Imputation strategies
First, I imputed data made missing by missingness mechanism 1 using imputation method 1. Next, I imputed data
made missing by missingness mechanism 2 using each of the following imputation strategies:
Imputation method 1 I imputed missing total cholesterol values using the two-fold FCS algorithm with 20
among-time iterations, 5 within-time iterations, 5 imputations and 1 time block window width, i.e. mea-
surements at time t-1 and t+1 were included in the imputation model (Figure 5.7).
Imputation method 2 I imputed missing total cholesterol values using the two-fold FCS algorithm with a 2 time
block window width so measurements at more time blocks included in the imputation model to inform
imputation. As well as including measurements at time block t-1 and t+1, measurements at time block t-2
and t+2 were also included in the imputation model to impute missing values at time t (Figure 5.7).
1 
 
Patient  t-3  t-2  t-1  t  t+1  t+2  t+3 
1    5.4  5.5  6.0    6.1   
2  4.5  4.5    4.2  4.1  4.0   
3    5.6      5.0     
4      4.5         
5    3.7  3.5  3.0      4.0 
6  4.5      5.1    5.2  4.1 
7          5.8     
 
Figure 5.7: Example of total cholesterol measurements recorded in THIN98 Chapter 5. Developing and evaluating the two-fold FCS algorithm
Imputation method 3 I imputed total cholesterol with a 1 time block window width. When the two-fold FCS
algorithm reached time t, values at adjacent time blocks were temporarily replaced (for this imputation step
only) with observed values at the next more extreme time blocks. For example, when imputing at time
block t, missing values at t-1 were replaced with observed values at t-2 and missing values at t+1 were
replaced with observed values at t+2 (Figure 5.8).
1 
 
Patient  t-3  t-2  t-1  t  t+1  t+2  t+3 
1    5.4  5.5  6.0  6.1  6.1   
2  4.5  4.5  4.5  4.2  4.1  4.0   
3    5.6  5.6    5.0     
4      4.5         
5    3.7  3.5  3.0      4.0 
6  4.5      5.1  5.2  5.2  4.1 
7          5.8     
 
Figure 5.8: Illustration of imputation method 3
Imputation method 4 I imputed total cholesterol with a 1 time block window width. Missing values at time
blocks adjacent to the imputed time block were replaced with the closest observed values at more extreme
time blocks (Figure 5.9).
1 
 
Patient  t-3  t-2  t-1  t  t+1  t+2  t+3 
1    5.4  5.5  6.0  6.1  6.1   
2  4.5  4.5  4.5  4.2  4.1  4.0   
3    5.6  5.6    5.0     
4      4.5         
5    3.7  3.5  3.0  4.0    4.0 
6  4.5    4.5  5.1  5.2  5.2  4.1 
7          5.8     
 
Figure 5.9: Illustration of imputation method 4
For imputation method 4, I included two variables which indicate the time block the measurement in time blocks
t 1 and t+1 were originally observed. The following argument justiﬁes including these variables. The equation
Ct = 0 +1t models the association between total cholesterol measurements and time. The difference between5.2. Simulation study to evaluate imputation strategies for missing total cholesterol 99
total cholesterol values at t + 1 and t + 2 was as follows:
Ct+1   Ct+2 = 0 + 1(t + 1)   0   1(t + 2)
= 1((t + 1)   (t + 2)) (5.6)
and by the same reasoning
Ct 1   Ct 2 = 1((t   1)   (t   2)) (5.7)
Therefore, we impute missing total cholesterol values at time block t conditional on observed values at t + 1 and
t   1 using the result from Equations 5.6 and 5.7 as follows:
Regress Ct on Ct+1, Ct 1 and other variables.
Regress Ct on Ct+2 + 1((t + 1)   (t + 2)), Ct 2 + 1((t   1)   (t   2)) and other variables.
Where ‘other variables’ refers to the usual other variables we condition on at the current two-fold FCS algorithm
step.
Smoking status was time-dependent so I imputed missing smoking status values using the method for imputing
time-dependent smoking status described previously in section 5.1.1.2, patients with only non-smoker records
during follow-up were assumed to be non-smokers at all time points and all other missing values were imputed
as either ex-smokers or current smokers.
I evaluated the two-fold FCS algorithm using the statistics described in section 5.1.100 Chapter 5. Developing and evaluating the two-fold FCS algorithm
5.2.2 Results
Table 5.7: Log hazard ratios from ﬁtting the exponential model to the THIN cohort, full simulated data, complete
records analysis and data imputed using baseline imputation and imputation method 1 in year 2000 (missingness
mechanism 1)
Variables THIN Full data Complete Baseline Method 1
cohort records imputation
Age group 40 - 44 -1.2305 -1.2671 -1.6946 -1.2797 -1.2673
(years) 45 - 49 -1.0175 -1.0294 -1.1018 -1.0260 -1.0289
50 - 54 -0.6248 -0.6328 -0.6467 -0.6201 -0.6328
55 - 59 -0.3236 -0.3256 -0.3278 -0.3107 -0.3264
60 - 64 -0.2448 -0.2460 -0.2569 -0.2316 -0.2464
65 - 69 -0.0414 -0.0425 -0.0407 -0.0365 -0.0425
70 + Reference
Townsend 1 Reference
deprivation 2 0.0700 0.0783 0.0822 0.0779 0.0777
score 3 0.1378 0.1387 0.1416 0.1397 0.1386
quintile 4 0.0843 0.0842 0.0812 0.0857 0.0851
5 0.3586 0.3686 0.3611 0.3702 0.3686
Weight (kg) 0.0020 0.0019 0.0016 0.0020 0.0019
Systolic blood pressure (mmHg) 0.0041 0.0042 0.0044 0.0042 0.0044
Total cholesterol (mmol l 1) 0.0737 0.0728 0.0731 0.0727 0.0719
Smoking Non-smoker Reference
status Ex-smoker 0.0457 0.0458 0.0501 0.0604 0.0400
Current smoker 0.1834 0.1819 0.1910 0.1790 0.1743
Lipid-modifying drugs 0.3363 0.3337 0.3313 0.3330 0.3335
Anti-hypertensive drug treatment 0.1655 0.1655 0.1641 0.1650 0.1631
Constant term -5.4483 -5.4471 -5.4951 -5.4815 -5.4767
From missingness mechanism 1, the total cholesterol coefﬁcients from analysing the complete records (0.0731),
after baseline imputation (0.0727) and after imputing using imputation method 1 (0.0719) were similar to the
THIN cohort (0.0737) and full data (0.0728) coefﬁcients (Table 5.7). The standard errors from the complete
records analysis were larger than the standard errors from the full data analysis because the complete records
analysis was based on a smaller sample size (Table 5.8). The results were more precise after baseline imputation
and even more precise after imputing using imputation method 1 (the two-fold FCS algorithm with 20 among-
time iterations, 5 within-time iterations, 5 imputations and 1 time block window width).
Looking at the total cholesterol coefﬁcients, the relative % biases from all methods were close to zero (Tables 5.9
and 5.10), p-value for Z-score for bias’ were greater than 0.05 and the coverage was close to 95%, suggesting
negligible bias in the total cholesterol estimates. However, imputation method 1 had the smallest mean square
error because the results using imputation method 1 were most precise.
With missingness mechanism 2, the total cholesterol coefﬁcient from the complete records analysis (0.0892)
was larger than the THIN cohort (0.0737) and full data (0.0728) estimates (Table 5.11). However, after baseline
imputation, the total cholesterol coefﬁcient (0.602) was smaller than the THIN cohort and full data estimates. The5.2. Simulation study to evaluate imputation strategies for missing total cholesterol 101
total cholesterol coefﬁcients were more precise after baseline imputation compared to complete records analysis
(Table 5.12).
After baseline imputation, the large relative % bias (-18.273) was similar magnitude but opposite signs for the
total cholesterol coefﬁcient compared to the complete records analysis relative % bias (21.061) (Table 5.13).
The mean square error was smaller for total cholesterol estimate after baseline imputation (0.055) compared to
the complete records analysis (0.159) because the estimate was more precise. However, for total cholesterol
coefﬁcients from complete records analysis and after baseline imputation, p-value for Z-score for bias’ were
small and the coverage’s were not as close to 95% compared to the full data estimate. The results suggested
total cholesterol estimates had some bias when using complete records analysis or baseline imputation with
missingness mechanism 2.
With missingness mechanism 2, the total cholesterol coefﬁcient (0.0496) after using imputation method 1 (Table
5.14) was attenuated compared to the total cholesterol estimate after baseline imputation (0.0602) (Table 5.11),
but the total cholesterol coefﬁcients from imputation methods 2, 3 and 4 (Table 5.14) were similar to the estimate
from baseline imputation (Table 5.11).
The total cholesterol coefﬁcient from imputation method 3 had the smallest standard errors out of the four im-
putation methods. The standard errors for imputation methods 1, 2 and 4 were similar to baseline imputation
(Table 5.15). As results after imputation method 3 were most precise out of baseline imputation and the four
imputation methods, it also had the smallest mean square error and coverage closest to 95% (Table 5.16 and 5.17).102 Chapter 5. Developing and evaluating the two-fold FCS algorithm
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Table 5.11: Log hazard ratios from ﬁtting the exponential model to the THIN cohort, full simulated data, complete
records analysis and data imputed using baseline imputation in year 2000 (missingness mechanism 2)
Variables THIN cohort Full data Complete Baseline
records imputation
Age group 40 - 44 -1.2305 -1.2671 -10.9481 -1.2861
(years) 45 - 49 -1.0175 -1.0294 -8.3496 -1.0281
50 - 54 -0.6248 -0.6328 -3.5515 -0.6205
55 - 59 -0.3236 -0.3256 -2.2484 -0.3121
60 - 64 -0.2448 -0.2460 -1.5564 -0.2317
65 - 69 -0.0414 -0.0425 -0.3912 -0.0373
70 + Reference
Townsend 1 Reference
deprivation 2 0.0700 0.0783 -0.2695 0.0772
score quintle 3 0.1378 0.1387 -0.4567 0.1362
4 0.0843 0.0842 -0.8428 0.0867
5 0.3586 0.3686 -1.6096 0.3665
Weight (kg) 0.0020 0.0019 0.0031 0.0021
Systolic blood pressure (mmHg) 0.0041 0.0042 0.0066 0.0042
Total cholesterol (mmol l 1) 0.0737 0.0728 0.0892 0.0602
Smoking status Non-smoker Reference
Ex-smoker 0.0457 0.0458 0.0991 0.0536
Current smoker 0.1834 0.1819 -0.2288 0.1856
Lipid-modifying drugs 0.3363 0.3337 -0.7624 0.3216
Anti-hypertensive drug treatment 0.1655 0.1655 0.2110 0.1651
Constant term -5.4483 -5.4471 -6.9917 -5.4859106 Chapter 5. Developing and evaluating the two-fold FCS algorithm
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Table 5.14: Log hazard ratios from ﬁtting the exponential model to the THIN cohort, full simulated data, and data
imputed using imputation methods 1, 2, 3 and 4 in year 2000 (missingness mechanism 2)
Variables Method 1 Method 2 Method 3 Method 4
Age group 40 - 44 -1.2705 -1.2706 -1.2745 -1.2703
(years) 45 - 49 -1.0195 -1.0188 -1.0338 -1.0398
50 - 54 -0.6284 -0.6320 -0.6339 -0.6353
55 - 59 -0.3184 -0.3207 -0.3272 -0.3268
60 - 64 -0.2472 -0.2441 -0.2442 -0.2478
65 - 69 -0.0429 -0.0466 -0.0411 -0.0425
70 + Reference
Townsend deprivation 1 Reference
score quintile 2 0.0784 0.0812 0.0799 0.0828
3 0.1403 0.1357 0.1364 0.1374
4 0.0900 0.0818 0.0818 0.0825
5 0.3715 0.3708 0.3676 0.3691
Weight (kg) 0.0018 0.0018 0.0021 0.0021
Systolic blood pressure (mmHg) 0.0043 0.0043 0.0041 0.0039
Total cholesterol (mmol l 1) 0.0496 0.0595 0.0599 0.0613
Smoking status Non-smoker Reference
Ex-smoker 0.0367 0.0350 0.0402 0.0359
Current smoker 0.1660 0.1657 0.1718 0.1685
Lipid-modifying drugs 0.3149 0.3184 0.3162 0.3185
Anti-hypertensive drug treatment 0.1639 0.1618 0.1657 0.1693
Constant term -5.3862 -5.4436 -5.4163 -5.42335.2. Simulation study to evaluate imputation strategies for missing total cholesterol 109
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5.2.3 Discussion
When approximately 70% of patients were missing total cholesterol measurements at each time block, enough
information was available at adjacent time points to inform imputation using imputation method 1 and achieve
estimates more precise than baseline imputation. These ﬁndings agree with the results from the simulation study
investigating imputing time-dependent weight, systolic blood pressure and smoking status using the two-fold
FCS algorithm in section 5.1. A small bias occurred in the lowest age group for the full data compared to the
THIN cohort. Therefore, maybe it was preferable to compare the estimates from the analysis of imputed data to
the full data values, the average of ﬁtting the model to each generated dataset and our best estimate of the true
parameter values under the data generating mechanism. However, the practical conclusions would be the same.
When the percentage of patients missing total cholesterol measurements decreased as time blocks increased from
97% in the ﬁrst time to 70% in the last time block, the total cholesterol coefﬁcients from analysing data imputed
using imputation method 1 were more biased than baseline imputation. However, out of the other imputation
methods, the total cholesterol coefﬁcients were similar to baseline imputation but most precise after imputation
method 3. Therefore, from these results, I recommend using imputation method 1 to impute missing total choles-
terol compared to baseline imputation, but using imputation method 3 for a high percentage of missing values,
say 95%.
5.2.4 Summary
I investigated different methods of imputing total cholesterol using two-fold FCS algorithm and concluded impu-
tation method 1 was suitable to apply the two-fold FCS algorithm to achieve accurate imputations. Even with a
high proportion of missing data when using missingness mechanism 2, although there is a small bias, results are
still clearly practically and clinically useful.
Before this chapter, I discovered the recording frequency of health indicators associated with CVD in THIN,
why recording changed over time and by age and sex and identiﬁed potential auxiliary variables to condition
on when applying multiple imputation to achieve a more plausible MAR assumption. However, I did not know
how the bias and precision from analysing data imputed using the two-fold FCS algorithm would compare to
other methods for handling missing data, such as a complete records analysis and analysing data imputed using
‘baseline imputation’. Also, I did not know how varying parameters associated with the two-fold FCS algorithm
(such as window width or among-time iterations) affects the results. Finally, I did not know if analysis of data
imputed using the two-fold FCS algorithm when high proportions of data are missing would achieve reasonably
unbiased results.
I used my contextual knowledge of THIN to simulate data and apply the two-fold FCS algorithm. The simulated
data provided a setting similar to THIN, so I could evaluate the best approach to apply the two-fold FCS algo-
rithm to impute missing data in the actual THIN database. In the analysis of data imputed using the two-fold
FCS algorithm, I found that time-dependent variables were more precisely estimated compared to complete5.2. Simulation study to evaluate imputation strategies for missing total cholesterol 113
records analysis or data imputed using ‘baseline imputation’. Also, correlations between repeated measurements
in the imputed data were closer to the correlations in the simulated data when I increased the window width or
among-time iterations.
Finally, with large proportions of missing data, estimates from analysing data imputed using the two-fold FCS
algorithm had small bias. With more missing data the chance of achieving unbiased estimates using multiple
imputation increases, even using the two-fold FCS algorithm. To minimise bias, as missing data increases it
becomes more and more imperative the underlying assumptions are adhered to; the MAR assumption is plausible
and the imputation model is congenial with the model of interest. However, with more missing data it may be
more difﬁcult to ensure MAR assumption plausibility.
In the next chapter I use the ﬁndings from this chapter to apply the two-fold FCS algorithm to impute missing
data in THIN.Chapter 6
Application of the two-fold fully conditional
speciﬁcation algorithm in substantive analysis of
The Health Improvement Network
Now I have explored and understood recording of health indicators associated with cardiovascular disease (CVD)
in THIN and evaluated the two-fold FCS algorithm using simulation studies using coronary heart disease (CHD)
as the outcome in the models of interest, the next step is to apply the two-fold FCS algorithm to impute missing
data in THIN. In this chapter, I perform two analyses of the THIN data and, because of missing health indicator
values, I report the results from analysing data imputed using the two-fold FCS algorithm and compare to other
methods for handling missing data to evaluate if two-fold FCS algorithm is the preferred method to impute
missing values in longitudinal, clinical data. Even though the simulation studies in chapter 5 I investigated health
indicators associated with CHD, in this section I chose to investigate associations with cardiovascular disease
(CVD) so the results were comparable to other studies, which tend to report associations between health indica-
tors and CVD rather than CHD.
6.1 Imputing missing data in THIN
In this section, I use THIN to investigate the association between established health indicators and subsequent
CVD. I included both total and high-density lipoprotein (HDL) cholesterol because HDL cholesterol may be
associated with CVD risk after adjusting for total cholesterol. I previously investigated total cholesterol recording
in THIN in chapter 4 to understand when data were missing, but not HDL cholesterol. However, I can assume
HDL cholesterol had a similar recording frequency to total cholesterol because they were both measured at the
same time, but HDL cholesterol was recorded less frequently. From the results in chapter 4, I found substantial
missing values, especially for total cholesterol but, given the results from the previous chapter, I can apply the
two-fold FCS algorithm with conﬁdence and compare the ﬁndings with ‘baseline’ (imputing missing values at
baseline conditional only on other missing values at baseline) and complete records analysis.6.1. Imputing missing data in THIN 115
6.1.1 Methods
For this part of my studies, I included patients described in section 4.1, with follow-up for each patient including
all valid time from 1 January 1995 to 31 December 2011. Outcome was time from the ﬁrst year of eligible data
to ﬁrst CVD event and I censored patients if a CVD event did not occur before 31 December 2011. I included
patients registered with the practice for at least two years and excluded patients if a CVD event occurred before
the ﬁrst year of patients follow-up.0.511.52N of events per 1000 patients registered0510152025Months since registration
Figure 6.1: Association between number of cardiovascular disease events and the time from registration to ﬁrst
cardiovascular disease event.
I analyse only incident (i.e. new) cases of CVD so, to identify (for subsequent exclusion) likely prevalent (patients
with a current rather than new CVD diagnosis) cases, I calculated the time from registration to ﬁrst CVD event
for patients registered during the follow-up period (Figure 6.1). The CVD events peaked at registration, dropped
following registration and levelled out after ﬁve months. For prevalent CVD cases, the diagnosis was entered onto
the patient record when the patient registered with the practice and it appears the patient was diagnosed during or
shortly after registration. I excluded patients with a diagnosis of CVD within ﬁve months of registration from the
analysis because it is likely this peak was due to prevalent CVD[99].
Out of 553 practices, I excluded nine practices because at least one health indicator measurement was missing for
more than 95% of patients for most calendar years, or more than 95% of patients were missing more than 95% of
measurements for all health indicators for at least three consecutive calendar years.
6.1.1.1 Model of interest
I used an exponential survival model as my model of interest (because I investigated time to an event), to ﬁnd the
association between time from registration to ﬁrst CVD event and health indicators recorded at baseline, deﬁned
as the ﬁrst year of analysis (i.e. the ﬁrst year of patient data included in the analysis). When a dataset consists of a
large number of patients followed-up over a longer time period, an exponential survival model may be preferable
to a Cox model because the assumption of a constant hazard over a longer time period may be violated. The116 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
model comprised of the following variables:
1. Complete variables:
 Fatal or non-fatal CVD event – either coronary heart disease (Read code list given in Appendix I) or
stroke (using QOF Read code list in Appendix B);
 Time from the end of baseline to the ﬁrst CVD event;
 Age at baseline;
 Sex;
 Townsend deprivation score quintile - measure of deprivation from 1 (least deprived) to 5 (most de-
prived).
2. Variables with missing values:
 BMI - calculated from height and weight (kgm 2);
 Systolic blood pressure (mmHg);
 Total cholesterol (mmol l 1);
 High-density lipoprotein (HDL) cholesterol (mmol l 1); and
 Smoking status (current smoker, ex-smoker and non-smoker).
For each calendar year, measurements for each health indicator were extracted. If more than one measurement
was recorded during a calendar year, one of the measurements was selected at random for analysis, instead of
using the mean of all measurements, to avoid artiﬁcially reducing the variability of the data. However, if more
than one measurement for smoking status was recorded, the highest risk category was selected (i.e. smokers over
ex-smokers) because the risk of CVD during the study duration was likely to remain as high for patients who stop
smoking as for those who continue smoking.
I did not include a term for practice in the model of interest as a ﬁxed or random effect because the MI did not
converge due to many practices included in the analysis with practice as a ﬁxed effect and currently the two-fold
FCS algorithm cannot impute to allow for a random effect. However, I ﬁtted the exponential survival model with
robust standard errors which adjusts the SEs to take account of dependence between many patients in the same
practice.
6.1.1.2 Analysis
Initially, I ﬁtted the exponential survival model to the observed data at baseline to perform a complete records
analysis. Next, I imputed the data by practice and sex stratum using baseline imputation and the two-fold FCS
algorithm in each strata separately to allow for possible practice and sex interactions. I imputed missing values at
baseline using 5 imputations conditional only on other explanatory variables included in the exponential survival
model recorded at baseline and outcome (as CVD event indicator and time-to-event variable) called baseline6.1. Imputing missing data in THIN 117
multiple imputation (MI). Finally, I imputed longitudinally using the two-fold FCS algorithm for all eligible
practices with ﬁve imputations, 20 among-time iterations, ﬁve within-time iterations and one year window width,
conditional on explanatory variables from the model of interest. I also considered including the auxiliary variables
listed below, recorded at baseline when included in baseline MI and recorded at each time point when included in
the two-fold FCS algorithm:
1. I used QOF Read code lists to identify patients with the following diseases, recorded at any time in the
patient record. In section 4.3, I found patients with a diagnosis of these diseases had health indicators
recorded more frequently:
 Diabetes (Appendix C);
 Chronic obstructive pulmonary disease (COPD, Appendix D);
 Schizophrenia, bipolar disorder and other psychoses (psychoses, Appendix K);
 Asthma (Appendix L);
 Chronic kidney disease (CKD, Appendix M); and
 Atrial ﬁbrillation (AF, Appendix N).
2. Patients prescribed following drugs were identiﬁed:
 Anti-hypertensive drug treatment - patients received anti-hypertensive drug treatment during a given
yearifprescribedtwo-ormoreofthefollowingdrugsduringthatyear; angiotensin-converting-enzyme
(ACE) inhibitors, angiotensin receptor blocker (ARB)-2, thiazide and related diuretics, calcium-
channel blockers or beta-adrenoceptor blocking drugs.
 Lipid-modifying drugs - patients received lipid-modifying drugs each calendar year if at least one of
the following lipid-regulating drugs was prescribed no more than six months before the total choles-
terol measurement in that year; statins, bile acid sequestrants, ezetimibe, ﬁbrate, nicotinic acid or
omega 3 polyunsaturated fatty acid ethyl esters.
3. Other auxiliary variables:
 Respiratory infection – each calendar year, patients had a respiratory infection if at least one Read
code from the section of acute respiratory infections was recorded (Appendix O).
 Alcohol consumption - current heavy drinker if the following was recorded at any time in the patient
record: male patients consume more than 5 units of alcohol per day; female patients consume more
than 4 units of alcohol per day or at least one Read code which indicated the patient was a heavy
drinker (Appendix P).
 Censored due to non-CVD death – censored patients either transferred out of the practice or died. I
created an indicator to identify censored patients who died from non-CVD death.
As explained in section 3.3.6, to obtain more precise estimates I also included auxiliary variables in the imputa-
tion models. Therefore, I investigated the auxiliary variables listed above for associations with the value of the118 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
variables with missing data or the probability the value is missing. Before MI, I performed a regression analysis
for each health indicator measured at baseline to ﬁnd which auxiliary variables were associated with the value
of the missing health indicators at baseline and a logistic regression analysis for each health indicator to ﬁnd
which auxiliary variables were associated with the probability of the health indicator being missing at baseline.
I considered the association signiﬁcant if p-value<0.100 because the auxiliary variables with a weak association
can still inﬂuence the imputation as well as those variables with a strong association. If these variables were also
associated with the probability of the value being missing, including them in the imputation model will increase
the MAR assumption plausibility.
I investigated the distributions of the continuous variables in the model of interest and found skewed total choles-
terol and HDL cholesterol distributions, so I also entered logged values of total cholesterol and HDL cholesterol
in the imputation model.
I also extracted data recorded in the 365 days before the ﬁrst date patients were included in the analysis to inform
imputation of missing values using the two-fold FCS algorithm in the ﬁrst year of follow-up. In some cases,
usually when the baseline year is the year the patients registered with the practice, the two-fold FCS algorithm did
not converge because of high proportions of missing data in the year before the ﬁrst date. When this happened, I
re-ﬁtted the imputation model without conditioning on the year before the ﬁrst date.
Initially, to investigate the computational issues which arose when imputing real data, I imputed missing data
using the two-fold FCS algorithm in all practice and sex strata using one imputation, one among-time iteration
and one within-time iteration. For any strata that did not converge, I investigated the reasons for non-convergence.
6.1.1.3 Sensitivity analysis
Morris et al.[56] recommend imputing logged values of variables included as ratios in the model of interest.
Therefore, I repeated the imputation using logged values of height and weight.
6.1.2 Results
In total, 498 practices out of 553 met the inclusion criteria. From investigating potential computational issues,
using the two-fold FCS algorithm with one imputation, one among-time iteration and one within-time iteration, I
found ten practices had insufﬁcient data recorded in all years and the two-fold FCS algorithm did not converge. I
excluded these practices from further analysis.
For 280 practices, some years at the beginning and end of follow-up had insufﬁcient data recorded and the two-
fold FCS algorithm did not converge when imputing missing values in these years. Therefore, I changed the start
and/or end years for these practices to exclude the years with insufﬁcient data recorded, changing the length of
follow-up (Table 6.1). Some of these practices had different ﬁrst/last years for male and female patients because
I investigated them separately.6.1. Imputing missing data in THIN 119
Table 6.1: Distribution of years of follow-up for the 488 practices before and after excluding years with insufﬁ-
cient data recorded.
Number of years of All patients, After exclusions, n (%)
follow-up before exclusions, n (%) Male patients Female patients
3 6 (1.2) 9 (1.8) 9 (1.8)
4 10 (2.1) 15 (3.1) 15 (3.1)
5 12 (2.5) 15 (3.1) 14 (2.9)
6 12 (2.5) 16 (3.3) 19 (3.9)
7 21 (4.3) 30 (6.2) 31 (6.4)
8 35 (7.2) 49 (10.0) 52 (10.7)
9 51 (10.5) 82 (16.8) 77 (15.8)
10 43 (8.8) 70 (14.3) 69 (14.1)
11 49 (10.0) 73 (15.0) 75 (15.4)
12 49 (10.0) 64 (13.1) 61 (12.5)
13 51 (10.5) 29 (5.9) 28 (5.7)
14 28 (5.7) 18 (3.7) 19 (3.9)
15 25 (5.1) 5 (1.0) 6 (1.2)
16 19 (3.9) 2 (0.4) 2 (0.4)
17 77 (15.8) 11 (2.3) 11 (2.3)
Total practice years of follow-up 5,676 4,792 4,783
After I applied these exclusions, 2,772,502 patients (1,347,844 men and 1,424,658 women) remained in the
analysis, aged between 30 and 99 years at the baseline year. 50,774 (3.8%) men and 41,836 (2.9%) women had
a CVD event during follow-up. Only 45,998 (3.4%) men and 47,371 (3.3%) women had complete records in the
baseline year of weight, height, systolic blood pressure, total and HDL cholesterol and smoking status.
From investigating the association between auxiliary variables and missing health indicator or the values them-
selves at baseline, I found all the variables were associated with the value of at least one health indicator (Tables
6.2 and 6.3). Therefore, I included all auxiliary variables in the baseline MI model and the two-fold FCS algo-
rithm.
In total, 93,369 patients were included in the complete records analysis, which showed CVD risk was greatest
for older, male and more deprived patients with higher blood pressure, higher total cholesterol and lower HDL
cholesterol. A CVD event was more likely if patients were ex-smokers compared to non-smokers and most likely
for current smokers compared to non or ex-smokers (Table 6.4).
Data imputed using baseline MI or two-fold FCS algorithm included 2,772,502 patients. The analysis from
ﬁtting the model of interest to the data imputed using baseline MI or the two-fold FCS algorithm found the
coefﬁcients for the fully observed variables age, sex and Townsend score quintile were more extreme compared
to complete records analysis, suggesting a stronger association between them and CVD risk. The standard errors
from analysing data imputed using baseline imputation were all smaller compared to complete records analysis,
so these estimates were more precise. This is expected for the fully observed variables because the number of
patients included in the analysis increased following imputation compared to the complete records analysis, i.e.
more statistical power. From ﬁtting the model of interest to the data imputed using the two-fold FCS algorithm,120 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
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coefﬁcients and standard errors of complete variables were similar to the baseline MI (Table 6.4).
BMI was the only variable with missing values which changed from non-signiﬁcant for the complete records
analysis and analysing data imputed using baseline MI to statistically signiﬁcant when analysing data imputed
using the two-fold FCS algorithm (Table 6.4).
The systolic blood pressure coefﬁcients and standard errors were similar from ﬁtting the model of interest to the
data imputed using baseline MI or two-fold FCS algorithm. For total cholesterol, HDL cholesterol and smoking
status, the standard errors were smaller from ﬁtting the model of interest to the data imputed using the two-fold
FCS algorithm compared to baseline MI, giving the most precise estimates for these variables (Table 6.4).
The complete records analysis found the strongest association between HDL cholesterol and CVD events. This
association was weaker when analysing data imputed using baseline MI, and weaker again when analysing data
imputed using the two-fold FCS algorithm (although all statistically signiﬁcant), and the HDL cholesterol IRR
from the complete records analysis was outside the HDL cholesterol 95% CI from analysing data imputed using
the baseline MI or the two-fold FCS algorithm.
6.1.2.1 Sensitivity analysis
Finally, when I repeated the analysis entering logged values of height, weight, total cholesterol and HDL choles-
terol in the imputation model, I found the baseline MI imputed some very extreme values and ﬁtting the model of
interest to the imputed data all coefﬁcients were highly signiﬁcant. I imputed data stratiﬁed by practice and sex,
and the observed values within some of the strata did not require transformations, so using the transformation
possibly introduced bias into the results because the variable became non-normally distributed. However, I do
not expect this biased the results found imputing un-logged values of height, weight total cholesterol and HDL
cholesterol because I did not include the ratio of cholesterol measurements in the model of interest and Morris et
al.[56] showed entering height and weight into the imputation model still achieved accurate estimates for BMI.
For accurate imputations, Morris et al. recommended logging total cholesterol and HDL cholesterol if analysing
the ratio of total cholesterol measurements because the denominator (HDL cholesterol) values become very close
to zero, which may result in imputing values below zero if un-logged.6.1. Imputing missing data in THIN 123
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6.1.3 Discussion
From the full data, the complete records analysis found older, male and more deprived patients with higher blood
pressure, higher total cholesterol and lower HDL cholesterol and either ex-smokers or current smokers were
associated with increased CVD events. Following imputation using the two-fold FCS algorithm, higher BMI
was also associated with increased CVD risk. In chapter 5 I showed the two-fold FCS algorithm worked reliably
in this setting and, in this section, I successfully used it to impute for the whole of THIN and applied a CVD
risk model to the imputed data. I also found that, as in chapter 5, the two-fold FCS algorithm successfully used
longitudinal data to recover information on sparsely observed variables.
These results showed time-dependent variables had smaller SEs from analysing data imputed using the two-fold
FCS algorithm compared to complete case analysis and analysing data imputed using baseline MI. The estimates
themselves following imputation using the two-fold FCS algorithm were either similar or slightly stronger asso-
ciation (more precise) than estimates following baseline MI, which agrees with the ﬁndings from the simulation
studies in chapter 5.
I compared the imputed coefﬁcients to those from other studies, but only broad comparisons were appropriate
because the models were probably adjusted differently. These studies ﬁtted Cox proportional hazards models,
rather than exponential survival models, so reported hazard ratios (HRs) instead of IRR. Even though the under-
lying model assumptions were different, the coefﬁcients are comparable because they both measure association
with time to an event.
QRISK2[10] is a widely used CVD risk prediction model developed using the UK primary care database
QRESEARCH[25]. QRISK2 found an association between BMI and CVD of HR 1.17 (95% CI 1.21 - 1.12) for
women and 1.19 (95% CI 1.23 - 1.14) for men, both for a 10kg m 2 increase in BMI. A meta analysis found a
similar association between BMI and CVD of HR 1.16 (95% CI 1.07 - 1.26) for a 10kg m 2 increase in BMI[84].
The IRR I found from data imputed using two-fold FCS algorithm of 1.08 (95% CI 1.05 - 1.12) was similar to
the IRR from analysing data imputed using baseline MI of 0.99 (95% CI 0.96 - 1.02), for a 10kg m 2 increase in
BMI, but the IRR from data imputed using the two-fold FCS algorithm was statistically signiﬁcant and closer to
the HR found from other studies compared to the IRR from analysing data imputed using baseline MI.
QRISK2 found an association between systolic blood pressure and CVD of HR 1.10 (95% CI 1.10 - 1.09) for
women and 1.09 (95% CI 1.10 - 1.08) for men, both for a 10mmHg increase in systolic blood pressure, which
were similar to the IRR I found from analysing data imputed using baseline MI 1.07 (95% CI 1.07 - 1.07) and
from data imputed using the two-fold FCS algorithm of 1.07 (95% CI 1.06 - 1.07) for a 10mmHg increase in
systolic blood pressure. However, another study study reported larger (1.20 to 1.67) HR per 10mmHg increase in
systolic blood pressure (across different ages and different cardiovascular diseases[100]) compared to this study
and QRISK2.6.1. Imputing missing data in THIN 125
HRs per mmol l 1 varied from 1.18 to 2.27 for the association between CHD risk and total cholesterol (across
different age groups[101]) which had a stronger association compared to the IRRs found for the association
between total cholesterol and CVD risk from analysing data imputed using baseline MI of 1.06 (95% CI 1.05 -
1.08) and data imputed using the two-fold FCS algorithm of 1.06 (95% CI 1.05 - 1.07). Finally, HRs per mmol
l 1 were 0.53 (95% CI 0.46 - 0.60) for the association between CHD risk and HDL cholesterol (across different
age groups[102]) which had a stronger association compared to the IRRs found for the association between total
cholesterol and CVD risk from analysing data imputed using baseline MI of 0.75 (95% CI 0.72 - 0.79) and data
imputed using the two-fold FCS algorithm of 0.79 (95% CI 0.77 - 0.82).
Therefore, from investigating other studies, we might expect stronger association between BMI, systolic blood
pressure, total cholesterol and HDL cholesterol and CVD compared to those found in this section, but they were
close and in the same direction. I could not compare total cholesterol and HDL cholesterol results to QRISK2
because they reported the ratio of total cholesterol to HDL cholesterol. The ultimate test would be to compare
the discrimination and calibration for the model of interest to other CVD risk prediction models. However, this is
beyond the scope of work for this thesis, but could be considered in future work.
6.1.4 Summary
In this section, I investigated imputing missing THIN data using the two-fold FCS algorithm. However, usually
epidemiological studies using electronic health records do not analyse the whole database. Therefore, in the next
section, I describe a epidemiological study using THIN which analyses patients with type 2 diabetes in THIN.
Again, the analysis includes variables with missing values, so I investigate using different imputation methods
including two-fold FCS imputation.126 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
6.2 Total cholesterol reduction after initiating statin treatment for pa-
tients diagnosed with type 2 diabetes
The aim of this epidemiological study is to determine the characteristics of patients with type 2 diabetes who
had a greater than average total cholesterol reduction after initiating statin treatment. To achieve this, I inves-
tigate different imputation methods to impute missing health indicator values. I impute missing values using
the two-fold fully conditional speciﬁcation (FCS) algorithm and compare this method to alternative approaches,
complete records analysis and applying multiple imputation to impute missing values 6 months before initiating
statin treatment, to determine if the two-fold FCS algorithm is the preferred method for handling missing data in
this context. This study received approval from the THIN Scientiﬁc Review Committee (Appendix Q).
6.2.1 Introduction and clinical motivation
Patients diagnosed with type 2 diabetes are at high risk of developing cardiovascular disease (CVD)[103]. To
reduce CVD risk, the National Institute for Health Care Excellence (NICE) recommends prescribing statins to all
patients diagnosed with diabetes to control lipids and CVD risk[103]. However, a recent review suggests initiating
statin therapy in patients with diabetes and atherogenic dyslipidaemia did not effectively reduce total cholesterol
and subsequent CVD risk[104]. Atherogenic dyslipidaemia is a blood fat disorder which commonly occurs in
patients with type II diabetes, causing artery walls to thicken and characterised by low levels of high-density
lipoprotein (HDL) cholesterol, high triglycerides and high low-density lipoprotein (LDL) cholesterol, resulting
in high total cholesterol.
In this study, I identify the characteristics of patients with type 2 diabetes and greater total cholesterol reduction
after initiating statin treatment to discover if statins effectively reduce total cholesterol in patients with type II
diabetes and if the associations found support the NICE guidance or the review. Clinicians can use these results
as guidance to identify the patients with type II diabetes most likely to respond to statin treatment i.e. the greatest
total cholesterol reduction.
I investigated GP records of patients with type 2 diabetes who initiated statin treatment to examine the association
between sociodemographic variables and health indicators measured before initiating statin treatment and the
greater total cholesterol reduction from before initiating statin treatment to within the ﬁrst 6 months after ﬁrst
statin treatment. In particular, I explored if patients with type 2 diabetes and lipid measurements which indicate
artherogenic dyslipidaemia before initiating statin treatment had smallest total cholesterol reduction. Many stud-
ies used CVD events to assess the performance of statins. However, CVD events may not occur for some time,
if at all, during the study period. Therefore, as total cholesterol is an independent predictor for CVD, it may
act as a surrogate measure for CVD risk if we assume a patients CVD risk reduces if total cholesterol reduces.
Another advantage is the study should have more power when analysing a continuous outcome. I was interested
in analysing LDL cholesterol levels because (out of the lipid measurements) LDL cholesterol is the strongest
risk factor for CVD[104], but an exploratory analysis of recording in the 15 month period before initiating6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 127
statin treatment found 35% of patients missing LDL cholesterol measurements and 4% of patients missing total
cholesterol measurements. Therefore, I chose to analyse total cholesterol instead of LDL cholesterol, not only
because of the improved recording but also because one of the components used to calculate total cholesterol is
LDL cholesterol[106], so I expect to ﬁnd similar results.
The Quality Outcomes Framework (QOF)[107] was introduced in 2004 to encourage GPs to regularly record
health indicators for people with chronic diseases like diabetes, discussed in section 3.1.4. Health indicators
associated with increased risk of the QOF speciﬁed diseases were more frequently recorded following the in-
troduction of QOF[8, 13]. For example, GPs recorded body mass index (BMI), smoking status, glycosylated
haemoglobin (HbA1c), blood pressure and total cholesterol measurements for patients diagnosed with type 1
or type 2 diabetes, as shown in section 4.3 (except for HbA1c). Therefore, I restricted the analysis to after the
introduction of QOF. Also, NICE identiﬁes the following health indicators associated with CVD risk in patients
diagnosed with diabetes: overweight, high blood pressure, high serum albumin, smoking and high-risk lipid
proﬁle (low HDL cholesterol and high LDL cholesterol)[103].
I investigated different methods for handling missing data. First, I performed a complete records analysis and
then I investigated three different approaches of imputing using multiple imputation (MI), described below, and
compared to the results of analysis using each imputed data to each other, and the complete records analysis, to
determine if the two-fold FCS algorithm is an appropriate imputation methods in this context.
 Impute missing values in the 6 months before initiating statin treatment conditional only on other measure-
ments recorded in the 6 months before initiating statin treatment;
 Impute missing values in the 6 months before initiating statin treatment using the two-fold FCS algorithm
conditional on measurements recorded every 6 month time block before initiating statin treatment; and
 Impute missing values in the 6 months before initiating statin treatment using the two-fold FCS algorithm
conditional on measurements recorded every 6 month time block before and after the 6 months before
initiating statin treatment.
6.2.2 Methods
6.2.2.1 Study population
For this study, in addition to the criteria to select patients from The Health Improvement Network (THIN) de-
scribed in section 4.1, I included patients:
1. diagnosed with type 2 diabetes. This included patients with at least one of the following:
 a type 2 diabetes Read code in the patient record. I assumed patients with non-speciﬁc diabetes were
type 2 diabetes and included them in the analysis;
 an additional health data (AHD) code for annual diabetes check, current diabetes status or insulin
dosage;128 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
 the data type of diabetic register, diabetic consultation or diabetes concerns; or
 prescribed type 2 diabetes speciﬁc medication.
2. with no previous CVD event before initiating statin treatment; and
3. permanently registered with the practice at some time from 1 January 2004 to 31 December 2012.
I included patients aged 30 years or over when they enter the study (study start date), which occurs at the latest
date of (i) ﬁrst type 2 diabetes diagnosis; (ii) ACU date; (iii) AMR date; (iv) when the patient registered with the
practice or (v) 1 January 2004. After the start date, the patient initiated statin treatment when ﬁrst prescribed one
of the statin drug codes from the relevant BNF chapter. I included patients with at least two statin prescriptions
within the ﬁrst 6 month after initiating statin treatment because receiving repeated statin prescriptions suggests
these patients adhered to statin treatment. I included patient measurements in the analysis up until the earliest
date of (i) death; (ii) when the patient transferred out of the practice; (iii) the last date the practice contributes
data to THIN or (iv) 31 December 2012. I excluded patients if the time between ﬁrst statin prescription and last
date was less than 6 months.
To exclude prevalent cases, I excluded patients prescribed statins before or within 6 months of the study start date.
6.2.2.2 Study variables
I analysed following explanatory variables measured within 6 months before initiating statin treatment, called
‘baseline’:
 Sociodemographic: age at ﬁrst statin prescription, sex, deprivation (quintiles of Townsend deprivation
scores) and ethnicity (white, black, South Asian or other).
 Health indicators: body mass index (BMI), systolic blood pressure, total cholesterol, HDL cholesterol,
LDL cholesterol, glycosylated haemoglobin (HbA1c), glomerular ﬁltration rate (GFR) and smoking status.
 Statin therapy: statin type and dose. I created categories using simvastatin dose and found equivalent doses
for statins other than simvastatin[108].
 Other variables: Calendar year of ﬁrst statin prescription and time from diagnosis of diabetes to ﬁrst statin
prescription.
Atherogenic dyslipidaemia is characterised by low HDL cholesterol and high LDL cholesterol so it was accounted
for in the analysis by adjusting for HDL cholesterol and LDL cholesterol. Also, I did not adjust for baseline total
cholesterol because I used baseline total cholesterol to calculate the outcome.
Typically, for most continuous health indicators, a low value indicates good health. However, for HDL cholesterol
and GFR, a high value indicates good health. If more than one measurement was recorded at baseline, I included
the measurement closest to initiating statin treatment in the analysis. When the data were extracted, I identiﬁed
and excluded outliers using the method described previously in section 4.4[4].6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 129
6.2.2.3 Analysis
To model total cholesterol reduction after initiating statin treatment, I calculated the difference between the total
cholesterol measurements recorded at baseline and within the ﬁrst 6 months after initiating statin treatment. I
investigated if this difference was normally distributed and produced a summary of the mean total cholesterol
at baseline and the mean total cholesterol reduction, stratiﬁed by the baseline characteristics described above. I
explored the proportions of missing data at baseline and in each 6 month time block before and after baseline.
I analysed the observed data (Figure 6.2, part 1) using a linear model of interest where the outcome was the
difference between total cholesterol measurements recorded at baseline and within the ﬁrst 6 months after ﬁrst
statin prescription.
Before imputation, I evaluated the plausibility of the MAR assumption to assess if MI was appropriate. In
section 3.3.6, I explained that auxiliary variables associated with the health indicator being missing increase the
plausibility of the MAR assumption when included in the imputation model, but only inﬂuences the imputed
values if also associated with the value of the health indicator with missing data. For example, when investigating
auxiliary variables to impute missing values for weight, if an auxiliary variable, say asthma, is associated with the
weight values I include it in the imputation model to impute missing weight values, regardless of its associated
with weight values being missing, increasing efﬁciency. However, if it is also associated with weight values being
missing, imputing missing weight values conditional on asthma increases the MAR assumption plausibility and,
hence, reduce bias.
To investigate the association between auxiliary variables and the values of the variables with missing values, I
ﬁtted regression models with each variable with missing values as the predictor. I also ﬁtted logistic regression
models for each variable with missing data, with the predictor indicating when variable with missing data was
missing. These regression analyses conditioned on all variables in the linear model of interest, including the out-
come, and all auxiliary variables. I included auxiliary variables in the imputation model if they were associated
with the value of the health indicator with missing values with p-value<0.100 because the auxiliary variables
with a weak association can still inﬂuence the imputation as well as those variables with a strong association.
If the distribution of the continuous variables with missing data was skewed, I transformed the data before
imputation[47]. Next, I imputed missing values at baseline using fully conditional speciﬁcation (FCS)[21] MI,
described in section 3.3.4 (Figure 6.2, part 2). In addition to the variables measured at baseline in the model of
interest (including the outcome variable), I included the following auxiliary variables in the imputation model if
associated with the value of the variable with missing data:
1. Patients diagnosed the following before initiating statin treatment, identiﬁed using QOF Read code lists:
chronic kidney disease (CKD, Appendix M); chronic obstructive pulmonary disease (COPD, Appendix D);
schizophrenia, bipolar disorder and other psychoses (psychoses, Appendix K); asthma (Appendix L); and
atrial ﬁbrillation (AF, Appendix N). I assumed patients without a Read code did not have the disease.130 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
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Figure 6.2: Figure to illustrate different imputation methods
2. Patients prescribed following drugs during baseline:
 Anti-hypertensive drug treatment.
 Other lipid-modifying drugs bile acid sequestrants; ezetimibe; ﬁbrate and omega 3 polyunsaturated
fatty acid ethyl esters. I excluded nicotinic acid from the imputation model for the binary model
because patients included in the analysis only had a few prescriptions of nicotinc acid.
3. Respiratory infection during the baseline period (Read code list in Appendix O).
4. Recognised alcohol problem (i.e. current heavy drinker) – the following was recorded at any time in the
patient record: male patient consumed more than 5 units of alcohol per day; female patient consumed more
than 4 units of alcohol per day or at least one Read code which indicated the patient was a heavy drinker
(Appendix P).
5. Death - patients died at the end of follow-up.
6. CVD event - I identiﬁed patients with a CVD event at any time after the ﬁrst statin prescription (separate
indicators for CHD and stroke) using Read code lists (Appendix I and Appendix B).6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 131
I did not include a variable measuring the time to death or CVD event because the models of interest were not
survival models.
I also imputed missing values at baseline again using the two-fold fully conditional speciﬁcation (FCS)[1] al-
gorithm, but now conditional on heath indicators recorded before baseline (Figure 6.2, part 3). The time before
baseline was divided into 6 month time blocks. I excluded the earliest time block if it was less than 6 months and
included up to 4 time blocks before baseline. If health indicators were recorded more than once during each time
block before baseline, I selected a measurement at random to include in the analysis, except smoking status. If
smoking status was recorded more than once, I selected the most frequently occurring category. In addition to the
sociodemographic variables, health indicators (measured during each time block) and outcome from the model
of interest. I also included the following auxiliary variables (described above): diseases diagnosed before ﬁrst
statin prescription, recognised alcohol problem, death and CVD event. Additionally, I included in the imputation
model anti-hypertensive drug treatment, other lipid-modifying drugs and respiratory infection recorded at each
time block.
Initially, I was going to condition on smoking status at each time point when using the two-fold FCS algorithm,
but there were not enough observed smoking status records at these time blocks and not enough patients with
each smoking status category recorded so perfect prediction errors occurred. Therefore, I condition on smoking
status at baseline only in the imputation model.
Next, I imputed missing values at baseline this time using the two-fold FCS algorithm, conditional on heath
indicators recorded before and after baseline (Figure 6.2, part 4). The time before and after baseline was divided
into 6 month time blocks, excluding the earliest or latest time block if it was less than 6 months, and selected
measurements during each time block using the method described earlier. I included up to 4 time blocks before
and after baseline. I investigated imputing using the two-fold FCS algorithm conditional on health indicators
recorded before and after baseline to determine if the additional information recorded after initiating statin treat-
ment included in the imputation model would affect the analysis of the imputed data. Patients who initiate statin
treatment may have more information recorded after they initiate statin treatment because they were monitored
by the GP, including the same auxiliary variables as before.
Each imputation approach generated 5 imputed datasets. The two-fold FCS algorithm used 5 within-time itera-
tions and 20 among-time iterations. After each imputation, I analysed the imputed data as follows for the linear
model of interest and compared to the results from the complete records analysis and the results of analysis using
the data imputed with different MI approaches:
 ﬁtted unadjusted models for each variable in the model of interest;
 adjusted models for each variable in the model of interest adjusted for age, sex and ethnicity; and
 the fully adjusted model of interest.132 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
Finally, I used a maximum likelihood, a numerical method which appropriately incorporates missing data by
ﬁnding the parameter values which make the likelihood function as large as possible. I compared these results
with the results of analysis using data imputed with MI to investigate if they agree. I used structural equation
modelling with full-information maximum likelihood (FIML) to obtain full dataset estimates[44], as described in
section 3.2.3.1. FIML obtains estimates and standard errors by directly maximizing the likelihood for the spec-
iﬁed model so I could compare them to the estimates and standard errors obtained from the results of analysing
data imputed using MI. Using structural equation modelling allowed me to include the same auxiliary variables
as the imputation model.
I found estimates and standard errors for the association between explanatory variables in the model of interest
(ﬁtted to measurements recorded at baseline) with the difference between total cholesterol measurements recorded
at baseline and within the ﬁrst 6 months following ﬁrst statin prescription.6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 133
6.2.3 Results
I identiﬁed 35,621 patients with type II diabetes; 21,242 (60.0%) had a total cholesterol measurement recorded
6 months before the ﬁrst statin treatment (baseline) and 6 months after ﬁrst statin treatment. After I excluded 5
additional patients because the type of statin prescribed was missing, 21,237 patients remained in the analysis.
The distribution of the difference between the total cholesterol measurements at baseline and the ﬁrst 6 months
following ﬁrst statin treatment was normally distributed (Figure 6.3).0246810121416Percent-7-6-5-4-3-2-1012345 Outcome (cholesterol after statins - cholesterol before statins
Figure 6.3: Histogram of total cholesterol difference between measures recorded 6 months before ﬁrst statin
treatment and 6 months after ﬁrst statin treatment
I investigated the percentage of missing values at baseline and each 6 month time blocks before and after baseline
for each health indicator with missing values. I found the percentage of missing values varied from 6.5% to 53%
at baseline, but more than 85% of health indicators were missing at other time blocks (Table 6.5).
Table 6.5: Percentage missing health indicators at baseline (6 months before initiating statin treatment) and each
6 month time block before (negative values) and after (positive values) baseline
Time Weight Systolic blood HDL LDL GFR HbA1c Smoking
block pressure cholesterol cholesterol status
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
-4 20,783 (97.9) 20,770 (97.8) 20,881 (98.3) 20,921 (98.5) 21,008 (98.9) 20,872 (98.3) 20,969 (98.7)
-3 20,601 (97.0) 20,564 (96.8) 20,817 (98.0) 20,810 (98.0) 20,943 (98.6) 20,732 (97.6) 20,880 (98.3)
-2 20,085 (94.6) 20,216 (95.2) 20,406 (96.1) 20,503 (96.5) 20,694 (97.4) 20,364 (95.9) 20,501 (96.5)
-1 19,668 (92.6) 19,590 (92.2) 20,207 (95.1) 20,325 (95.7) 20,444 (96.3) 20,014 (94.2) 20,249 (95.3)
Baseline 3,969 (18.7) 1,382 (6.5) 4,109 (19.3) 8,158 (38.4) 11,382 (53.6) 1,687 (7.9) 3,077 (14.5)
1 19,630 (92.4) 19,462 (91.6) 18,330 (86.3) 18,660 (87.9) 19,732 (92.9) 19,418 (91.4) 20,290 (95.5)
2 19,585 (92.2) 19,465 (91.7) 19,775 (93.1) 19,940 (93.9) 19,852 (93.5) 19,753 (93.0) 20,285 (95.5)
3 19,812 (93.3) 19,789 (93.2) 19,913 (93.8) 20,081 (94.6) 19,839 (93.4) 19,805 (93.3) 20,279 (95.5)
4 19,917 (93.8) 19,947 (93.9) 20,048 (94.4) 20,141 (94.8) 19,741 (93.0) 19,954 (94.0) 20,372 (95.9)
HDL: high-density lipoprotein; LDL: low-density ; HbA1c: glycosylated haemoglobin; GFR:glomerular ﬁltration
rate134 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
6.2.3.1 Descriptive analysis of total cholesterol reduction between before initiating statin
treatment and in the ﬁrst six months after ﬁrst statin treatment
Patients at different ages had similar mean total cholesterol values at baseline but older patients had a greater
total cholesterol reduction following ﬁrst statin treatment (Table 6.6). Female patients started with higher total
cholesterol and it reduced more after ﬁrst statin treatment compared to male patients. I observed similar total
cholesterol mean and reduction between the Townsend deprivation score quintiles. Mean total cholesterol was
similar for each ethnicity at baseline, but patients of white ethnicity had greater total cholesterol reduction and
patients of black ethnicity the smallest (Table 6.6).
Table 6.6: Mean total cholesterol at baseline (6 months before ﬁrst statin
treatment) and mean total cholesterol reduction between baseline and the
ﬁrst 6 months after ﬁrst statin treatment by each baseline characteristic
Baseline N (%) Mean total Mean total
characteristic cholesterol at cholesterol reduction
baseline (95% CI) (95% CI)
Total 21,237 (100.0) 5.60 (5.59, 5.61) 1.53 (1.54, 1.52)
Age (years) at 30 and <40 1,118 (5.3) 5.79 (5.73, 5.84) 1.43 (1.37, 1.49)
ﬁrst statin 40 and <50 3,579 (16.9) 5.67 (5.64, 5.70) 1.45 (1.42, 1.48)
prescription 50 and <60 5,223 (24.6) 5.65 (5.62, 5.67) 1.48 (1.46, 1.51)
60 and <70 5,553 (26.1) 5.54 (5.52, 5.57) 1.56 (1.53, 1.58)
70 and <80 4,178 (19.7) 5.48 (5.46, 5.51) 1.60 (1.57, 1.62)
80 1,586 (7.5) 5.65 (5.60, 5.69) 1.65 (1.61, 1.69)
Sex Male 11,307 (53.2) 5.44 (5.43, 5.46) 1.50 (1.48, 1.51)
Female 9,930 (46.8) 5.77 (5.76, 5.79) 1.57 (1.55, 1.59)
Townsend 1 (least) 5,044 (23.8) 5.59 (5.56, 5.61) 1.54 (1.52, 1.56)
deprivation 2 4,597 (21.6) 5.59 (5.57, 5.62) 1.56 (1.53, 1.58)
score 3 4,618 (21.7) 5.62 (5.59, 5.65) 1.53 (1.50, 1.55)
quintile 4 4,192 (19.7) 5.59 (5.57, 5.62) 1.52 (1.50, 1.55)
5 (most) 2,786 (13.1) 5.60 (5.56, 5.63) 1.47 (1.44, 1.51)
Ethnicity White 20,340 (95.8) 5.60 (5.59, 5.61) 1.53 (1.52, 1.55)
Black 244 (1.1) 5.47 (5.36, 5.57) 1.25 (1.13, 1.37)
South Asian 420 (2.0) 5.49 (5.41, 5.57) 1.43 (1.34, 1.52)
Other 233 (1.1) 5.62 (5.51, 5.74) 1.54 (1.42, 1.66)
BMI (kg m 2) Underweight 60 (0.3) 5.53 (5.30, 5.75) 1.37 (1.17, 1.57)
Normal 2,585 (12.2) 5.52 (5.49, 5.56) 1.46 (1.43, 1.50)
Overweight 6,075 (28.6) 5.56 (5.54, 5.58) 1.54 (1.52, 1.57)
Obese 8,517 (40.1) 5.58 (5.56, 5.60) 1.53 (1.51, 1.55)
Missing 4,000 (18.8) - -
Systolic blood 0 and <120 1,809 (8.5) 5.52 (5.48, 5.57) 1.47 (1.43, 1.52)
pressure (mmHg) 120 and <130 3,343 (15.7) 5.53 (5.50, 5.56) 1.46 (1.43, 1.49)
130 and <140 4,959 (23.4) 5.55 (5.53, 5.58) 1.52 (1.49, 1.54)
140 and <150 4,752 (22.4) 5.58 (5.55, 5.60) 1.54 (1.51, 1.56)
150 and <160 2,217 (10.4) 5.63 (5.59, 5.67) 1.58 (1.54, 1.62)
160 2,775 (13.1) 5.74 (5.70, 5.78) 1.60 (1.57, 1.63)
Missing 1,382 (6.5) - -
HDL cholesterol 0.00 and <1.00 2,861 (13.5) 5.27 (5.24, 5.30) 1.45 (1.42, 1.49)
(mmol l 1) 1.00 and <1.25 5,841 (27.5) 5.55 (5.53, 5.57) 1.55 (1.53, 1.57)
1.25 and <1.50 3,837 (18.1) 5.67 (5.64, 5.70) 1.59 (1.56, 1.62)
1.50 and <1.75 2,621 (12.3) 5.76 (5.73, 5.80) 1.55 (1.51, 1.58)
1.75 and <2.00 1,007 (4.7) 5.81 (5.76, 5.87) 1.52 (1.46, 1.57)
2.00 961 (4.5) 5.92 (5.87, 5.98) 1.44 (1.39, 1.49)6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 135
Table 6.6: (continued)
Baseline N (%) Mean total Mean total
characteristic cholesterol at cholesterol reduction
baseline (95% CI) (95% CI)
Missing 4,109 (19.3) - -
LDL cholesterol 0.0 and <2.0 355 (1.7) 4.11 (4.04, 4.18) 0.76 (0.68, 0.83)
(mmol l 1) 2.0 and <2.5 959 (4.5) 4.52 (4.49, 4.56) 0.95 (0.90, 1.00)
2.5 and <3.0 2,364 (11.1) 4.97 (4.95, 4.99) 1.21 (1.18, 1.24)
3.0 and <3.5 3,654 (17.2) 5.35 (5.34, 5.37) 1.42 (1.40, 1.44)
3.5 and <4.0 2,951 (13.9) 5.79 (5.77, 5.81) 1.61 (1.58, 1.64)
4.0 and <4.5 1,576 (7.4) 6.31 (6.29, 6.34) 1.89 (1.85, 1.93)
4.5 1,220 (5.7) 7.17 (7.13, 7.20) 2.28 (2.22, 2.33)
Missing 8,158 (38.4) - -
HbA1c (%) 0.0 and <6.0 2,249 (10.6) 5.58 (5.54, 5.62) 1.52 (1.48, 1.55)
6.0 and <6.5 2,940 (13.8) 5.56 (5.53, 5.59) 1.53 (1.50, 1.56)
6.5 and <7.0 3,333 (15.7) 5.53 (5.50, 5.56) 1.51 (1.48, 1.54)
7.0 and <7.5 2,852 (13.4) 5.48 (5.45, 5.51) 1.52 (1.49, 1.55)
7.5 and <8.0 2,214 (10.4) 5.45 (5.41, 5.48) 1.48 (1.45, 1.52)
8.0 and <9.0 2,803 (13.2) 5.51 (5.48, 5.55) 1.48 (1.45, 1.51)
9.0 3,158 (14.9) 5.72 (5.68, 5.75) 1.52 (1.48, 1.55)
Missing 1,688 (8.0) - -
GFR 0 and <50.0 648 (3.1) 5.57 (5.49, 5.65) 1.65 (1.58, 1.73)
(ml min 1) 50.0 and <59.9 953 (4.5) 5.57 (5.51, 5.63) 1.61 (1.55, 1.66)
60 1,900 (8.9) 5.59 (5.55, 5.63) 1.54 (1.50, 1.58)
60.1 and <69.9 1,206 (5.7) 5.54 (5.49, 5.59) 1.52 (1.47, 1.57)
70.0 and <79.9 1,647 (7.8) 5.57 (5.53, 5.62) 1.52 (1.48, 1.56)
80.0 and <89.9 1,511 (7.1) 5.58 (5.53, 5.62) 1.45 (1.41, 1.50)
90 1,479 (7.0) 5.57 (5.52, 5.62) 1.44 (1.39, 1.48)
90.1 511 (2.4) 5.52 (5.44, 5.60) 1.37 (1.29, 1.45)
Missing 11,382 (53.6) - -
Smoking Never smoked 9,294 (43.8) 5.61 (5.59, 5.63) 1.54 (1.52, 1.56)
status Ex-smoker 5,815 (27.4) 5.53 (5.51, 5.56) 1.54 (1.52, 1.56)
Current smoker 3,051 (14.4) 5.66 (5.63, 5.70) 1.47 (1.43, 1.50)
Missing 3,077 (14.5) - -
Statin dose 10 2,331 (11.0) 5.49 (5.46, 5.53) 1.24 (1.20, 1.27)
(simvastatin 20 9,662 (45.5) 5.58 (5.56, 5.60) 1.47 (1.46, 1.49)
or equivalent) 40 9,114 (42.9) 5.64 (5.62, 5.66) 1.66 (1.64, 1.68)
(mg) 80 130 (0.6) 6.02 (5.80, 6.25) 1.94 (1.73, 2.16)
Time from 0 and <1 3,694 (17.4) 5.83 (5.81, 5.86) 1.60 (1.57, 1.63)
diabetes 1 and <2 4,335 (20.4) 5.71 (5.69, 5.74) 1.58 (1.55, 1.61)
diagnosis 2 and <3 2,360 (11.1) 5.64 (5.60, 5.68) 1.57 (1.53, 1.61)
to ﬁrst 3 and <4 1,753 (8.3) 5.59 (5.54, 5.63) 1.56 (1.52, 1.61)
statin 4 and <6 2,422 (11.4) 5.53 (5.49, 5.57) 1.51 (1.48, 1.55)
treatment 6 and <8 1,649 (7.8) 5.45 (5.41, 5.50) 1.48 (1.44, 1.52)
(years) 8 and <10 1,247 (5.9) 5.39 (5.34, 5.44) 1.46 (1.41, 1.50)
10 and <15 1,808 (8.5) 5.40 (5.36, 5.44) 1.43 (1.39, 1.47)
15 and <20 885 (4.2) 5.37 (5.30, 5.43) 1.44 (1.39, 1.50)
20 1,084 (5.1) 5.40 (5.34, 5.45) 1.36 (1.31, 1.41)
Calendar year 2004 3,026 (14.2) 5.75 (5.72, 5.78) 1.58 (1.55, 1.61)
of ﬁrst 2005 4,336 (20.4) 5.66 (5.64, 5.69) 1.57 (1.54, 1.60)
statin 2006 3,829 (18.0) 5.46 (5.43, 5.49) 1.50 (1.47, 1.52)
prescription 2007 2,428 (11.4) 5.48 (5.44, 5.52) 1.45 (1.41, 1.49)
2008 2,270 (10.7) 5.49 (5.45, 5.53) 1.46 (1.43, 1.50)
2009 1,858 (8.7) 5.59 (5.54, 5.63) 1.55 (1.51, 1.59)
2010 1,384 (6.5) 5.64 (5.59, 5.69) 1.54 (1.50, 1.59)
2011 1,396 (6.6) 5.74 (5.69, 5.80) 1.54 (1.49, 1.59)
2012 710 (3.3) 5.73 (5.66, 5.81) 1.59 (1.52, 1.66)
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density ; HbA1c: glycosylated haemoglobin; GFR:
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Patients with higher systolic blood pressure, HDL cholesterol, LDL cholesterol, HbA1c (>9%), statin dose,
short time between diabetes diagnosis and statin prescription and current smokers had higher total cholesterol
measurements at baseline. Patients with higher BMI, systolic blood pressure, LDL cholesterol, lower GFR, being
never or ex-smoker, higher statin dose and short time between diabetes diagnosis and statin prescription had the
greatest total cholesterol reduction after initiating statin treatment (Table 6.6).
6.2.3.2 Association with greater total cholesterol reduction between before initiating statin
treatment and in the ﬁrst six months after ﬁrst statin treatment
In total, 4,496 (19.0%) patients were included in the complete records analysis (Table 6.7). For the model of
interest with total cholesterol reduction outcome reported here, the coefﬁcients are reductions in total cholesterol
on the total cholesterol scale (mmol l 1) per relevant change in the explanatory variable.
Older patients with higher systolic blood pressure, high LDL cholesterol, low HbA1c, high simvastatin dose,
shorter time from diabetes diagnosis to ﬁrst statin prescription and calender year were associated with greater
total cholesterol reduction in the unadjusted analysis. The associations in the adjusted analysis (for age, sex and
ethnicity) was similar to the unadjusted, except HbA1c, which was no longer associated with total cholesterol
reduction.
These associations attenuated even more in the fully adjusted analysis and systolic blood pressure became non-
signiﬁcant. The fully adjusted analysis showed older patients with higher LDL cholesterol (-0.46, 95% CI
-0.49,0.43), lower GFR (0.24, 95% CI 0.10, 0.38) and higher statin dose at baseline were associated with greater
total cholesterol reduction. Calendar year was also associated with greater total cholesterol reduction but the
coefﬁcients do not suggest a direct relationship (Table 6.7).
Before performing MI, I considered the MAR assumption plausibility for the variables with missing data. From
chapter 4, I concluded a plausible MAR assumption for height, weight, systolic blood pressure and smoking
status in all patients in THIN. I concluded the MAR assumption was plausible for this cohort because QOF rec-
ommends these health indicators were measured regularly for patients with type II diabetes. I did not investigate
this assumption for HbA1c, but QOF also recommends HbA1c was measured regularly for patients with type II
diabetes, so the MAR assumption was plausible for this variable in this cohort.
The QOF guidance for patients with type 2 diabetes does not include recording HDL and LDL cholesterol or
GFR. HDL and LDL cholesterol can be measured the same time as total cholesterol, but they were recorded less
frequently in THIN (Table 6.6). GFR is a risk factor for CKD so it is important to measure this for patients with
type II diabetes, with high CKD risk. However, this cohort had many missing GFR values at baseline (Table
6.6). Therefore, I increased the MAR assumption plausibility for these health indicators by including auxiliary
variables listed in the methods section in the imputation model.6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 137
After investigating which auxiliary variables were associated with missing health indicator values or the values
themselves at baseline, the variables from the model of interest age, Townsend deprivation score quintile, ethnic-
ity, time from ﬁrst diabetes diagnosis and calendar year were associated with both the value of HDL cholesterol
and HDL cholesterol being missing (Table 6.9). I observed the same associations for GFR (Table 6.11). All
variables from the model of interest were associated with both the value of LDL cholesterol and LDL cholesterol
being missing (Table 6.10).
The auxiliary variables anti-hypertensive drug treatment and omega 3 were associated with both the value of HDL
cholesterol and HDL cholesterol being missing at baseline (Table 6.9), so conditioning on these variables in the
imputation model increased the MAR assumption plausibility for HDL cholesterol. The auxiliary variables CKD
and anti-hypertensive drug treatment were associated with both the value of LDL cholesterol and LDL cholesterol
being missing at baseline (Table 6.10), and the same for GFR (Table 6.11), so all imputation models condition on
these auxiliary variables to increase the MAR assumption plausibility for these variables with missing data.138 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
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All of the auxiliary variables were associated with the value of at least one of the variables with missing data, so
I included all of them in the imputation model.
I observed some differences when comparing the results from analysing data imputed using baseline MI (to im-
pute missing values at baseline) compared to the complete records analysis. Female patients were not associated
with greater total cholesterol reduction in the complete records analysis, but from analysing data imputed using
baseline MI, they were associated with greater total cholesterol reduction in the unadjusted analysis and adjusted
analysis (for age, sex and ethnicity). In the fully adjusted analysis, male patients were associated with greater total
cholesterol reduction(Table 6.13). As well as female patients, I found other completely observed variables were
also signiﬁcant in the analysis of data imputed using baseline MI but not complete records analysis; Townsend
deprivation score quintile (not fully adjusted analysis), ethnicity and time from diabetes diagnosis to ﬁrst statin
treatment (Table 6.13).
I observed similar ﬁndings from analysing data imputed using baseline MI and complete records analysis for
imputed variables, except for HDL cholesterol and HbA1c. HDL cholesterol was not associated with greater total
cholesterol reduction in the complete case analysis, but it was for the adjusted baseline MI (possibly because
this analysis is also adjusted for LDL cholesterol) (Table 6.13). In the complete records analysis, lower HbA1c
was associated with greater total cholesterol reduction, opposite to the expected direction of association, in the
unadjusted analysis, but not associated the adjusted or fully adjusted analysis. However, from analysing data
imputed using baseline MI, HbA1c was not signiﬁcantly associated with greater total cholesterol reduction, but
greater HbA1c was associated with greater total cholesterol reduction in the adjusted and fully adjusted analysis
(Table 6.13). The direction of association changed to the expected direction in the fully adjusted analysis of data
imputed using baseline MI.
The fully adjusted analysis showed older, male patients of white ethnicity with higher LDL cholesterol, higher
HbA1c, lower GFR, non or ex-smokers, higher statin dose, shorter time from ﬁrst diabetes diagnosis and earlier
calendar years were associated with greater total cholesterol reduction. These ﬁndings agreed more closely with
the descriptive analysis ﬁndings compared to the complete records analysis, except for sex. The descriptive
analysis suggested female patients had greater total cholesterol reduction.
The analysis using FIML produced similar results as the fully adjusted analysis of data imputed using baseline MI
(Table 6.13) and from analysing data imputed using the two-fold FCS algorithm, conditional on measurements
recorded before baseline imputation (Table 6.14). In the fully adjusted analysis of data imputed using baseline
MI, Townsend deprivation score quintile, BMI and systolic blood pressure were not signiﬁcantly associated with
greater total cholesterol reduction. However,there was some association (p-values between 0.060 and 0.064)
from the fully adjusted analysis of data imputed using the two-fold FCS algorithm conditional on measurements
recorded before and after baseline (Table 6.15).6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 141
Table 6.8: Association between the outcome variable (difference between total cholesterol 6 months before initi-
ating statin treatment and 6 months after ﬁrst statin treatment), covariates and auxiliary variables and the chance
of observing height and weight and their respective values at baseline
Variable Height (cm) Weight (kg)
Missing Value Missing Value
OR (95% CI) Coefﬁcient (95% CI) OR (95% CI) Coefﬁcient (95% CI)
Outcome 0.95 (0.72,1.25) 0.18 (0.07,0.29) 0.96 (0.93,1.00) 0.14 (-0.15,0.43)
Age (years) 30 and <40 1.93 (0.72,5.20) 2.39 (1.93,2.84) 1.09 (0.92,1.29) 8.64 (7.42,9.86)
at ﬁrst 40 and <50 0.51 (0.18,1.44) 1.69 (1.39,1.99) 1.07 (0.96,1.20) 7.73 (6.92,8.53)
statin 50 and <60 1.22 (0.60,2.51) 0.84 (0.58,1.1) 0.99 (0.90,1.10) 5.03 (4.32,5.74)
prescription 60 and <70 Ref Ref Ref Ref
70 and <80 1.28 (0.59,2.74) -1.23 (-1.51,0.95) 1.03 (0.92,1.14) -6.86 (-7.62,-6.10)
80 2.24 (0.95,5.27) -3.07 (-3.47,2.66) 1.19 (1.03,1.38) -14.59 (-15.69,-13.48)
Sex 1.36 (0.83,2.23) -14.18 (-14.37,13.99) 1.06 (0.99,1.14) -9.46 (-9.98,-8.94)
Townsend 1 Ref Ref Ref Ref
deprivation 2 1.11 (0.55,2.24) -0.46 (-0.73,0.18) 0.93 (0.84,1.03) 0.16 (-0.58,0.90)
score 3 1.03 (0.51,2.11) -1.26 (-1.52,0.98) 0.98 (0.89,1.09) 0.72 (-0.02,1.46)
quintile 4 1.18 (0.59,2.40) -1.52 (-1.8,1.24) 1.02 (0.92,1.13) 1.00 (0.23,1.76)
5 0.55 (0.20,1.52) -2.20 (-2.51,1.87) 1.05 (0.94,1.19) 1.18 (0.31,2.05)
Ethnic White Ref Ref Ref Ref
group Black 1.54 (0.21,11.56) 0.03 (-0.84,0.9) 1.32 (0.97,1.78) -5.50 (-7.91,-3.08)
South Asian - -4.99 (-5.66,4.33) 1.08 (0.84,1.38) -13.81 (-15.62,-11.99)
Other - -4.29 (-5.17,3.4) 1.57 (1.17,2.11) -11.31 (-13.84,-8.79)
CKD 0.78 (0.39,1.58) 0.12 (-0.14,0.38) 0.98 (0.89,1.08) 1.67 (0.97,2.38)
Statin dose 10 0.87 (0.35,2.17) -0.20 (-0.52,0.13) 0.92 (0.81,1.04) -1.71 (-2.59,-0.84)
(simvastatin 20 1.04 (0.61,1.79) -0.13 (-0.34,0.08) 0.98 (0.91,1.06) -0.57 (-1.13,-0.01)
or equivalent) 40 Ref Ref Ref Ref
(mg) 80 - -0.40 (-1.59,0.79) 1.35 (0.90,2.03) 1.19 (-2.15,4.52)
Time from 0 and <1 Ref Ref Ref Ref
diabetes 1 and <2 0.87 (0.42,1.82) -0.07 (-0.37,0.23) 1.10 (0.98,1.24) 0.07 (-0.74,0.88)
diagnosis 2 and <3 0.65 (0.25,1.72) 0.21 (-0.14,0.56) 1.17 (1.02,1.33) 0.70 (-0.26,1.66)
to ﬁrst 3 and <4 0.60 (0.20,1.86) 0.09 (-0.3,0.48) 1.11 (0.96,1.29) -0.04 (-1.09,1.02)
statin 4 and <6 0.73 (0.28,1.92) 0.39 (0.03,0.74) 1.15 (1.01,1.32) -0.29 (-1.24,0.67)
treatment 6 and <8 1.13 (0.43,2.99) 0.52 (0.12,0.93) 1.15 (0.99,1.34) 0.47 (-0.61,1.56)
(years) 8 and <10 0.91 (0.29,2.82) 0.26 (-0.18,0.71) 1.20 (1.02,1.42) -1.95 (-3.15,-0.75)
10 and <15 - 0.28 (-0.1,0.67) 1.10 (0.95,1.28) -2.08 (-3.13,-1.02)
15 and <20 2.12 (0.82,5.46) 0.07 (-0.44,0.58) 1.14 (0.94,1.38) -5.19 (-6.56,-3.82)
20 1.56 (0.58,4.19) -0.23 (-0.7,0.24) 1.05 (0.88,1.26) -10.8 (-12.06,-9.54)
Calender 2004 0.44 (0.16,1.20) -0.17 (-0.61,0.28) 0.93 (0.79,1.10) -1.84 (-3.05,-0.62)
year of 2005 0.19 (0.06,0.58) -0.12 (-0.54,0.3) 0.93 (0.79,1.09) -1.70 (-2.85,-0.55)
ﬁrst 2006 0.40 (0.15,1.06) 0.15 (-0.27,0.58) 0.87 (0.74,1.02) -1.53 (-2.68,-0.37)
statin 2007 0.48 (0.18,1.31) 0.24 (-0.21,0.69) 0.88 (0.74,1.04) -0.83 (-2.06,0.39)
prescription 2008 0.36 (0.12,1.11) 0.13 (-0.32,0.59) 1.01 (0.86,1.20) -0.65 (-1.90,0.59)
2009 0.27 (0.07,1.01) 0.31 (-0.17,0.78) 1.03 (0.86,1.23) 0.45 (-0.85,1.74)
2010 Ref Ref Ref Ref
2011 1.58 (0.64,3.91) 0.23 (-0.27,0.74) 1.17 (0.98,1.41) 1.37 (-0.02,2.76)
2012 1.78 (0.64,4.99) 0.91 (0.29,1.53) 1.26 (1.01,1.58) 2.01 (0.30,3.71)
COPD 0.83 (0.25,2.80) 0.04 (-0.41,0.49) 0.87 (0.74,1.04) 0.87 (-0.34,2.08)
Psychosis 1.33 (0.17,10.16) 1.28 (0.3,2.26) 0.91 (0.63,1.32) 1.73 (-0.91,4.36)
Asthma 0.39 (0.14,1.09) -0.33 (-0.6,0.05) 1.04 (0.93,1.15) 1.92 (1.16,2.67)
Atrial ﬁbrilation 1.22 (0.46,3.22) 1.89 (1.49,2.3) 1.03 (0.89,1.20) 3.94 (2.84,5.04)
Anti-hypertensive 0.62 (0.37,1.04) -0.06 (-0.25,0.14) 1.06 (0.99,1.15) 5.08 (4.54,5.62)
drug treatment
Bile acid - -1.35 (-5.22,2.52) 3.37 (1.06,10.67) -8.35 (-20.71,4.02)
Ezetimibe 7.99 (1.75,36.43) -0.34 (-1.97,1.29) 1.23 (0.70,2.15) -4.85 (-9.32,-0.39)
Fibrate - -0.01 (-0.76,0.75) 1.34 (1.03,1.74) 0.24 (-1.87,2.35)
Nicotinic acid - 0.50 (-4.58,5.6) - 2.71 (-9.72,15.14)
Omega 3 - 0.86 (-1.53,3.25) 1.58 (0.72,3.48) 2.09 (-4.78,8.96)
Respiratory infection 1.56 (0.70,3.47) -0.21 (-0.55,0.15) 1.07 (0.94,1.21) 0.76 (-0.20,1.72)
Heavy drinker 0.46 (0.16,1.30) 0.08 (-0.19,0.35) 1.02 (0.92,1.14) -0.42 (-1.16,0.32)
CHD 0.33 (0.05,2.43) -0.20 (-0.63,0.23) 1.01 (0.86,1.19) -0.29 (-1.47,0.88)
Stroke 0.40 (0.05,2.95) -0.22 (-0.76,0.32) 1.30 (1.08,1.57) -1.22 (-2.71,0.28)
Death 4.19 (2.06,8.52) -0.32 (-0.69,0.06) 1.27 (1.11,1.45) 0.01 (-1.03,1.04)
OR: odds ratio; CI: conﬁdence interval; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary
disease; Psychoses: schizophrenia, bipolar disorder and other psychoses; CHD: coronary heart disease; Ref:
reference category
In bold if variable is associated (p-value<0.100) with the chance of observing height and weight and their
respective values at baseline142 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
Table 6.9: Association between the outcome (difference between total cholesterol 6 months before initiating statin
treatment and 6 months after ﬁrst statin treatment), covariates and auxiliary variables and the chance of observing
systolic blood pressure and HDL cholesterol and their respective values at baseline
Variable Systolic blood pressure (mmHg) HDL cholesterol (mmol l 1)
Missing Value Missing Value
OR (95% CI) Coefﬁcient (95% CI) OR (95% CI) Coefﬁcient (95% CI)
Outcome 0.95 (0.89,1.01) -0.72 (-0.99,-0.44) 1.04 (1.00,1.08) 0.00 (-0.00,0.01)
Age (years) 30 and <40 1.30 (1.03,1.65) -7.23 (-8.39,-6.07) 1.24 (1.05,1.47) -0.10 (-0.13,-0.08)
at ﬁrst 40 and <50 1.11 (0.93,1.32) -4.22 (-4.98,-3.46) 1.15 (1.03,1.29) -0.09 (-0.11,-0.08)
statin 50 and <60 1.10 (0.94,1.29) -1.42 (-2.09,-0.75) 1.10 (0.99,1.21) -0.04 (-0.05,-0.02)
prescription 60 and <70 Ref Ref Ref Ref
70 and <80 0.94 (0.78,1.12) 0.51 (-0.20,1.22) 1.03 (0.93,1.14) 0.05 (0.03,0.06)
80 0.96 (0.74,1.24) 2.32 (1.31,3.34) 1.07 (0.92,1.24) 0.14 (0.12,0.16)
Sex 1.19 (1.06,1.34) -0.22 (-0.70,0.27) 0.96 (0.89,1.03) 0.21 (0.20,0.22)
Townsend 1 Ref Ref Ref Ref
deprivation 2 1.08 (0.91,1.28) 0.11 (-0.58,0.81) 0.99 (0.89,1.09) 0.01 (-0.00,0.03)
score 3 1.09 (0.93,1.29) 0.00 (-0.69,0.70) 0.97 (0.88,1.08) -0.02 (-0.03,-0.00)
quintile 4 1.09 (0.92,1.29) -0.64 (-1.35,0.08) 1.05 (0.94,1.16) -0.04 (-0.06,-0.02)
5 1.18 (0.98,1.43) -0.22 (-1.03,0.60) 1.11 (0.99,1.25) -0.06 (-0.08,-0.04)
Ethnic White Ref Ref Ref Ref
group Black 1.21 (0.75,1.96) 2.92 (0.69,5.15) 0.72 (0.50,1.03) 0.10 (0.05,0.14)
South Asian 0.87 (0.58,1.30) -3.60 (-5.30,-1.91) 0.52 (0.38,0.71) -0.05 (-0.08,-0.01)
Other 1.54 (1.01,2.35) -1.09 (-3.41,1.22) 0.52 (0.34,0.80) -0.01 (-0.06,0.04)
CKD 0.99 (0.84,1.18) 1.03 (0.37,1.69) 1.04 (0.95,1.15) -0.05 (-0.07,-0.04)
Statin dose 10 0.93 (0.76,1.14) -0.19 (-1.02,0.63) 0.81 (0.72,0.91) 0.01 (-0.01,0.03)
(simvastatin 20 1.09 (0.96,1.24) -0.50 (-1.03,0.03) 0.89 (0.83,0.97) 0.01 (-0.01,0.02)
or equivalent) 40 Ref Ref Ref Ref
(mg) 80 1.50 (0.81,2.76) -0.83 (-3.90,2.24) 0.96 (0.62,1.47) -0.02 (-0.09,0.04)
Time from 0 and <1 Ref Ref Ref Ref
diabetes 1 and <2 1.01 (0.85,1.21) -0.15 (-0.92,0.61) 1.08 (0.96,1.21) 0.02 (0.01,0.04)
diagnosis 2 and <3 1.08 (0.87,1.33) -0.43 (-1.34,0.47) 1.04 (0.90,1.19) 0.02 (-0.00,0.04)
to ﬁrst 3 and <4 1.05 (0.82,1.33) -0.77 (-1.77,0.22) 1.09 (0.94,1.26) 0.02 (0.00,0.05)
statin 4 and <6 1.20 (0.98,1.48) -0.13 (-1.03,0.77) 1.11 (0.97,1.27) 0.01 (-0.01,0.03)
treatment 6 and <8 1.15 (0.90,1.46) -0.29 (-1.31,0.73) 1.20 (1.03,1.40) 0.04 (0.01,0.06)
(years) 8 and <10 1.19 (0.92,1.55) -0.08 (-1.21,1.04) 1.32 (1.13,1.56) 0.05 (0.02,0.07)
10 and <15 1.08 (0.85,1.38) -0.22 (-1.21,0.77) 1.28 (1.11,1.48) 0.09 (0.07,0.11)
15 and <20 1.36 (1.01,1.81) -0.22 (-1.51,1.08) 1.67 (1.40,2.00) 0.15 (0.12,0.18)
20 1.25 (0.96,1.64) -1.56 (-2.76,-0.37) 1.67 (1.42,1.97) 0.29 (0.27,0.32)
Calender 2004 0.84 (0.64,1.09) 4.11 (2.97,5.25) 2.28 (1.89,2.73) 0.08 (0.05,0.10)
year of 2005 0.81 (0.63,1.04) 3.12 (2.04,4.21) 2.10 (1.76,2.51) 0.08 (0.06,0.10)
ﬁrst 2006 0.88 (0.69,1.13) 1.50 (0.41,2.59) 1.64 (1.37,1.96) 0.06 (0.04,0.09)
statin 2007 0.75 (0.57,0.99) 0.44 (-0.71,1.60) 1.68 (1.39,2.03) 0.02 (-0.00,0.05)
prescription 2008 1.03 (0.79,1.34) 0.95 (-0.23,2.12) 1.36 (1.12,1.65) 0.02 (-0.01,0.04)
2009 1.11 (0.85,1.45) 0.70 (-0.51,1.92) 1.25 (1.02,1.53) 0.02 (-0.01,0.05)
2010 Ref Ref Ref Ref
2011 1.32 (1.00,1.74) 0.65 (-0.66,1.96) 0.92 (0.73,1.16) 0.02 (-0.00,0.05)
2012 1.34 (0.96,1.85) 0.62 (-0.98,2.21) 0.95 (0.72,1.26) 0.02 (-0.02,0.05)
COPD 1.03 (0.79,1.36) -0.85 (-1.99,0.29) 1.18 (1.01,1.38) 0.02 (-0.01,0.04)
Psychosis 1.01 (0.61,1.68) -3.35 (-5.87,-0.83) 1.22 (0.85,1.74) -0.10 (-0.16,-0.04)
Asthma 1.14 (0.97,1.33) -0.57 (-1.28,0.14) 1.02 (0.92,1.13) 0.03 (0.01,0.04)
Atrial ﬁbrilation 0.88 (0.66,1.17) -3.52 (-4.53,-2.50) 1.03 (0.89,1.19) -0.03 (-0.05,-0.01)
Anti-hypertensive 0.42 (0.37,0.47) 8.41 (7.90,8.92) 1.11 (1.03,1.20) -0.05 (-0.06,-0.04)
drug treatment
Bile acid 3.00 (0.63,14.28) -0.75 (-11.19,9.69) 0.39 (0.05,3.07) 0.23 (0.03,0.44)
Ezetimibe 0.84 (0.30,2.34) -4.40 (-8.48,-0.32) 0.88 (0.46,1.68) -0.02 (-0.11,0.06)
Fibrate 1.00 (0.63,1.60) -1.31 (-3.24,0.61) 0.99 (0.75,1.31) -0.15 (-0.19,-0.10)
Nicotinic acid 1.00 (1.00,1.00) -5.33 (-17.87,7.21) 0.71 (0.08,6.06) -0.39 (-0.67,-0.12)
Omega 3 3.12 (1.16,8.40) 0.37 (-6.02,6.76) 0.14 (0.02,1.04) -0.11 (-0.23,0.01)
Respiratory infection 0.75 (0.60,0.94) -0.83 (-1.72,0.06) 1.06 (0.93,1.20) -0.03 (-0.05,-0.01)
Heavy drinker 1.06 (0.89,1.24) 1.40 (0.70,2.10) 0.99 (0.89,1.10) 0.13 (0.11,0.14)
CHD 1.03 (0.79,1.36) 1.40 (0.30,2.49) 1.05 (0.90,1.23) -0.04 (-0.07,-0.02)
Stroke 1.10 (0.79,1.53) 1.69 (0.32,3.06) 1.00 (0.83,1.22) 0.00 (-0.03,0.03)
Death 1.28 (1.02,1.60) -0.07 (-1.02,0.88) 1.10 (0.96,1.25) -0.02 (-0.04,0.01)
OR: odds ratio; CI: conﬁdence interval; HDL: high-density lipoprotein; CKD: chronic kidney disease; COPD:
chronic obstructive pulmonary disease; Psychoses: schizophrenia, bipolar disorder and other psychoses; CHD:
coronary heart disease; Ref: reference category
In bold if variable is associated (p-value<0.100) with the chance of observing systolic blood pressure and HDL
cholesterol and their respective values at baseline6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 143
Table 6.10: Association between the outcome (difference between total cholesterol 6 months before initiating
statin treatment and 6 months after ﬁrst statin treatment), covariates and auxiliary variables and the chance of
observing LDL cholesterol and HbA1c and their respective values at baseline
Variable LDL cholesterol (mmol l 1) HbA1c (%)
Missing Value Missing Value
OR (95% CI) Coefﬁcient (95% CI) OR (95% CI) Coefﬁcient (95% CI)
Outcome 0.95 (0.92,0.98) -0.39 (-0.41,-0.38) 0.75 (0.70,0.79) -0.05 (-0.07,-0.03)
Age (years) 30 and <40 1.47 (1.28,1.68) 0.13 (0.07,0.19) 0.96 (0.75,1.22) 0.81 (0.71,0.91)
at ﬁrst 40 and <50 1.36 (1.24,1.49) 0.09 (0.06,0.13) 0.73 (0.62,0.86) 0.56 (0.50,0.63)
statin 50 and <60 1.14 (1.06,1.24) 0.06 (0.03,0.10) 0.86 (0.75,0.99) 0.35 (0.29,0.41)
prescription 60 and <70 Ref Ref Ref Ref
70 and <80 1.02 (0.93,1.11) -0.02 (-0.06,0.01) 0.93 (0.80,1.08) -0.30 (-0.36,-0.23)
80 1.13 (1.00,1.28) 0.06 (0.01,0.12) 0.82 (0.65,1.02) -0.45 (-0.54,-0.35)
Sex 0.88 (0.83,0.94) 0.16 (0.13,0.18) 1.46 (1.31,1.62) -0.03 (-0.07,0.01)
Townsend 1 Ref Ref Ref Ref
deprivation 2 1.14 (1.05,1.24) -0.03 (-0.06,0.01) 0.89 (0.76,1.03) 0.06 (-0.01,0.12)
score 3 1.07 (0.98,1.16) -0.02 (-0.05,0.02) 0.92 (0.80,1.07) 0.08 (0.02,0.15)
quintile 4 1.16 (1.07,1.27) -0.05 (-0.09,-0.02) 0.85 (0.73,0.99) 0.15 (0.09,0.22)
5 1.31 (1.19,1.45) -0.05 (-0.09,-0.01) 0.90 (0.76,1.07) 0.27 (0.19,0.34)
Ethnic White Ref Ref Ref Ref
group Black 0.55 (0.41,0.73) 0.29 (0.19,0.40) 1.17 (0.74,1.85) 0.07 (-0.12,0.27)
South Asian 0.51 (0.41,0.64) -0.04 (-0.12,0.04) 1.07 (0.74,1.53) 0.07 (-0.08,0.23)
Other 0.63 (0.47,0.85) 0.05 (-0.06,0.15) 0.90 (0.55,1.47) 0.08 (-0.13,0.28)
CKD 1.20 (1.11,1.30) -0.06 (-0.10,-0.03) 0.87 (0.76,1.01) 0.07 (0.01,0.13)
Statin dose 10 0.77 (0.70,0.85) 0.07 (0.03,0.12) 1.03 (0.85,1.24) -0.24 (-0.31,-0.17)
(simvastatin 20 0.76 (0.71,0.81) 0.05 (0.03,0.08) 1.15 (1.03,1.29) -0.18 (-0.23,-0.14)
or equivalent) 40 Ref Ref Ref Ref
(mg) 80 0.92 (0.64,1.31) 0.10 (-0.07,0.26) 1.39 (0.78,2.49) 0.26 (-0.02,0.53)
Time from 0 and <1 Ref Ref Ref Ref
diabetes 1 and <2 1.06 (0.96,1.16) -0.10 (-0.14,-0.07) 1.27 (1.08,1.49) -0.12 (-0.19,-0.06)
diagnosis 2 and <3 1.07 (0.96,1.19) -0.13 (-0.18,-0.09) 1.41 (1.17,1.71) 0.05 (-0.03,0.13)
to ﬁrst 3 and <4 1.18 (1.04,1.32) -0.22 (-0.27,-0.17) 1.40 (1.14,1.72) 0.24 (0.15,0.33)
statin 4 and <6 1.10 (0.99,1.23) -0.23 (-0.28,-0.19) 1.14 (0.94,1.39) 0.39 (0.31,0.47)
treatment 6 and <8 1.15 (1.02,1.30) -0.28 (-0.33,-0.22) 1.12 (0.89,1.41) 0.67 (0.58,0.76)
(years) 8 and <10 1.09 (0.96,1.25) -0.31 (-0.37,-0.25) 1.17 (0.91,1.50) 0.72 (0.62,0.82)
10 and <15 1.24 (1.10,1.39) -0.33 (-0.38,-0.28) 1.09 (0.87,1.36) 0.93 (0.84,1.02)
15 and <20 1.36 (1.17,1.58) -0.28 (-0.35,-0.21) 0.89 (0.65,1.23) 1.03 (0.91,1.14)
20 1.55 (1.35,1.79) -0.33 (-0.39,-0.26) 1.09 (0.82,1.43) 0.93 (0.83,1.04)
Calender 2004 2.08 (1.81,2.39) 0.08 (0.02,0.14) 0.40 (0.32,0.51) 0.23 (0.12,0.33)
year of 2005 1.81 (1.59,2.07) 0.01 (-0.04,0.07) 0.45 (0.36,0.55) 0.25 (0.15,0.35)
ﬁrst 2006 1.43 (1.25,1.63) -0.10 (-0.15,-0.04) 0.41 (0.33,0.51) 0.15 (0.05,0.25)
statin 2007 1.17 (1.02,1.35) -0.03 (-0.09,0.02) 0.65 (0.52,0.81) 0.11 (0.00,0.21)
prescription 2008 1.04 (0.90,1.20) -0.03 (-0.09,0.03) 0.65 (0.52,0.81) 0.08 (-0.02,0.19)
2009 1.07 (0.92,1.25) -0.04 (-0.10,0.02) 0.85 (0.68,1.06) 0.12 (0.00,0.23)
2010 Ref Ref Ref Ref
2011 1.05 (0.89,1.23) 0.08 (0.02,0.14) 1.05 (0.84,1.32) -0.05 (-0.17,0.07)
2012 1.14 (0.94,1.38) 0.03 (-0.05,0.11) 1.22 (0.93,1.59) 0.06 (-0.08,0.21)
COPD 1.09 (0.95,1.25) -0.07 (-0.13,-0.01) 0.95 (0.74,1.21) 0.16 (0.05,0.26)
Psychosis 1.18 (0.88,1.58) 0.03 (-0.10,0.16) 1.64 (1.06,2.54) -0.27 (-0.50,-0.05)
Asthma 0.98 (0.90,1.07) 0.03 (-0.01,0.06) 1.08 (0.93,1.25) -0.04 (-0.10,0.02)
Atrial ﬁbrilation 1.08 (0.96,1.22) -0.06 (-0.11,-0.01) 1.32 (1.07,1.62) 0.04 (-0.06,0.13)
Anti-hypertensive 1.06 (0.99,1.12) -0.13 (-0.16,-0.11) 1.11 (1.00,1.24) -0.17 (-0.22,-0.12)
drug treatment
Bile acid 0.59 (0.16,2.19) 0.30 (-0.16,0.75) 6.48 (1.89,22.22) -1.26 (-2.30,-0.22)
Ezetimibe 0.89 (0.54,1.48) 0.03 (-0.17,0.23) 1.47 (0.72,3.01) 0.10 (-0.28,0.47)
Fibrate 1.04 (0.83,1.31) 0.00 (-0.10,0.10) 1.22 (0.82,1.82) 0.11 (-0.07,0.28)
Nicotinic acid 1.13 (0.25,5.21) 0.34 (-0.34,1.02) 1.00 (1.00,1.00) -0.42 (-1.53,0.69)
Omega 3 0.44 (0.19,1.03) -0.06 (-0.33,0.21) 1.72 (0.63,4.67) -0.54 (-1.11,0.03)
Respiratory infection 0.99 (0.89,1.11) -0.02 (-0.07,0.02) 1.13 (0.94,1.36) -0.02 (-0.10,0.06)
Heavy drinker 1.03 (0.94,1.12) 0.04 (0.00,0.07) 1.11 (0.95,1.29) -0.22 (-0.29,-0.16)
CHD 1.01 (0.89,1.16) 0.07 (0.01,0.13) 1.34 (1.07,1.68) 0.11 (0.01,0.21)
Stroke 0.92 (0.78,1.09) 0.05 (-0.02,0.12) 1.15 (0.85,1.54) 0.26 (0.13,0.38)
Death 1.10 (0.98,1.23) -0.02 (-0.07,0.03) 0.94 (0.75,1.17) 0.09 (0.00,0.17)
OR: odds ratio; CI: conﬁdence interval; LDL: low-density lipoprotein; HbA1c: glycosylated haemoglobin; CKD:
chronic kidney disease; COPD: chronic obstructive pulmonary disease; Psychoses: schizophrenia, bipolar
disorder and other psychoses; CHD: coronary heart disease; Ref: reference category
In bold if variable is associated (p-value<0.100) with the chance of observing LDL cholesterol and HbA1c and
their respective values at baseline144 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
Table 6.11: Association between the outcome (difference between total cholesterol 6 months before initiating
statin treatment and 6 months after ﬁrst statin treatment), covariates and auxiliary variables and the chance of
observing GFR and its values at baseline
Variable GFR (ml min 1)
Missing Value
OR (95% CI) Coefﬁcient (95% CI)
Outcome 0.99 (0.96,1.03) 0.83 (0.50,1.15)
Age (years) 30 and <40 1.29 (1.10,1.53) 8.13 (6.72,9.53)
at ﬁrst 40 and <50 1.09 (0.98,1.22) 5.13 (4.22,6.03)
statin 50 and <60 1.07 (0.97,1.18) 2.60 (1.80,3.41)
prescription 60 and <70 Ref Ref
70 and <80 1.03 (0.93,1.15) -2.93 (-3.81,-2.04)
80 0.87 (0.75,1.02) -6.21 (-7.46,-4.97)
Sex 1.02 (0.95,1.10) -1.51 (-2.10,-0.92)
Townsend 1 Ref Ref
deprivation 2 1.16 (1.04,1.28) -0.38 (-1.22,0.46)
score 3 1.23 (1.11,1.36) -0.57 (-1.41,0.27)
quintile 4 1.27 (1.15,1.42) -0.54 (-1.40,0.33)
5 1.24 (1.10,1.40) -0.95 (-1.94,0.03)
Ethnic White Ref Ref
group Black 1.16 (0.85,1.58) -1.73 (-4.31,0.85)
South Asian 1.07 (0.84,1.37) 0.82 (-1.18,2.82)
Other 0.80 (0.58,1.11) -0.28 (-2.72,2.15)
CKD 0.89 (0.81,0.99) -17.68 (-18.52,-16.84)
Statin dose 10 0.80 (0.71,0.91) 0.67 (-0.36,1.71)
(simvastatin 20 0.93 (0.86,1.00) 0.51 (-0.13,1.14)
or equivalent) 40 Ref Ref
(mg) 80 1.47 (0.91,2.38) 0.18 (-4.57,4.94)
Time from 0 and <1 Ref Ref
diabetes 1 and <2 0.80 (0.71,0.89) -0.45 (-1.33,0.43)
diagnosis 2 and <3 0.84 (0.73,0.95) 0.20 (-0.87,1.27)
to ﬁrst 3 and <4 0.82 (0.71,0.95) -0.55 (-1.76,0.67)
statin 4 and <6 0.84 (0.74,0.96) 0.10 (-1.00,1.19)
treatment 6 and <8 0.91 (0.78,1.05) 0.30 (-0.94,1.55)
(years) 8 and <10 0.93 (0.79,1.10) 0.03 (-1.36,1.43)
10 and <15 0.90 (0.77,1.04) -0.66 (-1.91,0.59)
15 and <20 0.96 (0.79,1.15) -0.85 (-2.48,0.79)
20 0.99 (0.83,1.18) -2.18 (-3.70,-0.66)
Calender 2004 71.19 (58.04,87.33) 0.49 (-1.75,2.73)
year of 2005 30.55 (25.88,36.05) 3.55 (2.08,5.03)
ﬁrst 2006 8.75 (7.50,10.20) 1.36 (0.19,2.52)
statin 2007 1.92 (1.63,2.26) -0.66 (-1.75,0.44)
prescription 2008 1.26 (1.07,1.50) -0.11 (-1.19,0.97)
2009 1.08 (0.91,1.30) -0.49 (-1.61,0.62)
2010 Ref Ref
2011 0.98 (0.81,1.19) -1.18 (-2.37,0.01)
2012 1.07 (0.85,1.35) -1.43 (-2.88,0.03)
COPD 1.05 (0.89,1.25) -0.07 (-1.49,1.36)
Psychosis 0.77 (0.53,1.11) -0.58 (-3.31,2.16)
Asthma 0.91 (0.82,1.02) 0.24 (-0.61,1.09)
Atrial ﬁbrilation 1.02 (0.88,1.19) -0.14 (-1.44,1.16)
Anti-hypertensive 0.91 (0.84,0.98) -1.00 (-1.61,-0.39)
drug treatment
Bile acid 1.03 (0.24,4.41) 0.66 (-10.86,12.19)
Ezetimibe 1.26 (0.72,2.18) 0.04 (-4.43,4.51)
Fibrate 1.24 (0.93,1.66) -3.77 (-6.22,-1.31)
Nicotinic acid 1.00 (1.00,1.00) -
Omega 3 0.76 (0.31,1.90) -0.29 (-6.84,6.27)
Respiratory infection 0.94 (0.82,1.07) -1.12 (-2.19,-0.05)
Heavy drinker 0.95 (0.86,1.06) 1.65 (0.82,2.49)
CHD 0.94 (0.79,1.10) 0.70 (-0.77,2.17)
Stroke 1.07 (0.87,1.31) -0.01 (-1.91,1.89)
Death 1.08 (0.93,1.25) -0.04 (-1.41,1.34)
OR: odds ratio; CI: conﬁdence interval; GFR: glomerular ﬁltration rate; CKD: chronic kidney disease; COPD:
chronic obstructive pulmonary disease; Psychoses: schizophrenia, bipolar disorder and other psychoses; CHD:
coronary heart disease; Ref: reference category
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Table 6.12: Association between the outcome (difference between total cholesterol 6 months before initiating
statin treatment and 6 months after ﬁrst statin treatment), covariates and auxiliary variables and the chance of
observing smoking status and its values at baseline
Variable Smoking status
Ex-smokers Current smokers
Missing Value Value
OR (95% CI) Coefﬁcient (95% CI) Coefﬁcient (95% CI)
Outcome -0.01 (-0.05,0.03) -0.01 (-0.05,0.03) 0.05 (0.00,0.10)
Age (years) 30 and <40 -0.78 (-0.97,-0.59) -0.78 (-0.97,-0.59) 0.39 (0.21,0.57)
at ﬁrst 40 and <50 -0.71 (-0.83,-0.60) -0.71 (-0.83,-0.60) 0.21 (0.08,0.34)
statin 50 and <60 -0.40 (-0.50,-0.30) -0.40 (-0.50,-0.30) 0.04 (-0.08,0.16)
prescription 60 and <70 Ref Ref Ref
70 and <80 -0.07 (-0.17,0.03) -0.07 (-0.17,0.03) -0.54 (-0.69,-0.39)
80 -0.02 (-0.16,0.12) -0.02 (-0.16,0.12) -1.02 (-1.28,-0.76)
Sex -0.80 (-0.87,-0.73) -0.80 (-0.87,-0.73) -0.40 (-0.49,-0.31)
Townsend 1 Ref Ref Ref
deprivation 2 0.00 (-0.10,0.10) 0.00 (-0.10,0.10) 0.10 (-0.04,0.24)
score 3 0.05 (-0.05,0.15) 0.05 (-0.05,0.15) 0.51 (0.38,0.64)
quintile 4 0.10 (-0.00,0.20) 0.10 (-0.00,0.20) 0.69 (0.56,0.83)
5 0.20 (0.07,0.32) 0.20 (0.07,0.32) 0.92 (0.78,1.07)
Ethnic White Ref Ref Ref
group Black -0.84 (-1.20,-0.48) -0.84 (-1.20,-0.48) -0.72 (-1.13,-0.31)
South Asian -1.38 (-1.71,-1.06) -1.38 (-1.71,-1.06) -1.41 (-1.79,-1.04)
Other -0.96 (-1.34,-0.58) -0.96 (-1.34,-0.58) -0.85 (-1.28,-0.42)
CKD 0.02 (-0.08,0.11) 0.02 (-0.08,0.11) -0.17 (-0.30,-0.03)
Statin dose 10 0.08 (-0.04,0.20) 0.08 (-0.04,0.20) -0.03 (-0.19,0.13)
(simvastatin 20 0.04 (-0.04,0.12) 0.04 (-0.04,0.12) 0.01 (-0.09,0.10)
or equivalent) 40 Ref Ref Ref
(mg) 80 0.29 (-0.17,0.75) 0.29 (-0.17,0.75) 0.35 (-0.16,0.87)
Time from 0 and <1 Ref Ref Ref
diabetes 1 and <2 0.02 (-0.09,0.14) 0.02 (-0.09,0.14) -0.04 (-0.18,0.10)
diagnosis 2 and <3 0.03 (-0.10,0.16) 0.03 (-0.10,0.16) 0.02 (-0.14,0.18)
to ﬁrst 3 and <4 0.15 (0.00,0.29) 0.15 (0.00,0.29) -0.05 (-0.24,0.13)
statin 4 and <6 0.11 (-0.02,0.24) 0.11 (-0.02,0.24) -0.04 (-0.20,0.13)
treatment 6 and <8 0.05 (-0.09,0.20) 0.05 (-0.09,0.20) -0.08 (-0.27,0.10)
(years) 8 and <10 -0.06 (-0.22,0.11) -0.06 (-0.22,0.11) -0.17 (-0.38,0.04)
10 and <15 0.06 (-0.09,0.20) 0.06 (-0.09,0.20) -0.01 (-0.19,0.18)
15 and <20 -0.15 (-0.34,0.04) -0.15 (-0.34,0.04) -0.18 (-0.43,0.06)
20 -0.44 (-0.63,-0.25) -0.44 (-0.63,-0.25) -0.08 (-0.29,0.13)
Calender 2004 -0.25 (-0.42,-0.08) -0.25 (-0.42,-0.08) -0.10 (-0.31,0.10)
year of 2005 -0.10 (-0.25,0.06) -0.10 (-0.25,0.06) -0.07 (-0.27,0.12)
ﬁrst 2006 0.00 (-0.16,0.15) 0.00 (-0.16,0.15) -0.13 (-0.33,0.06)
statin 2007 0.04 (-0.13,0.21) 0.04 (-0.13,0.21) -0.01 (-0.22,0.20)
prescription 2008 0.02 (-0.15,0.19) 0.02 (-0.15,0.19) -0.03 (-0.24,0.18)
2009 0.10 (-0.07,0.28) 0.10 (-0.07,0.28) 0.01 (-0.20,0.23)
2010 Ref Ref Ref
2011 -0.03 (-0.22,0.16) -0.03 (-0.22,0.16) 0.07 (-0.16,0.30)
2012 -0.15 (-0.39,0.08) -0.15 (-0.39,0.08) -0.08 (-0.36,0.20)
COPD 1.68 (1.47,1.90) 1.68 (1.47,1.90) 2.35 (2.11,2.58)
Psychosis 0.45 (0.03,0.87) 0.45 (0.03,0.87) 1.22 (0.84,1.60)
Asthma 0.12 (0.02,0.23) 0.12 (0.02,0.23) -0.20 (-0.33,-0.07)
Atrial ﬁbrilation 0.05 (-0.10,0.19) 0.05 (-0.10,0.19) -0.33 (-0.56,-0.10)
Anti-hypertensive 0.03 (-0.05,0.10) 0.03 (-0.05,0.10) -0.40 (-0.49,-0.31)
drug treatment
Bile acid -0.70 (-2.32,0.92) - -
Ezetimibe -0.44 (-1.09,0.21) -0.44 (-1.09,0.21) -0.10 (-0.85,0.65)
Fibrate 0.21 (-0.06,0.49) 0.21 (-0.06,0.49) -0.03 (-0.39,0.33)
Nicotinic acid -0.31 (-2.15,1.54) -0.31 (-2.15,1.54) 0.20 (-2.16,2.56)
Omega 3 0.05 (-0.90,0.99) 0.05 (-0.90,0.99) 0.44 (-0.59,1.48)
Respiratory infection 0.12 (-0.01,0.26) 0.12 (-0.01,0.26) 0.15 (-0.00,0.31)
Heavy drinker 0.43 (0.32,0.53) 0.43 (0.32,0.53) 0.70 (0.58,0.82)
CHD 0.20 (0.04,0.36) 0.20 (0.04,0.36) 0.31 (0.11,0.51)
Stroke -0.04 (-0.24,0.17) -0.04 (-0.24,0.17) 0.41 (0.17,0.66)
Death 0.10 (-0.04,0.24) 0.10 (-0.04,0.24) 0.48 (0.30,0.66)
OR: odds ratio; CI: conﬁdence interval; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary
disease; Psychoses: schizophrenia, bipolar disorder and other psychoses; CHD: coronary heart disease; Ref:
reference category
In bold if variable is associated (p-value<0.100) with the chance of observing smoking status and its values at
baseline146 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
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6.2.4 Discussion
In this chapter, I used routinely collected, primary care data to investigate which health indicators measured in
the 6 months before initiating statin treatment were associated with greater total cholesterol reduction before and
after initiating statin treatment in patients with type II diabetes. The motivation for this study was to discover
which patients with type II diabetes clinicians could identify as unlikely to respond to statin treatment, such as
those with atherogenic dyslipidaemia, and suggest a possible alternative procedure for treating these patients.
The main strength of this study is analysing a large, nationally representative primary care database. However,
one limitation is the substantial missing health indicator values, which could potentially result in biased estimates
and SE because a plausible MCAR assumption is unlikely. Therefore, I also considered different imputation
approaches, which give unbiased estimates and standard errors under the more plausible MAR assumption, and
including auxiliary variables in the imputation model increased the MAR assumption plausibility. The simulation
results in chapter 5 found the estimates for time-dependent variables from analysing data imputed using the
two-fold FCS algorithm were more precise compared to a ‘baseline’ imputation, so it is a suitable method to
consider in this context.
To aid interpretation of the results in sections 6.2.3.2, I produced a summary table of the p-values (Table 6.16).
The complete records analysis found older patients with higher LDL cholesterol, lower GFR and larger statin
dose were associated with greater total cholesterol reduction (Table 6.16). These ﬁndings may suggest older
patients had a higher total cholesterol at baseline and, therefore, more room for reduction compared to younger
patients prescribed a lower statin dose at baseline. Another possible explanation is older patients with higher total
cholesterol at baseline may be more likely to adhere to the statin treatment because they had higher CVD risk
compared to younger patients with low total cholesterol measurement at baseline. These observations contradict
one study which showed a higher treated total cholesterol (>5mmol l 1) and younger age (<51 years) were less
likely to adhere to statin treatment[109].
Low GFR (due to nephropathy) is common in patients with type 2 diabetes indicating higher risk of CKD[110]
and CVD[111]. From the complete records analysis, patients with lower GFR had greater total cholesterol reduc-
tion after initiating statin treatment, again potentially because patients with higher CVD risk were more likely to
adhere to statin treatment.6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 153
Table 6.16: Summary of p-values from using different methods of handling missing data for fully adjusted anal-
ysis to investigate the association between the baseline variables and the difference between total cholesterol
measurements records before initiating statin treatment and in the ﬁrst six months after ﬁrst statin treatment for
patients with type II diabetes
Complete records Baseline MI Two-fold FCS algorithm
analysis (before baseline) (before and
after baseline)
p-value p-value p-value p-value
Age (years) at ﬁrst <0.001 <0.001 <0.001 <0.001
statin prescription
Sex 0.119 0.026 0.019 0.044
Townsend deprivation 0.456 0.219 0.090 0.064
score quintile
Ethnic group 0.188 <0.001 <0.001 0.001
BMI (per 100kg m 2) 0.952 0.111 0.132 0.060
Systolic blood pressure 0.569 0.130 0.104 0.064
(per 100mmHg)
HDL cholesterol (mmol l 1) 0.345 0.718 0.745 0.810
LDL cholesterol (mmol l 1) <0.001 <0.001 <0.001 <0.001
HbA1c (per 100%) 0.244 0.002 0.007 0.006
GFR (per 100ml min 1) 0.001 <0.001 <0.001 0.009
Smoking status 0.195 <0.001 <0.001 <0.001
Statin dose (mg) <0.001 <0.001 <0.001 <0.001
Time from diabetes diagnosis to 0.329 0.029 0.014 0.007
ﬁrst statin treatment (years)
Calender year of ﬁrst 0.005 <0.001 <0.001 <0.001
statin prescription
FCS: fully conditional speciﬁcation BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; HbA1c: glycosylated haemoglobin; GFR: glomerular ﬁltration rate
The analysis gained power when analysing data imputed using MI compared to complete records analysis. From
analysing greater total cholesterol reduction following baseline MI, in addition to variables from the complete
records analysis, male patients, white ethnicity, higher HbA1c, not current smokers, shorter time from ﬁrst dia-
betes diagnosis to initiating statin treatment and calendar year were also associated with greater total cholesterol
reduction (Table 6.16).
Analysing data imputed using the two-fold FCS algorithm imputation method conditional on measurements
before baseline had a little more power but found similar results to analysing data imputed using baseline MI154 Chapter 6. Application of the two-fold FCS algorithm to substantive analysis of THIN
for the analysis of greater total cholesterol reduction. A possible explanation for ﬁnding similar results could be
because of the substantial missing data for the health indicators at time blocks except baseline and the two-fold
FCS algorithm can not gain much additional information from these time blocks. However, Townsend deprivation
score quintile, BMI and systolic blood pressure were almost statistically signiﬁcantly associated with greater total
cholesterol reduction from analysing data imputed using the two-fold FCS algorithm conditional on measure-
ments before and after baseline. The two-fold FCS algorithm could compensate for the substantial missing data
at each time point by gaining more information from the additional time points after baseline.
Ferro et al. found FIML analysis showed the same results as MI[112] and recommended investigating FIML
analysis compared to MI which conditions on the longitudinal data. Therefore, I compared FIML to using the
two-fold FCS algorithm and I found they gave similar results, which agrees with Ferro et al. ﬁndings. FIML may
not be a suitable method in this context because it was not developed to use the longitudinal data.
The two-fold FCS algorithm conditional on measurements before and after baseline was preferred to complete
records analysis because more variables were associated with greater total cholesterol reduction following base-
line MI compared to the complete records analysis, and these ﬁndings were similar to the descriptive analysis
results (i.e. in the expected direction). The coefﬁcient for HbA1c and statin dose 80 also change direction of
association, but all other coefﬁcients were similar to the complete records analysis. Possibly just having more
power resulted in these variables becoming signiﬁcant, but also some of the odds ratios increased, for example
ethnicity. Even though time from diabetes diagnosis to ﬁrst statin treatment and calendar year of ﬁrst statin
prescription were statistically signiﬁcantly associated with greatest total cholesterol reduction, it was only small
differences and these are possibly not clinically signiﬁcant differences (Table 6.16).
One limitation of this study was the 6 time blocks may have been too small when using the two-fold FCS algo-
rithm. One possible explanation why the two-fold FCS algorithm did not improve the precision of more variables
is because recording was low at other time blocks except baseline due to the small time blocks, so the correlations
between repeated measurements at different time blocks were underestimated, even though I analysed data after
2004 when QOF was introduced to try and minimise the missing data. However, QOF required measurements
every 15 month for these health indicators, so using 6 month time blocks reduced the records within each time
block. I chose to use 6 month time blocks because I was interested in total cholesterol with 6 months after
initiating statin treatment, so I kept all time blocks as 6 months for consistency. However, the two-fold FCS
algorithm is ﬂexible and can impute missing values in time blocks of varying size. Using these wider time points,
the associations between Townsend deprivation score quintile, BMI, systolic blood pressure with greater total
cholesterol reduction from analysing data imputed using the two-fold FCS algorithm conditional on measure-
ments before and after baseline the two-fold FCS algorithm would possibly have been stronger.
A limitation for all MI methods was that I could only include smoking status measured at baseline in the imputa-
tion model because it was too sparsely recorded at other time blocks. But, as I showed in section 5.1, imputing6.2. Total cholesterol reduction after initiating statin treatment for patients diagnosed with type 2 diabetes 155
using repeated smoking status measurements gave more precise estimates compared to imputing at a single time
block.
I chose to investigate total cholesterol reduction in the short time period before and after initiating statin treatment,
rather than modelling the data longitudinally, because patients respond very quickly to statin treatment and after
this initial reduction, total cholesterol levels remain constant if the patient adheres to statin treatment. Patients
must adhere to statin therapy to keep a low total cholesterol. Lamberts et al. showed patients who initiate statin
treatment after the initiation of oral anti-diabetic treatment (which would be the case for patients included in this
cohort) were more likely to discontinue statin treatment than patients who initiate statin treatment before the start
of oral anti-diabetics[113].
The health indicator measures at baseline for patients with smaller total cholesterol reduction suggest these
patients had lower CVD risk at baseline compared to those with greater total cholesterol reduction. However,
patients with smaller total cholesterol reduction were more likely to smoke compared to patients with greater
total cholesterol reduction, which usually increases CVD risk. One possible explanation for this is because these
patient may consider themselves at low risk of CVD so do not consider smoking to be a risk for them.
Recent update to the NICE lipid modiﬁcation clinical guideline[114] proposes to offer high-intensity statin treat-
ment for the primary prevention of CVD to people with type 2 diabetes and lower 10-year risk of developing
CVD, from 20% to 10%, estimating risk using the UK prospective Diabetes Study assessment tool, but patients
with low CVD risk may be reluctant to be prescribed long term statin treatment[115].
6.2.4.1 Clinical implications
This study showed that statins reduce total cholesterol in patients with type II diabetes, contrary to Standl et
al[104]. Patients with type II diabetes prescribed a high dose statin therapy had the largest reduction in total
cholesterol, possibly because these patients had high total cholesterol and CVD risk when statin treatment was
initiated (such as those with atherogenic dyslipidaemia) and may be more likely to adhere to statin treatment.
I found that patients with type II diabetes had a greater reduction in total cholesterol if GFR was low when statins
were initiated. After using MI, the analysis found that male patients, white ethnicity, high HbA1c, not current
smokers and longer time from diabetes diagnosis were also important predictors of greater total cholesterol
reduction. Clinicians can use these ﬁndings to assess the potential CVD risk of patients with type II diabetes and
initiate the appropriate statin therapy.
I recommend analysing data imputed using MI, but the selected method depends on the available longitudinal
data. If regularly recorded, longitudinal data is available the two-fold FCS algorithm may be more beneﬁcial than
a ‘baseline’ MI.Chapter 7
Discussion
7.1 Overview
The motivation for this thesis was to develop and validate a practical approach for addressing the issues raised
by missing data in longitudinal studies using electronic clinical databases, such as The Health Improvement
Network (THIN). Missing data is a common problem for many epidemiological studies using electronic health
record databases of information collected in routine clinical practice and na¨ ıve application of ‘ad–hoc’ methods
(such as complete records) can result in non-trivial bias and substantial loss of power. Appropriate use of multiple
imputation (MI) can give unbiased estimates and standard errors under the assumption the data is missing at
random (MAR)[15] and the model of interest and imputation model are congenial (the imputation models condi-
tional distribution is the same as the model of interests predictive distribution)[20]. However, when I started this
PhD, no established, validated imputation approach existed for missing data in longitudinal, electronic, clinical
databases with many individuals, many time points, many variables and large proportions of missing data.
In previous work, Nevalainen et al.[1] proposed the two-fold fully conditional speciﬁcation (FCS) to potentially
impute missing data in longitudinal databases. Nevalainen et al. validated the two-fold FCS algorithm in a simple
setting with 3 time points and a few variables with no validation of the two-fold FCS algorithm in complex
electronic, health record settings such as THIN, and no published, validated software. Therefore, the overarching
aim of this thesis was to adapt and evaluate the two-fold FCS algorithm and implement it to impute missing data
in large primary care database to take into account the longitudinal and dynamic structures of these data.
The speciﬁc objectives were to:
1. investigate the extent and patterns of missing data in a longitudinal clinical database for health indicators
associated with risk of cardiovascular disease;
2. develop methods to identify and remove outliers before imputation;
3. adapt and develop the two-fold FCS multiple imputation algorithm to impute missing values in longitudinal
clinical data for variables associated with cardiovascular disease;
4. validate the two-fold FCS algorithm through challenging simulation studies; and7.2. Summary of thesis and ﬁndings 157
5. apply the two-fold FCS algorithm in THIN to (i) model risk for cardiovascular disease and (ii) understand
factors associated with greater total cholesterol reduction in patients with type II diabetes.
In this discussion chapter, I ﬁrstly summarise the thesis and the ﬁndings. Secondly, I discuss the methodological
issues I overcame. Next, I discuss the implications of the ﬁndings, and ﬁnally I present my overall conclusions
and review possible areas of future research.
7.2 Summary of thesis and ﬁndings
In this thesis, I ﬁrst described The Health Improvement Network (THIN)[11] primary care database of longitudi-
nal, electronic health records in section 3.1. The data issues raised by missing data directly motivated this thesis.
Primary care databases are a valuable resource for research for the following reasons: they contain information
on populations not eligible for cohort studies or clinical trials, such as pregnant women and children[5, 6]; large
patient numbers allow research on rare conditions[7]; and long follow-up time enable the development of risk
prediction models in clinically relevant populations[8, 10]. Primary care databases contain records on patient
characteristics, diagnoses, prescriptions and health indicators, such as weight, systolic blood pressure and smok-
ing status, captured through routine consultations with a GP or nurse. For valid inferences, we require repeated
measurements of many health indicators. However, issues arise when using data collected to address direct
clinical need for research. For example, primary care databases may have substantial missing health indicator
measurements if patients did not attend a consultation with a GP or nurse or if they attended a consultation and
only information relevant to the consultation was recorded. Analyses of primary care data may be biased if
missing data are not handled appropriately.
The THIN data both directly motivated the project and provided an ideal setting to achieve my aims of develop-
ing, implementing and evaluating the two-fold FCS algorithm because data was collected for patient care, not for
research, so there was a substantial missing data. The large (11 million patients), nationally representative[29],
routinely collect data has great potential for research use. However, missing data issues have to be effectively
addressed if THINs (and other electronic health records) potential for answering research questions is to be
realised.
I addressed many practical considerations before using THIN. The principal ones were selecting the cohort of
patients to include in the analysis, or the time period to use. To develop Read code lists[26] for each disease,
I received feedback on the lists from the GPs (Irwin Nazareth and Kate Walters) in the MRC funded project
‘Missing data imputation in clinical databases: development of a longitudinal model for cardiovascular risk
factors’ Steering Group. The patient records in THIN are also not immediately available for analysis so, once
these decisions were made, I performed considerable data manipulation and management to extract the required
data and prepare it for analysis.
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methods typically attempt a simple ‘ﬁx’ for the missing data, yielding a dataset on which we can perform the in-
tended substantive analysis but, unfortunately, not derived using statistical reasoning so highly unlikely to achieve
valid inferences for data with missingness mechanisms which were probably not plausible in THIN. For example,
a complete records analysis (only patients with observed data for all records were included in the analysis) can
achieve unbiased estimates if the missing completely at random (MCAR) assumption is plausible, and observed
data are representative of all the data, but will overestimate the SEs because of loss of power[15]. A complete
records analysis of THIN would probably give biased results because health indicator data were mainly recorded
for unwell patients who attend a consultation and, therefore, were more likely to be included in the complete
records analysis compared to well patients, who do not require a consultation. This suggests the observed data
would not represent all the data and a complete records analysis would achieve biased estimates and SEs.
Multiple imputation (MI) is an alternative method for handling missing data based on sound statistical
reasoning[18]. I described MI in Section 3.3 and explained it was more suitable to impute missing values
compared to ‘ad–hoc’ methods because it gave unbiased estimates as well as standard errors under the assump-
tion the data was missing at random (MAR, missingness was independent of the missing values conditional on the
observed data) and the model of interest and imputation model are congenial (the imputation models conditional
distribution is the same as the model of interests predictive distribution)[20]. The MAR assumption is a more
plausible assumption about the THIN data than MCAR. Suppose we have a model of interest and a dataset we
wish to ﬁt the model of interest to, but some values of explanatory variables have missing values. We can use
MI to create multiple imputed datasets. First, we specify the imputation model (different from the model of
interest). MI imputes the missing data by selecting random draws from the conditional predictive distribution
of the missing data given the observed so each imputed dataset is ‘complete’. The model of interest is ﬁtted to
each ‘complete’ dataset and the results are correctly combined for ﬁnal inference using Rubin’s MI rules[18].
We can increase the MAR assumption plausibility by including auxiliary variables associated with the chance
of observing variables with missing data in the imputation model[20]. Another advantage of MI is we can also
include auxiliary variables associated with the value of the variables with missing data in the imputation model
to reduce bias and increase precision in the analysis of the imputed data[20]. The attraction of MI is that it is
established as broadly applicable and very ﬂexible, so it is an ideal approach to adapt and develop methods to
overcome missing data issues in this setting.
Traditionally, the MI proceeds by ﬁtting a joint, adjusted normal conditional distribution. However, a multivariate
normal distribution and the model of interest may not be appropriate, for example if the variables are ordered, as in
longitudinal primary care data, or categorical, because the appropriate joint distribution is difﬁcult to deﬁne[21].
In this situation, a more ﬂexible and convenient method is fully conditional speciﬁcation (FCS)[21]. This method
avoids explicitly specifying the joint distribution, though is consistent with the multivariate normal distribution
if appropriate assumptions are satisﬁed[49], and instead uses a series of conditional regression models. FCS
proceeds as follows:
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in the imputation model in turn.
2. ‘Filled-in’ values in the ﬁrst variable are discarded. A regression model for this variable conditional on
other variables in the imputation model is speciﬁed and the missing values are replaced by random draws
from the conditional distribution.
3. step 2 is repeated for each variable in turn. Imputed draws are ‘proper’, reﬂecting uncertainty in the param-
eter estimates. Once each variable is imputed, one ‘cycle’ is complete.
4. steps 2 and 3 are repeated for a pre-speciﬁed number of cycles, considered sufﬁcient for convergence.
FCS is a useful and ﬂexible alternative when we cannot specify a convenient and realistic joint distribution[45]
and allows us to specify the correct distribution for each variable with missing data under the MAR assumption
and compatibility of conditionals (the underlying joint multivariate normal distribution exists).
Before this thesis, we did not know which MI approach was most appropriate to impute missing data in longi-
tudinal clinical records like THIN to take account of the longitudinal and dynamic structure of the data. Two
possible approaches to impute longitudinal, clinical data are either to impute missing data at all time blocks
separately or at all time blocks simultaneously. Imputing each time block separately results in imputed data
which underestimates the correlations between time blocks. We can overcome this problem by imputing all time
blocks simultaneously, but this may result in non-convergence due to co-linearity because of the high correlations
between repeated measures of the same health indicators at different time blocks in large databases with many
time blocks.
An alternative approach is to exploit the temporal structure of the data by simplifying the simultaneous method
using the two-fold FCS algorithm[1], described in section 3.3.10. The two-fold FCS algorithm avoids co-linearity
problems by restricting the time blocks included in the imputation model to a small time window but also takes
account of the longitudinal structure of the data because imputation models included measurements at nearby
time blocks. The two-fold FCS algorithm assumes conditional independence i.e. measurements outside of the
time window are independent if we condition on measurements closer in time. The two-fold FCS algorithm
readily copes with the intermittent missingness pattern because the imputation models condition on observed
measurements before and after the time block of interest. Various parameters associated with the two-fold FCS
algorithm, such as the window width, within-time iterations and among-time iterations, can be modiﬁed if appro-
priate for the missing data context.
7.2.1 Investigate the extent and patterns of missing data in a longitudinal clinical
database for health indicators associated with risk of cardiovascular disease
I assessed the plausibility of the MAR assumption by investigating recording of health indicators (e.g. height,
weight and systolic blood pressure) associated with cardiovascular disease (CVD). Initially I explored health
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because recording varied by age and sex. From this investigation, I found higher height, weight and systolic
blood pressure annual recording for female patients aged less than 75 years compared to male patients. After age
75 years, annual recording decreased similarly for male and female patients. Most health indicator recording per
consultation was similar for men and women. However, male patients aged less than 75 years had higher height
measurement recording per consultation compared to female patients aged less than 75 years, and female patients
had higher weight and systolic blood pressure recording per consultation below age 40 years. The distribution of
annual recording of total cholesterol measurements was similar for male and female patients but, after adjusting
for number of consultations, male patient had a higher recording of total cholesterol measurements compared to
female patients. Male patients consult less frequently than female patients[80] and the health indicators recorded
during consultations varied dependent on sex. Female patients were more likely to have weight and systolic
blood recorded compared to men, especially at aged less than 40 years, which could be explained by female
patients attending contraception or pregnancy related consultations. Male patients were more likely to have total
cholesterol recorded compared to female patients, which might be because they have higher CVD risk compared
to female patients.
I also investigated health indicator recording from 1995 to 2011 to explore the effects of two incentives intro-
duced by the Department of Health (DoH). The ﬁrst was ‘new patient health checks’, ﬁnancial incentives which
encouraged GPs to record health indicators for all newly registered patients, introduced in 1992[12]. The second
was the Quality Outcomes Framework (QOF)[14], introduced in 2004, to encourage practices to record health
indicators relevant to monitor patients with speciﬁc diseases.
I found the MCAR assumption appeared most plausible in the year after registration because practices performed
‘new patient health checks’ so GPs collected information regardless of age, sex or health status but conditional
on registration status. However, after registration approximately two times more patients had health indicators
recorded if diagnosed with one of the Quality Outcomes Framework (QOF) speciﬁed diseases (such as CVD
or diabetes), which is evidence of a MAR assumption. Conditioning on these diseases in the imputation model
increases the MAR assumption plausibility because it is less likely the probability of the variable being missing
will depend on the missing values themselves, conditional on these observed auxiliary variables[20].
Total cholesterol recording over time was different to other health indicators, with substantially more missing data
at registration (5% observed) but recording steadily increased over time. One possible reasons is because total
cholesterol is not recorded at registration as part of the ‘new patient health check’. Another possible reason is
because a blood sample was required to measure total cholesterol, so it was mainly recorded if the GP suspected
the patient had a disease, or presented with another indicator for CVD such as high body mass index (BMI) or
high blood pressure, and a total cholesterol measurement was required to conﬁrm high CVD risk. However, total
cholesterol recording improved after 1999, at approximately 10%, when statins (a lipid-modifying drug) became
more commonly prescribed. Statins and other lipid-modifying drugs lower total cholesterol, so GPs monitor
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also increased with the introduction of QOF in 2004, to approximately 20%, and GPs were required to monitor
total cholesterol for patients with QOF speciﬁed diseases, such as CVD or diabetes. These results suggest total
cholesterol measurements themselves recorded in THIN were probably abnormal (total cholesterol recording
more likely for patients with higher total cholesterol) if the patient had one of the QOF speciﬁed diseases, but
normal if the patient was treated with a lipid modifying drug. Therefore, to ensure a plausible MAR assumption
to imputing missing total cholesterol, I included the QOF speciﬁed diseases and lipid-modifying drug treatment
in the imputation model.
I next considered the best approach to impute smoking status, which required additional reﬂection because it
is a categorical variable (not normally distributed) with three categories non-smoker, ex-smoker and current
smoker. In particular, the added complexity of imputing smoking status over time arises when trying to avoid
impute impossible values. For example, not imputing previous current smokers as non-smokers. From discussing
smoking habits with GPs, I discovered GPs recorded only a few smoking status records for non-smokers during
follow-up because adult non-smokers were unlikely to start smoking so thought it unnecessary to update smoking
status regularly. However, ever smokers might change smoking status so GPs update smoking status regularly
for these patients; ex-smokers would start smoking again and current smokers would stop smoking. Based on
these ﬁndings, I interrogated THIN to ﬁnd if the data recorded agreed with the GPs observations. I found that if I
assumed that patients who only ever had non-smoker smoking status recorded in THIN were non-smokers at all
time, this increased the percentage of non-smokers to a similar percentage of non-smokers reported by the 2006
Health Survey for England (HSE)[77]. Applying this assumption to the data also greatly reduced the missing data
and I imputed the remaining missing values to either ex-smoker or current smoker, which substantially simpliﬁes
the problem.
7.2.2 Develop methods to identify and remove outliers before imputation
The last data recording issue I considered before using the two-fold FCS algorithm was incorrectly recorded
values, i.e. outliers, which are a common occurrence in electronic health records such as primary care databases.
If I used MI when outliers were still in the data, they could bias the conditional distribution of the data and
inﬂuence the imputation of the missing values and bias the associations between the variables. However, because
THIN consists of millions of patients, some genuine extreme values may exist in the data and I did not want to
lose the diversity of the data. I required a method which would distinguish between genuine extreme values and
incorrectly recorded values.
Existing methods to remove outliers did not take account of repeated measures over time. Therefore, I developed
a method to remove outliers in two stages. First, I identiﬁed population level outliers (values substantially outside
the range of the distribution of measurements from the general population) as measurements more extreme than
age and gender speciﬁc ranges from the 1998 and 2008 HSE data[76, 78]. Once the population level outliers
were removed, the next stage was to identify individual level outliers (highly implausible values in the context
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patient speciﬁc random intercept and slope. This allowed me to identify measurements very different from the
mean of all observations for that patient, after allowing for the trend in their measurements over time. Therefore,
I identiﬁed measurements as outliers if standardised residuals were more extreme than a given cut-off. In total, I
identiﬁed 1,643 (0.3%) height measurements as outliers after application of both methods to identify population
level outliers and individual level outliers using a ‘cut off’ of  10 standardised residuals[4].
This new method to identify outliers in longitudinal data is available for other users to identify outliers in longi-
tudinal data prior to analysis. Although I only identiﬁed a relatively small number of individual level outliers this
should still give users conﬁdence in the consistency of remaining data. Pharmacoepidemiology and Drug Safety
journal published a paper describing this method[4].
7.2.3 Adapt and develop the two-fold FCS multiple imputation algorithm to impute
missing values in longitudinal clinical data for variables associated with CVD
The original study, reported by Nevalainen et al.[1], validated the two-fold FCS algorithm using simulated data
in a simple setting with measurements at three time points and up to 40% missing values. I implemented a more
ﬂexible two-fold FCS algorithm which imputes time-independent as well as time-dependent variables, increase
the time window width and imputes missing data for subjects with different entry and exit time points.
I developed a Stata command twofold, which implements the two-fold FCS algorithm used in this study in real
electronic health care data. The twofold command is available for other users to impute missing data in any
other large, clinical, longitudinal dataset with a intermittent missingness[2].
A possible advantage of the two-fold FCS algorithm compared to baseline MI is conditioning on repeated mea-
surements at other time blocks potentially increases the MAR assumption plausibility. Measurements at other
time blocks may be associated with the probability of the values being missing at the time blocks of interest. For
example, if a patient had a high total cholesterol measurement, they may be more likely to have it recorded again
at the next time block because the GP will wish to take repeated measurement to monitor the high total cholesterol.
The two-fold FCS algorithm exploits the longitudinal structure, with stronger local dependencies, to simplify the
imputation process: values at a given time block were imputed using only measurements at nearby time blocks
(plus outcome and time-independent variables). In all settings, we must carefully consider if the simpliﬁcation is
reasonable for the data. For example, if an exploratory analysis found measurements further away in time provide
independent information given the adjacent time blocks, we can increase the time window width.
As with standard FCS MI, the two-fold FCS algorithm is iterative, and must perform a sufﬁcient iterations and
imputations to ensure the algorithm converges to its stationary distribution. I found the two-fold FCS algorithm
converged with relatively few within-time iterations (i.e. 5) and a larger among-time iterations (10-20). The
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but data imputed with more among-time iterations had correlations closer to those from the simulated data before
values were made missing. However, as with standard FCS MI, to assess if enough within-time and among-time
iterations were selected we can evaluate diagnostics (such as plotting means and standard deviations of the im-
puted data by iteration number) to empirically assess convergence and, if necessary, perform more iterations.
In this thesis I used 5 imputations, which is not uncommon for relative comparisons of methods using simulation,
to achieve valid inferences (for which 5 is sufﬁcient[50]) but more would substantially increase computational
time. Some studies recommended more imputations, around 30[58, 73, 116], to reduce the impact of the random
sampling inherent in MI procedures. Other studies suggest 100-200 imputations were required before the results
were sufﬁciently accurate for critical inferences[46]. However, this depended on what was considered an accept-
able loss of power. Statistical power for small effect sizes diminishes as imputations decreases, and Graham et al.
found the rate of this power fall off was much greater than predicted by changes in relative efﬁciency[116]. Even
if coefﬁcient estimates are accurately imputed, this does not necessarily imply p-values are also accurate[17].
Therefore, if an accurate estimate of the p-value or fraction of missing information are required, use approxi-
mately 100 imputations[20].
FCS is only valid if an underlying joint conditional model exists[21]. Even though I did not investigate the
validity of this for the two-fold FCS algorithm, I assumed that it was true because, despite a lack of theoretical
justiﬁcation, simulation studies showed FCS works acceptably well[46]. Investigations of direct vs. indirect
imputation found similar results are expected from both[47]. However, I validated the two-fold FCS algorithm
for imputing data in a longitudinal data setting using simulation studies, which builds on the previous studies, to
establish the validity of this approach in a range of settings.
7.2.4 Validate the two-fold FCS algorithm through challenging simulation studies
Once I ﬁnished investigating data recording in THIN, the next aim was to evaluate the two-fold FCS algorithm
using simulated data. This project is the ﬁrst study to validate the two-fold FCS algorithm in longitudinal clinical
data using comprehensive simulation studies directly informed by, and closely modelled on, the THIN data, a
good example of a setting which would beneﬁt from these methods.
An advantage of simulation studies is it allowed me to compare the imputed data to the original data to evaluate
the two-fold FCS algorithm because the original coefﬁcients were known from the data generation mechanism.
Also, I could re-run the analysis with different among-time iterations and window width to investigate conver-
gence. I directly developed the simulation study with a survival model using THIN data, so the results validate
using the two-fold FCS algorithm for commonly used survival models using THIN. Performing a simulation
study required careful programming.
I created simulations as realistic as possible to a real life epidemiological analysis. First I simulated data to mimic
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and a future coronary heart disease (CHD) event over 10 time blocks adjusted for age, Townsend deprivation
quintile and anti-hypertensive drug treatment. I used an exponential model of interest, a time-to-event model
computational tractable for the simulation study (rather than a proportional hazards model, which introduces
considerable additional coding complexity).
I ﬁtted the model of interest to the full simulated data to obtain estimates and standard errors for the data with no
missing values. Next, I changed measurements in the simulated data to missing for weight, systolic blood pressure
and smoking status using a MCAR mechanism because both the complete records analysis and analysis of data
imputed using MI should be unbiased under a MCAR mechanism. Another beneﬁt of a MCAR mechanism was
I could directly compare the SEs for the full, complete records and analyses of data imputed using MI, if no bias
exists after imputation, to see how they compared in terms of recovering information.
First, the FCS imputation model imputed missing values in all time blocks by entering measurements at each time
block as separate variables in the imputation model, i.e. the ‘full imputation’ model. Next, I imputed the missing
data using the two-fold FCS algorithm, investigated two different approaches for handling missing smoking sta-
tus. For the ﬁrst method, I imputing smoking status as a time-independent variable (measured only at baseline).
For the second method, I imputed smoking status as time-dependent variable using the two-fold FCS algorithm,
assuming all patients who only ever had non-smoker smoking status recorded were non-smokers at all time blocks
and imputed any remaining missing values as either ex-smoker or current smoker. I evaluated the approaches by
comparing bias and precision of estimates from ﬁtting the model of interest to the original simulated data, com-
plete records analysis and data imputed using a ‘baseline MI’ and both methods using the two-fold FCS algorithm.
The ‘full imputation’ model did not converge on approximately 25% of datasets because repeated measure-
ments of the same health indicator at different time blocks included in the imputation model caused convergence
problems. As explained earlier, we expected potential convergence problems due to high correlations between
repeated measurements. The simulation study showed that data imputed using the two-fold FCS algorithm
improved estimate precision (closer to the ‘true’ precision in the full data) for time-dependent variables. The
improvement was greater for variables with stronger correlations between repeated measurements such as weight.
The simulation study also showed improved precision for smoking status when I imputed it as a time-dependent
variable compared to time-independent. This result suggest it is preferable, if possible, to use deterministic
methods which apply our knowledge of the data to impute missing values before using MI. Similar methods
could be applied to impute other categorical variables with missing values with a few categories, such as alcohol
consumption (e.g. abstain, moderate drinker, heavy drinker etc.).
Simulated data imputed using the two-fold FCS algorithm achieved more accurate (closer to the ‘true’ correla-
tions) estimated correlations between repeated measurements with more among-time iterations and for health
indicators with high ‘true’ correlations, possibly because the higher correlations contain more information, which
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I also investigated how increasing the window width to include variables recorded at more time blocks in the
imputation model affected the correlation estimates in the imputed data. This additional information achieved
correlation estimates closer to the ‘true’ value for repeated measurements within the speciﬁed time window width,
systematically underestimating correlations at greater distance. I remedied this to a limited extent by increasing
the number of among-time iterations, but this did not eliminate the bias completely and worked less well if
the underlying correlations were lower. In practice, therefore, consider a window width the same length as the
distance of the correlations to accurately estimate.
I encountered a few issues when performing the simulation study. Firstly, the imputations did not converge
if I changed 70% of values for each variable to missing at each time block because of the sparsely observed
data. However, I found fewer imputation issues when I switched to a contextually more plausible missing data
mechanism. I assigned 30% to have a ‘consultation’ and I changed all measurements to missing for those who
did not consult and, for each health indicator, randomly selected 5% of patients who did consult to change values
to missing. This missingness mechanism reﬂects real life data recording patterns in THIN and the imputation
models converged because many patients had more than one health indicator recorded. Therefore, it is unlikely
the two-fold FCS algorithm will not converge when imputing missing data in a primary care database like THIN
because multiple health indicators measurements were probably recorded for patients who attend consultations.
I also performed a second simulation study to investigate different ways to apply the two-fold FCS algorithm
to impute missing total cholesterol values in section 5.2. I used the same model of interest as the previous
simulation study, but additionally including the variables total cholesterol and lipid modifying drugs, measured at
the baseline time block. I included both because, as explained earlier, total cholesterol recording is different for
patients prescribed lipid-modifying drugs compared to those not prescribed lipid-modifying drugs.
I changed more total cholesterol values to missing compared to the previous simulation study. With a high
percentage of missing data, just including data recorded at adjacent time blocks in the two-fold FCS algorithm
may not be sufﬁcient additional information to achieve unbiased and precise estimates from ﬁtting the model of
interest to the imputed data. Therefore, I analysed data imputed using three different imputation approaches, listed
below, applying the two-fold FCS algorithm which incorporates measurements at more distant time blocks, and
compared the estimates and standard errors to analysing data imputed using the two-fold FCS algorithm with one
time block window width. I imputed missing total cholesterol measurements using the two-fold FCS algorithm
with a:
 2 time block window width so measurements at more time blocks were included in the imputation model
to inform imputation.
 1 time block window width. Missing values at time blocks adjacent to the imputed time block were replaced
with observed values at the next more extreme time blocks.
 1 time block window width. Missing values at time blocks adjacent to the imputed time block were replaced166 Chapter 7. Discussion
with the closest observed values at more extreme time blocks. Additional variables were included in the
imputation model to indicate which time block the measurement was observed to account for the difference
between measurements at those time blocks.
None of these methods gave signiﬁcantly less bias or more precise estimates compared to using the two-fold FCS
algorithm with one time block window width. This result suggests that the additional information at time blocks
at more extreme time blocks added very little additional information after conditioning on adjacent time blocks,
possibly because of the substantial missing data.
7.2.5 Apply the two-fold FCS algorithm in THIN
In this thesis, I investigated recording of health indicators in THIN and concluded a plausible MAR assumption
for health indicators associated with CVD and used simulation studies to evaluate the best imputation approach
using the two-fold FCS algorithm. Next, I implemented the two-fold FCS algorithm to impute missing values
in THIN. I applied the Stata program described above to address two substantive research questions using THIN
data, in which missing data could potentially bias estimates and standard errors.
In Section 6.1, I extracted data for patients actively registered to a THIN practice in the year 2000 and followed
them up until a CVD event, left the practice or died. Follow-up was censored at 2009. I used an exponential
survival model to ﬁnd the association between health indicators recorded in the year 2000 and future CVD risk
adjusted for age, sex and Townsend deprivation score quintile. First I performed a complete records analysis and
compared the results to an analysing data imputed using baseline MI (imputing missing values at the baseline time
block, year 2000, conditional on observed measurements at the baseline time block) and used the two-fold FCS
algorithm to impute missing data for the health indicators height, weight, systolic blood pressure, total cholesterol
and HDL cholesterol. I included auxiliary variables in the imputation model to reduce bias of estimates and SEs
and to increase the MAR assumption plausibility. I stratiﬁed THIN by sex and practice and imputed each strata
separately to make the imputations manageable and to account for interactions of sex and practice.
I was encouraged to reach the same conclusions as the simulation study. Speciﬁcally, I found that the estimates
for the time-dependent health indicators in the exponential survival model were more precise when analysing data
imputed using the two-fold FCS algorithm compared to complete records analysis or baseline MI, with similar
estimates to other studies.
In section 6.2, I also implemented the two-fold FCS algorithm in an epidemiological study. The motivation
for this study was to discover which patients with type II diabetes had a greater than average total cholesterol
reduction after initiating statin treatment. For this study, I compared the results from complete records analysis,
baseline MI and using the two-fold FCS algorithm in two ways: ﬁrstly, the imputation model including covariate
information recorded before baseline. Secondly, the imputation model included covariate information recorded
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The results from the complete records analysis showed that patients with lower glomerular ﬁltration rate (GFR)
had larger total cholesterol reduction after initiating statin treatment. However, after using baseline MI (imputing
missing values at baseline conditional on observed values at baseline only) more variables (male patients, white
ethnicity, higher HbA1c and not current smokers) were also important predictors of larger total cholesterol re-
duction. The extra power gained by using more information in the analysis of data imputed using baseline MI
compared to the complete records analysis resulted in a change in the estimates and increased precision. The
health indicators for patients with greater total cholesterol reduction indicated greater CVD risk so they were
possibly more likely to adhere to statin treatment and prescribed a higher statin dose compared to patients with
lower CVD risk and, therefore, smaller total cholesterol reduction. Also, these patients probably had a higher
total cholesterol measurement when statins were initiated, so had more room for reduction.
Analysing data imputed using the two-fold FCS algorithm imputation method conditional on measurements
before baseline had a little more power but found similar results to analysing data imputed using baseline MI
for the analysis of greater total cholesterol reduction, possibly because of the substantial missing data for the
health indicators at time blocks, except baseline, and the two-fold FCS algorithm can not gain much additional
information from these time blocks. However, Townsend deprivation score quintile, BMI and systolic blood
pressure were almost statistically signiﬁcantly associated with greater total cholesterol reduction from analysing
data imputed using the two-fold FCS algorithm conditional on measurements before and after baseline. The
two-fold FCS algorithm could compensate for the substantial missing data at each time point by gaining more
information from the additional time points after baseline. Therefore, I would still recommend using the two-fold
FCS algorithm because we do not know the extent of the information in the longitudinal data in advance of the
analysis, but we can explore recording frequency before using MI.
7.3 Methodological implications
This thesis is the ﬁrst to extensively report the recording of health indicators in a primary care database and
understand the reasons for missing data, which could be useful information for other studies using primary care
databases.
This project is also the ﬁrst to examine utility of the two-fold FCS algorithm on a large clinically substantive
analysis of THIN data.
7.4 Applied implications
Other studies investigating MI in longitudinal databases considered simpler settings compared to the setting I in-
vestigated for this thesis. For example, one study used data with a monotone missing pattern[117], some imputed
missing data at a single time point[71, 118], others used a small dataset so included measurements at all time
points in the imputation model without any computational issues arising[119, 120] and one other imputed the
outcome in a longitudinal cohort study[121]. Similar studies could alternatively use the two-fold FCS algorithm168 Chapter 7. Discussion
to allow more complex imputations and analysis.
7.5 Conclusions
In this project, I investigated the recording of health indicators in THIN, implemented the two-fold FCS algorithm
in Stata to impute missing values in longitudinal clinical data, evaluated it using simulated data and used the ﬁnd-
ings to implemented it to impute missing data in THIN. From the simulation studies, I found the two-fold FCS
algorithm improved the estimate precision of the regression analysis for time-dependent variables. The precision
was more accurately estimated when stronger correlations existed between the repeated measurements. I found
the same results from imputing missing values in THIN using the two-fold FCS algorithm.
A few recommendations for researchers planning on using the two-fold FCS algorithm. Firstly, explore the data
in detail prior to analysis to evaluate if the MAR assumption is plausible within the relevant dataset. To gain sufﬁ-
cient understanding of the missingness mechainism, I advise consultation with experts in the research area. These
experts can possibly suggest reasons why data are missing. Next, build the imputation model so it is congenial
with the model of interest. Including several auxiliary variables may increase the MAR assumption plausibility.
For example, disease markers such as diabetes and respiratory infections as well as demographic variables. The
two-fold FCS algorithm is more efﬁcient compared to other approaches when imputing time-dependent variables,
so include repeated measurements for as many variables as possible. If only a few auxiliary variables are avail-
able, including many time blocks will increase the MAR assumption plausibility. The two-fold FCS algorithm
is also beneﬁcial when there is substantial missing data at each time block, because it can condition on any
observed measurements during follow-up. More traditional imputation methods might be preferred if the data
has a small number of time points, small amount of missing data or stronger correlations exist within-time rather
than among-time.
Next, I suggest a few considerations for future work involving the two-fold FCS algorithm not covered in this
thesis.
7.6 Future work
In this thesis, I assumed the two-fold FCS algorithm imputations were congenial with the model of interest.
However, further work is required to assess this assumptions plausibility when using the two-fold FCS algorithm
to impute longitudinal data. We need further research to explore how to impute longitudinal data with interactions
and non-linear effects using the two-fold FCS algorithm. In this thesis, I simpliﬁed the problem and handled
interactions by dividing the data into stratum and imputed each strata separately. It may be possible to impute
all strata together by combining the two-fold FCS algorithm with substantive model compatible MI to ensure
compatibility of conditionals[55].
I used ﬁve imputations when imputing missing data in this project. However, many imputations may not be7.6. Future work 169
necessary for the two-fold FCS algorithm because of the combination of within-time and among-time iterations
used in each imputation, but further work is required to investigate this.
In clinical datasets, recording was more complete in recent years compared to earlier time periods, as shown in
chapter 4.3. The two-fold FCS algorithm allows researchers to capture and make use of data recorded in more
recent years, to inform and improve the precision of baseline survival models. This has particular relevance to
studies using clinical data with a long lag between the exposure of interest and outcome, and researchers may
wish to maximize follow-up time and select early cohort entry dates[122]. Also, the two-fold FCS algorithm may
be more beneﬁcial than a ‘baseline’ MI model for studies with smaller sample size, as it can obtain additional
information recorded at other times.
For this study, I focused on implementing the two-fold FCS algorithm in longitudinal, electronic health records.
However, the two-fold FCS algorithm can potentially be implemented in any observational study with repeated
measurements. For example, survey data. Where there are gaps between recording when participants have missed
a survey, potentially this information could be imputed using the two-fold FCS algorithm, which may be the best
approach because it uses the recorded information when surveys were completed before and after the missing
survey data.
Finally, I only investigated models of interest with explanatory variables measured at a single time block. Further
work is required to investigate if the two-fold FCS algorithm achieves unbiased results for models using infor-
mation at more than one time block, for example with time-updated coefﬁcients. Potentially, the two-fold FCS
algorithm could also be used to impute missing values in dataset used for developing risk prediction models that
include time-updated coefﬁcients.Appendix A
Quality outcomes framework coronary heart
disease Read code list
Read code Description
G3...00 Ischaemic heart disease
G3...11 Arteriosclerotic heart disease
G3...12 Atherosclerotic heart disease
G3...13 IHD - Ischaemic heart disease
G30..00 Acute myocardial infarction
G30..11 Attack - heart
G30..12 Coronary thrombosis
G30..13 Cardiac rupture following myocardial infarction (MI)
G30..14 Heart attack
G30..15 MI - acute myocardial infarction
G30..16 Thrombosis - coronary
G30..17 Silent myocardial infarction
G300.00 Acute anterolateral infarction
G301.00 Other speciﬁed anterior myocardial infarction
G301000 Acute anteroapical infarction
G301100 Acute anteroseptal infarction
G301z00 Anterior myocardial infarction NOS
G302.00 Acute inferolateral infarction
G303.00 Acute inferoposterior infarction
G304.00 Posterior myocardial infarction NOS
G305.00 Lateral myocardial infarction NOS
G306.00 True posterior myocardial infarction
G307.00 Acute subendocardial infarction
G307000 Acute non-Q wave infarction
G307100 Acute non-ST segment elevation myocardial infarction
G308.00 Inferior myocardial infarction NOS
G309.00 Acute Q-wave infarct
G30A.00 Mural thrombosis
G30B.00 Acute posterolateral myocardial infarction
G30X.00 Acute transmural myocardial infarction of unspecif site
G30X000 Acute ST segment elevation myocardial infarction
G30y.00 Other acute myocardial infarction
G30y000 Acute atrial infarction
G30y100 Acute papillary muscle infarction
G30y200 Acute septal infarction
G30yz00 Other acute myocardial infarction NOS
G30z.00 Acute myocardial infarction NOS
G31..00 Other acute and subacute ischaemic heart disease
G310.00 Postmyocardial infarction syndrome
G310.11 Dressler’s syndrome
G311.00 Preinfarction syndrome
G311.11 Crescendo angina
G311.12 Impending infarction
G311.13 Unstable angina
G311.14 Angina at rest
G311000 Myocardial infarction aborted171
G311011 MI - myocardial infarction aborted
G311100 Unstable angina
G311200 Angina at rest
G311300 Refractory angina
G311400 Worsening angina
G311500 Acute coronary syndrome
G311z00 Preinfarction syndrome NOS
G312.00 Coronary thrombosis not resulting in myocardial infarction
G31y.00 Other acute and subacute ischaemic heart disease
G31y000 Acute coronary insufﬁciency
G31y100 Microinfarction of heart
G31y200 Subendocardial ischaemia
G31y300 Transient myocardial ischaemia
G31yz00 Other acute and subacute ischaemic heart disease NOS
G32..00 Old myocardial infarction
G32..11 Healed myocardial infarction
G32..12 Personal history of myocardial infarction
G33..00 Angina pectoris
G330.00 Angina decubitus
G330000 Nocturnal angina
G330z00 Angina decubitus NOS
G331.00 Prinzmetal’s angina
G331.11 Variant angina pectoris
G332.00 Coronary artery spasm
G33z.00 Angina pectoris NOS
G33z000 Status anginosus
G33z100 Stenocardia
G33z200 Syncope anginosa
G33z300 Angina on effort
G33z400 Ischaemic chest pain
G33z500 Post infarct angina
G33z600 New onset angina
G33z700 Stable angina
G33zz00 Angina pectoris NOS
G34..00 Other chronic ischaemic heart disease
G340.00 Coronary atherosclerosis
G340.11 Triple vessel disease of the heart
G340.12 Coronary artery disease
G340000 Single coronary vessel disease
G340100 Double coronary vessel disease
G342.00 Atherosclerotic cardiovascular disease
G343.00 Ischaemic cardiomyopathy
G344.00 Silent myocardial ischaemia
G34y.00 Other speciﬁed chronic ischaemic heart disease
G34y000 Chronic coronary insufﬁciency
G34y100 Chronic myocardial ischaemia
G34yz00 Other speciﬁed chronic ischaemic heart disease NOS
G34z.00 Other chronic ischaemic heart disease NOS
G34z000 Asymptomatic coronary heart disease
G35..00 Subsequent myocardial infarction
G350.00 Subsequent myocardial infarction of anterior wall
G351.00 Subsequent myocardial infarction of inferior wall
G353.00 Subsequent myocardial infarction of other sites
G35X.00 Subsequent myocardial infarction of unspeciﬁed site
G36..00 Certain current complication follow acute myocardial infarct
G360.00 Haemopericardium/current comp folow acut myocard infarct
G361.00 Atrial septal defect/curr comp folow acut myocardal infarct
G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn
G363.00 Ruptur cardiac wall w’out haemopericard/cur comp fol ac MI
G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct
G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct
G366.00 Thrombosis atrium,auric append and vent/curr comp foll acute MI
G38..00 Postoperative myocardial infarction
G380.00 Postoperative transmural myocardial infarction anterior wall
G381.00 Postoperative transmural myocardial infarction inferior wall
G382.00 Postoperative transmural myocardial infarction other sites
G383.00 Postoperative transmural myocardial infarction unspec site
G384.00 Postoperative subendocardial myocardial infarction
G38z.00 Postoperative myocardial infarction, unspeciﬁed
G3y..00 Other speciﬁed ischaemic heart disease
G3z..00 Ischaemic heart disease NOSAppendix B
Quality outcomes framework stroke Read code list
Read code Description
G65..00 Transient cerebral ischaemia
G65..11 Drop attack
G65..12 Transient ischaemic attack
G65..13 Vertebro-basilar insufﬁciency
G650.00 Basilar artery syndrome
G650.11 Insufﬁciency - basilar artery
G651.00 Vertebral artery syndrome
G651000 Vertebro-basilar artery syndrome
G652.00 Subclavian steal syndrome
G653.00 Carotid artery syndrome hemispheric
G654.00 Multiple and bilateral precerebral artery syndromes
G656.00 Vertebrobasilar insufﬁciency
G65y.00 Other transient cerebral ischaemia
G65z.00 Transient cerebral ischaemia NOS
G65z000 Impending cerebral ischaemia
G65z100 Intermittent cerebral ischaemia
G65zz00 Transient cerebral ischaemia NOS
F423600 Amaurosis fugax
G61..00 Intracerebral haemorrhage
G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage
G61..12 Stroke due to intracerebral haemorrhage
G610.00 Cortical haemorrhage
G611.00 Internal capsule haemorrhage
G612.00 Basal nucleus haemorrhage
G613.00 Cerebellar haemorrhage
G614.00 Pontine haemorrhage
G615.00 Bulbar haemorrhage
G616.00 External capsule haemorrhage
G618.00 Intracerebral haemorrhage, multiple localized
G61X.00 Intracerebral haemorrhage in hemisphere, unspeciﬁed
G61X000 Left sided intracerebral haemorrhage, unspeciﬁed
G61X100 Right sided intracerebral haemorrhage, unspeciﬁed
G61z.00 Intracerebral haemorrhage NOS
G63y000 Cerebral infarct due to thrombosis of precerebral arteries
G63y100 Cerebral infarction due to embolism of precerebral arteries
G64..00 Cerebral arterial occlusion
G64..11 CVA - cerebral artery occlusion
G64..12 Infarction - cerebral
G64..13 Stroke due to cerebral arterial occlusion
G640.00 Cerebral thrombosis
G640000 Cerebral infarction due to thrombosis of cerebral arteries
G641.00 Cerebral embolism
G641.11 Cerebral embolus
G641000 Cerebral infarction due to embolism of cerebral arteries
G64z.00 Cerebral infarction NOS
G64z.11 Brainstem infarction NOS
G64z.12 Cerebellar infarction
G64z000 Brainstem infarction
G64z100 Wallenberg syndrome
G64z111 Lateral medullary syndrome
G64z200 Left sided cerebral infarctionAppendix C
Quality outcomes framework diabetes Read code
list
Read code Description
C10E.00 Type 1 diabetes mellitus
C10E.11 Type I diabetes mellitus
C10E.12 Insulin dependent diabetes mellitus
C10E000 Type 1 diabetes mellitus with renal complications
C10E011 Type I diabetes mellitus with renal complications
C10E012 Insulin-dependent diabetes mellitus with renal complications
C10E100 Type 1 diabetes mellitus with ophthalmic complications
C10E111 Type I diabetes mellitus with ophthalmic complications
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps
C10E200 Type 1 diabetes mellitus with neurological complications
C10E211 Type I diabetes mellitus with neurological complications
C10E212 Insulin-dependent diabetes mellitus with neurological comps
C10E300 Type 1 diabetes mellitus with multiple complications
C10E311 Type I diabetes mellitus with multiple complications
C10E312 Insulin dependent diabetes mellitus with multiple complicat
C10E400 Unstable type 1 diabetes mellitus
C10E411 Unstable type I diabetes mellitus
C10E412 Unstable insulin dependent diabetes mellitus
C10E500 Type 1 diabetes mellitus with ulcer
C10E511 Type I diabetes mellitus with ulcer
C10E512 Insulin dependent diabetes mellitus with ulcer
C10E600 Type 1 diabetes mellitus with gangrene
C10E611 Type I diabetes mellitus with gangrene
C10E612 Insulin dependent diabetes mellitus with gangrene
C10E700 Type 1 diabetes mellitus with retinopathy
C10E711 Type I diabetes mellitus with retinopathy
C10E712 Insulin dependent diabetes mellitus with retinopathy
C10E800 Type 1 diabetes mellitus - poor control
C10E811 Type I diabetes mellitus - poor control
C10E812 Insulin dependent diabetes mellitus - poor control
C10E900 Type 1 diabetes mellitus maturity onset
C10E911 Type I diabetes mellitus maturity onset
C10E912 Insulin dependent diabetes maturity onset
C10EA00 Type 1 diabetes mellitus without complication
C10EA11 Type I diabetes mellitus without complication
C10EA12 Insulin-dependent diabetes without complication
C10EB00 Type 1 diabetes mellitus with mononeuropathy
C10EB11 Type I diabetes mellitus with mononeuropathy
C10EB12 Insulin dependent diabetes mellitus with mononeuropathy
C10EC00 Type 1 diabetes mellitus with polyneuropathy
C10EC11 Type I diabetes mellitus with polyneuropathy
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy
C10ED00 Type 1 diabetes mellitus with nephropathy
C10ED11 Type I diabetes mellitus with nephropathy
C10ED12 Insulin dependent diabetes mellitus with nephropathy
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma
C10EE11 Type I diabetes mellitus with hypoglycaemic coma
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma174 Appendix C. Quality outcomes framework diabetes Read code list
Read code Description
C10EF00 Type 1 diabetes mellitus with diabetic cataract
C10EF11 Type I diabetes mellitus with diabetic cataract
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy
C10EG11 Type I diabetes mellitus with peripheral angiopathy
C10EG12 Insulin dependent diab mell with peripheral angiopathy
C10EH00 Type 1 diabetes mellitus with arthropathy
C10EH11 Type I diabetes mellitus with arthropathy
C10EH12 Insulin dependent diabetes mellitus with arthropathy
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy
C10EJ12 Insulin dependent diab mell with neuropathic arthropathy
C10EK00 Type 1 diabetes mellitus with persistent proteinuria
C10EK11 Type I diabetes mellitus with persistent proteinuria
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria
C10EL11 Type I diabetes mellitus with persistent microalbuminuria
C10EM00 Type 1 diabetes mellitus with ketoacidosis
C10EM11 Type I diabetes mellitus with ketoacidosis
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma
C10EN11 Type I diabetes mellitus with ketoacidotic coma
C10EP00 Type 1 diabetes mellitus with exudative maculopathy
C10EP11 Type I diabetes mellitus with exudative maculopathy
C10EQ00 Type 1 diabetes mellitus with gastroparesis
C10ER00 Latent autoimmune diabetes mellitus in adult
C10F.00 Type 2 diabetes mellitus
C10F.11 Type II diabetes mellitus
C10F000 Type 2 diabetes mellitus with renal complications
C10F011 Type II diabetes mellitus with renal complications
C10F100 Type 2 diabetes mellitus with ophthalmic complications
C10F111 Type II diabetes mellitus with ophthalmic complications
C10F200 Type 2 diabetes mellitus with neurological complications
C10F211 Type II diabetes mellitus with neurological complications
C10F300 Type 2 diabetes mellitus with multiple complications
C10F311 Type II diabetes mellitus with multiple complications
C10F400 Type 2 diabetes mellitus with ulcer
C10F411 Type II diabetes mellitus with ulcer
C10F500 Type 2 diabetes mellitus with gangrene
C10F511 Type II diabetes mellitus with gangrene
C10F600 Type 2 diabetes mellitus with retinopathy
C10F611 Type II diabetes mellitus with retinopathy
C10F700 Type 2 diabetes mellitus - poor control
C10F711 Type II diabetes mellitus - poor control
C10F900 Type 2 diabetes mellitus without complication
C10F911 Type II diabetes mellitus without complication
C10FA00 Type 2 diabetes mellitus with mononeuropathy
C10FA11 Type II diabetes mellitus with mononeuropathy
C10FB00 Type 2 diabetes mellitus with polyneuropathy
C10FB11 Type II diabetes mellitus with polyneuropathy
C10FC00 Type 2 diabetes mellitus with nephropathy
C10FC11 Type II diabetes mellitus with nephropathy
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma
C10FD11 Type II diabetes mellitus with hypoglycaemic coma
C10FE00 Type 2 diabetes mellitus with diabetic cataract
C10FE11 Type II diabetes mellitus with diabetic cataract
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy
C10FF11 Type II diabetes mellitus with peripheral angiopathy
C10FG00 Type 2 diabetes mellitus with arthropathy
C10FG11 Type II diabetes mellitus with arthropathy
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy
C10FH11 Type II diabetes mellitus with neuropathic arthropathy
C10FJ00 Insulin treated Type 2 diabetes mellitus
C10FJ11 Insulin treated Type II diabetes mellitus
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
C10FL00 Type 2 diabetes mellitus with persistent proteinuria
C10FL11 Type II diabetes mellitus with persistent proteinuria
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria
C10FM11 Type II diabetes mellitus with persistent microalbuminuria
C10FN00 Type 2 diabetes mellitus with ketoacidosis
C10FN11 Type II diabetes mellitus with ketoacidosis
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma
C10FP11 Type II diabetes mellitus with ketoacidotic coma
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy
C10FQ11 Type II diabetes mellitus with exudative maculopathy
C10FR00 Type 2 diabetes mellitus with gastroparesis
C10FS00 Maternally inherited diabetes mellitusAppendix D
Quality outcomes framework coronary obstructive
pulmonary disease Read code list
Read code Description
H3...00 Chronic obstructive pulmonary disease
H3...11 Chronic obstructive airways disease
H31..00 Chronic bronchitis
H310.00 Simple chronic bronchitis
H310000 Chronic catarrhal bronchitis
H310z00 Simple chronic bronchitis NOS
H311.00 Mucopurulent chronic bronchitis
H311000 Purulent chronic bronchitis
H311100 Fetid chronic bronchitis
H311z00 Mucopurulent chronic bronchitis NOS
H312.00 Obstructive chronic bronchitis
H312000 Chronic asthmatic bronchitis
H312011 Chronic wheezy bronchitis
H312100 Emphysematous bronchitis
H312300 Bronchiolitis obliterans
H312z00 Obstructive chronic bronchitis NOS
H313.00 Mixed simple and mucopurulent chronic bronchitis
H31y.00 Other chronic bronchitis
H31y100 Chronic tracheobronchitis
H31yz00 Other chronic bronchitis NOS
H31z.00 Chronic bronchitis NOS
H32..00 Emphysema
H320.00 Chronic bullous emphysema
H320000 Segmental bullous emphysema
H320100 Zonal bullous emphysema
H320200 Giant bullous emphysema
H320300 Bullous emphysema with collapse
H320311 Tension pneumatocoele
H320z00 Chronic bullous emphysema NOS
H321.00 Panlobular emphysema
H322.00 Centrilobular emphysema
H32y.00 Other emphysema
H32y000 Acute vesicular emphysema
H32y100 Atrophic (senile) emphysema
H32y111 Acute interstitial emphysema
H32y200 MacLeod’s unilateral emphysema
H32yz00 Other emphysema NOS
H32yz11 Sawyer - Jones syndrome
H32z.00 Emphysema NOS
H36..00 Mild chronic obstructive pulmonary disease
H37..00 Moderate chronic obstructive pulmonary disease
H38..00 Severe chronic obstructive pulmonary disease
H39..00 Very severe chronic obstructive pulmonary disease
H3y..00 Other speciﬁed chronic obstructive airways disease
H3y..11 Other speciﬁed chronic obstructive pulmonary disease
H3y0.00 Chronic obstruct pulmonary dis with acute lower resp infectn
H3y1.00 Chron obstruct pulmonary dis wth acute exacerbation, unspec
H3z..00 Chronic obstructive airways disease NOS
H3z..11 Chronic obstructive pulmonary disease NOSAppendix E
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Figure E.1: Percentage of female patients (left) and male patients (right) in each cohort with and without coronary
heart disease (CHD, top) or stroke (bottom) and at least one systolic blood pressure measurement recorded each
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Figure E.2: Percentage of female patients (left) and male patients (right) in each cohort with and without coronary
heart disease (CHD, top), stroke (middle) or coronary heart disease (bottom) and at least one smoking status
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Figure E.3: Percentage of female patients (left) and male patients (right) in each cohort with and without coronary
heart disease (CHD, top) or stroke (bottom) and at least one total cholesterol measurement recorded each year
during follow-up.Appendix F
Outliers results
Table F.1: Maximum +10% and minimum -10% values of weight, systolic blood pressure, diastolic blood pres-
sure, total serum cholesterol and HDL cholesterol found in Health Survey for England data from 1998 and 2008
by age and sex
Health indicator Age range Male Female
(years) Min-10% Max+10% Min-10% Max+10%
Weight 18 - 24 36.1 141.5 31.8 142.5
(kg) 25 - 34 41.0 143.0 32.7 143.0
35 - 44 44.9 143.0 28.4 143.0
45 - 54 40.1 143.0 33.3 143.0
55 - 64 34.6 142.9 31.7 143.0
65 - 74 34.8 143.0 27.5 141.7
75+ 36.0 131.7 29.7 137.3
Systolic blood 18 - 24 68.4 207.9 52.2 194.7
pressure (mmHg) 25 - 34 61.2 214.5 72.0 221.1
35 - 44 55.8 218.9 64.8 235.4
45 - 54 55.8 242.0 54.9 269.5
55 - 64 63.0 256.3 72.0 256.3
65 - 74 72.0 253.0 54.9 255.2
75+ 78.3 249.7 61.2 265.1
Diastolic blood 18 - 24 29.7 128.7 27.9 127.6
pressure (mmHg) 25 - 34 36.0 139.7 30.6 125.4
35 - 44 29.7 141.9 35.1 144.1
45 - 54 27.9 159.5 27.9 163.9
55 - 64 28.8 157.3 35.1 167.2
65 - 74 35.1 154.0 34.2 165.0
75+ 33.3 158.4 34.2 161.7
Total serum 18 - 24 1.8 8.9 2.5 9.1
cholesterol 25 - 34 2.0 13.1 2.4 11.8
(mmol l 1) 35 - 44 2.5 13.0 2.3 10.0
45 - 54 2.4 12.3 2.8 11.3
55 - 64 2.9 16.8 2.8 11.6
65 - 74 1.9 12.3 2.6 13.2
75+ 1.8 9.2 2.3 12.4
HDL 18 - 24 0.4 3.3 0.5 3.2
cholesterol 25 - 34 0.4 3.2 0.5 3.7
(mmol l 1) 35 - 44 0.5 3.3 0.5 4.1
45 - 54 0.3 3.6 0.7 4.7
55 - 64 0.5 3.4 0.3 3.7
65 - 74 0.4 3.4 0.5 3.9
75+ 0.3 3.9 0.6 3.9180 Appendix F. Outliers results
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Two-stage method to remove population- and
individual-level outliers from longitudinal data in a
primary care database - articleAppendix H
Evaluation of two-fold fully conditional
speciﬁcation multiple imputation for longitudinal
electronic health record data - articleAppendix I
Coronary heart disease Read code list
Read code Description
14AL.00 H/O: Treatment for ischaemic heart disease
792..00 Coronary artery operations
792..11 Coronary artery bypass graft operations
7920.00 Saphenous vein graft replacement of coronary artery
7920.11 Saphenous vein graft bypass of coronary artery
7920000 Saphenous vein graft replacement of one coronary artery
7920100 Saphenous vein graft replacement of two coronary arteries
7920200 Saphenous vein graft replacement of three coronary arteries
7920300 Saphenous vein graft replacement of four+ coronary arteries
7920y00 Saphenous vein graft replacement of coronary artery OS
7920z00 Saphenous vein graft replacement coronary artery NOS
7921.00 Other autograft replacement of coronary artery
7921.11 Other autograft bypass of coronary artery
7921000 Autograft replacement of one coronary artery NEC
7921100 Autograft replacement of two coronary arteries NEC
7921200 Autograft replacement of three coronary arteries NEC
7921300 Autograft replacement of four of more coronary arteries NEC
7921y00 Other autograft replacement of coronary artery OS
7921z00 Other autograft replacement of coronary artery NOS
7922.00 Allograft replacement of coronary artery
7922.11 Allograft bypass of coronary artery
7922000 Allograft replacement of one coronary artery
7922100 Allograft replacement of two coronary arteries
7922200 Allograft replacement of three coronary arteries
7922300 Allograft replacement of four or more coronary arteries
7922y00 Other speciﬁed allograft replacement of coronary artery
7922z00 Allograft replacement of coronary artery NOS
7923.00 Prosthetic replacement of coronary artery
7923.11 Prosthetic bypass of coronary artery
7923000 Prosthetic replacement of one coronary artery
7923100 Prosthetic replacement of two coronary arteries
7923200 Prosthetic replacement of three coronary arteries
7923300 Prosthetic replacement of four or more coronary arteries
7923y00 Other speciﬁed prosthetic replacement of coronary artery
7923z00 Prosthetic replacement of coronary artery NOS
7924.00 Revision of bypass for coronary artery
7924000 Revision of bypass for one coronary artery
7924100 Revision of bypass for two coronary arteries
7924200 Revision of bypass for three coronary arteries
7924300 Revision of bypass for four or more coronary arteries
7924400 Revision of connection of thoracic artery to coronary artery
7924500 Revision of implantation of thoracic artery into heart
7924y00 Other speciﬁed revision of bypass for coronary artery
7924z00 Revision of bypass for coronary artery NOS
7925.00 Connection of mammary artery to coronary artery
7925.11 Creation of bypass from mammary artery to coronary artery
7925000 Double anastomosis of mammary arteries to coronary arteries
7925011 LIMA sequential anastomosis
7925012 RIMA sequential anastomosis
7925100 Double implant of mammary arteries into coronary arteries
7925200 Single anast mammary art to left ant descend coronary art205
Read code Description
7925300 Single anastomosis of mammary artery to coronary artery NEC
7925311 LIMA single anastomosis
7925312 RIMA single anastomosis
7925400 Single implantation of mammary artery into coronary artery
7925y00 Connection of mammary artery to coronary artery OS
7925z00 Connection of mammary artery to coronary artery NOS
7926.00 Connection of other thoracic artery to coronary artery
7926000 Double anastom thoracic arteries to coronary arteries NEC
7926100 Double implant thoracic arteries into coronary arteries NEC
7926200 Single anastomosis of thoracic artery to coronary artery NEC
7926300 Single implantation thoracic artery into coronary artery NEC
7926y00 Connection of other thoracic artery to coronary artery OS
7926z00 Connection of other thoracic artery to coronary artery NOS
7927300 Transposition of coronary artery NEC
7927400 Exploration of coronary artery
7927500 Open angioplasty of coronary artery
7927y00 Other speciﬁed other open operation on coronary artery
7927z00 Other open operation on coronary artery NOS
7928.00 Transluminal balloon angioplasty of coronary artery
7928.11 Percutaneous balloon coronary angioplasty
7928000 Percut transluminal balloon angioplasty one coronary artery
7928100 Percut translum balloon angioplasty mult coronary arteries
7928200 Percut translum balloon angioplasty bypass graft coronary a
7928300 Percut translum cutting balloon angioplasty coronary artery
7928y00 Transluminal balloon angioplasty of coronary artery OS
7928z00 Transluminal balloon angioplasty of coronary artery NOS
7929.00 Other therapeutic transluminal operations on coronary artery
7929000 Percutaneous transluminal laser coronary angioplasty
7929100 Percut transluminal coronary thrombolysis with streptokinase
7929111 Percut translum coronary thrombolytic therapy- streptokinase
7929200 Percut translum inject therap subst to coronary artery NEC
7929300 Rotary blade coronary angioplasty
7929400 Insertion of coronary artery stent
7929500 Insertion of drug-eluting coronary artery stent
7929600 Percutaneous transluminal atherectomy of coronary artery
7929y00 Other therapeutic transluminal op on coronary artery OS
7929z00 Other therapeutic transluminal op on coronary artery NOS
792A.00 Diagnostic transluminal operations on coronary artery
792Ay00 Diagnostic transluminal operation on coronary artery OS
792Az00 Diagnostic transluminal operation on coronary artery NOS
792B.00 Repair of coronary artery NEC
792B000 Endarterectomy of coronary artery NEC
792By00 Other speciﬁed repair of coronary artery
792Bz00 Repair of coronary artery NOS
792C.00 Other replacement of coronary artery
792C000 Replacement of coronary arteries using multiple methods
792Cy00 Other speciﬁed replacement of coronary artery
792Cz00 Replacement of coronary artery NOS
792D.00 Other bypass of coronary artery
792Dy00 Other speciﬁed other bypass of coronary artery
792Dz00 Other bypass of coronary artery NOS
792y.00 Other speciﬁed operations on coronary artery
792z.00 Coronary artery operations NOS
793G.00 Perc translumin balloon angioplasty stenting coronary artery
793G000 Perc translum ball angio insert 1-2 drug elut stents cor art
793G100 Perc tran ball angio ins 3 or more drug elut stents cor art
793G200 Perc translum balloon angioplasty insert 1-2 stents cor art
793G300 Percutaneous cor balloon angiop 3 more stents cor art NEC
793Gy00 OS perc translumina balloon angioplast stenting coronary art
793Gz00 Perc translum balloon angioplasty stenting coronary art NOS
793H.00 Transluminal operations on cardiac conduit
793H000 Percutaneous transluminal balloon dilation cardiac conduit
7A54500 Rotary blade angioplasty
7A6G100 Peroperative angioplasty
7A6H300 Prosthetic graft patch angioplasty
7A6H400 Percutaneous transluminal angioplasty of vascular graft
G3...00 Ischaemic heart disease
G3...11 Arteriosclerotic heart disease
G3...12 Atherosclerotic heart disease
G3...13 IHD - Ischaemic heart disease
G30..00 Acute myocardial infarction206 Appendix I. Coronary heart disease Read code list
Read code Description
G30..11 Attack - heart
G30..12 Coronary thrombosis
G30..13 Cardiac rupture following myocardial infarction (MI)
G30..14 Heart attack
G30..15 MI - acute myocardial infarction
G30..16 Thrombosis - coronary
G30..17 Silent myocardial infarction
G300.00 Acute anterolateral infarction
G301.00 Other speciﬁed anterior myocardial infarction
G301000 Acute anteroapical infarction
G301100 Acute anteroseptal infarction
G301z00 Anterior myocardial infarction NOS
G302.00 Acute inferolateral infarction
G303.00 Acute inferoposterior infarction
G304.00 Posterior myocardial infarction NOS
G305.00 Lateral myocardial infarction NOS
G306.00 True posterior myocardial infarction
G307.00 Acute subendocardial infarction
G307000 Acute non-Q wave infarction
G307100 Acute non-ST segment elevation myocardial infarction
G308.00 Inferior myocardial infarction NOS
G309.00 Acute Q-wave infarct
G30A.00 Mural thrombosis
G30B.00 Acute posterolateral myocardial infarction
G30X.00 Acute transmural myocardial infarction of unspecif site
G30X000 Acute ST segment elevation myocardial infarction
G30y.00 Other acute myocardial infarction
G30y000 Acute atrial infarction
G30y100 Acute papillary muscle infarction
G30y200 Acute septal infarction
G30yz00 Other acute myocardial infarction NOS
G30z.00 Acute myocardial infarction NOS
G31..00 Other acute and subacute ischaemic heart disease
G310.00 Postmyocardial infarction syndrome
G310.11 Dressler’s syndrome
G311.00 Preinfarction syndrome
G311.11 Crescendo angina
G311.12 Impending infarction
G311.13 Unstable angina
G311.14 Angina at rest
G311000 Myocardial infarction aborted
G311011 MI - myocardial infarction aborted
G311100 Unstable angina
G311200 Angina at rest
G311300 Refractory angina
G311400 Worsening angina
G311500 Acute coronary syndrome
G311z00 Preinfarction syndrome NOS
G312.00 Coronary thrombosis not resulting in myocardial infarction
G31y.00 Other acute and subacute ischaemic heart disease
G31y000 Acute coronary insufﬁciency
G31y100 Microinfarction of heart
G31y200 Subendocardial ischaemia
G31y300 Transient myocardial ischaemia
G31yz00 Other acute and subacute ischaemic heart disease NOS
G32..00 Old myocardial infarction
G32..11 Healed myocardial infarction
G32..12 Personal history of myocardial infarction
G33..00 Angina pectoris
G330.00 Angina decubitus
G330000 Nocturnal angina
G330z00 Angina decubitus NOS
G331.00 Prinzmetal’s angina
G331.11 Variant angina pectoris
G332.00 Coronary artery spasm
G33z.00 Angina pectoris NOS
G33z000 Status anginosus
G33z100 Stenocardia
G33z200 Syncope anginosa
G33z300 Angina on effort
G33z400 Ischaemic chest pain207
Read code Description
G33z500 Post infarct angina
G33z600 New onset angina
G33z700 Stable angina
G33zz00 Angina pectoris NOS
G34..00 Other chronic ischaemic heart disease
G340.00 Coronary atherosclerosis
G340.11 Triple vessel disease of the heart
G340.12 Coronary artery disease
G340000 Single coronary vessel disease
G340100 Double coronary vessel disease
G342.00 Atherosclerotic cardiovascular disease
G343.00 Ischaemic cardiomyopathy
G344.00 Silent myocardial ischaemia
G34y.00 Other speciﬁed chronic ischaemic heart disease
G34y000 Chronic coronary insufﬁciency
G34y100 Chronic myocardial ischaemia
G34yz00 Other speciﬁed chronic ischaemic heart disease NOS
G34z.00 Other chronic ischaemic heart disease NOS
G34z000 Asymptomatic coronary heart disease
G35..00 Subsequent myocardial infarction
G350.00 Subsequent myocardial infarction of anterior wall
G351.00 Subsequent myocardial infarction of inferior wall
G353.00 Subsequent myocardial infarction of other sites
G35X.00 Subsequent myocardial infarction of unspeciﬁed site
G36..00 Certain current complication follow acute myocardial infarct
G360.00 Haemopericardium/current comp folow acut myocard infarct
G361.00 Atrial septal defect/curr comp folow acut myocardal infarct
G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn
G363.00 Ruptur cardiac wall w’out haemopericard/cur comp fol ac MI
G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct
G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct
G366.00 Thrombosis atrium,auric append and vent/curr comp foll acute MI
G38..00 Postoperative myocardial infarction
G380.00 Postoperative transmural myocardial infarction anterior wall
G381.00 Postoperative transmural myocardial infarction inferior wall
G382.00 Postoperative transmural myocardial infarction other sites
G383.00 Postoperative transmural myocardial infarction unspec site
G384.00 Postoperative subendocardial myocardial infarction
G38z.00 Postoperative myocardial infarction, unspeciﬁed
G3y..00 Other speciﬁed ischaemic heart disease
G3z..00 Ischaemic heart disease NOS
G501.00 Post infarction pericarditis
Gyu3.00 [X]Ischaemic heart diseases
Gyu3100 [X]Other current complicatns following acute myocard infarct
Gyu3200 [X]Other forms of acute ischaemic heart disease
Gyu3300 [X]Other forms of chronic ischaemic heart disease
Gyu3400 [X]Acute transmural myocardial infarction of unspecif site
Gyu3500 [X]Subsequent myocardial infarction of other sites
Gyu3600 [X]Subsequent myocardial infarction of unspeciﬁed site
ZV45700 [V]Presence of aortocoronary bypass graft
ZV45800 [V]Presence of coronary angioplasty implant and graft
ZV45K00 [V]Presence of coronary artery bypass graft
ZV45K11 [V]Presence of coronary artery bypass graft - CABG
ZV45L00 [V]Status following coronary angioplasty NOSAppendix J
Application of multiple imputation using the
two-fold fully conditional speciﬁcation algorithm -
articleAppendix K
Quality outcomes framework schizophrenia,
bipolar disorder and other psychoses Read code
list
Read code Description
E10..00 Schizophrenic disorders
E100.00 Simple schizophrenia
E100.11 Schizophrenia simplex
E100000 Unspeciﬁed schizophrenia
E100100 Subchronic schizophrenia
E100200 Chronic schizophrenic
E100300 Acute exacerbation of subchronic schizophrenia
E100400 Acute exacerbation of chronic schizophrenia
E100500 Schizophrenia in remission
E100z00 Simple schizophrenia NOS
E101.00 Hebephrenic schizophrenia
E101000 Unspeciﬁed hebephrenic schizophrenia
E101100 Subchronic hebephrenic schizophrenia
E101200 Chronic hebephrenic schizophrenia
E101300 Acute exacerbation of subchronic hebephrenic schizophrenia
E101400 Acute exacerbation of chronic hebephrenic schizophrenia
E101500 Hebephrenic schizophrenia in remission
E101z00 Hebephrenic schizophrenia NOS
E102.00 Catatonic schizophrenia
E102000 Unspeciﬁed catatonic schizophrenia
E102100 Subchronic catatonic schizophrenia
E102200 Chronic catatonic schizophrenia
E102300 Acute exacerbation of subchronic catatonic schizophrenia
E102400 Acute exacerbation of chronic catatonic schizophrenia
E102500 Catatonic schizophrenia in remission
E102z00 Catatonic schizophrenia NOS
E103.00 Paranoid schizophrenia
E103000 Unspeciﬁed paranoid schizophrenia
E103100 Subchronic paranoid schizophrenia
E103200 Chronic paranoid schizophrenia
E103300 Acute exacerbation of subchronic paranoid schizophrenia
E103400 Acute exacerbation of chronic paranoid schizophrenia
E103500 Paranoid schizophrenia in remission
E103z00 Paranoid schizophrenia NOS
E104.00 Acute schizophrenic episode
E104.11 Oneirophrenia
E105.00 Latent schizophrenia
E105000 Unspeciﬁed latent schizophrenia
E105100 Subchronic latent schizophrenia
E105200 Chronic latent schizophrenia
E105300 Acute exacerbation of subchronic latent schizophrenia
E105400 Acute exacerbation of chronic latent schizophrenia
E105500 Latent schizophrenia in remission224Appendix K. Quality outcomes framework schizophrenia, bipolar disorder and other psychoses Read code list
Read code Description
E105z00 Latent schizophrenia NOS
E106.00 Residual schizophrenia
E106.11 Restzustand - schizophrenia
E107.00 Schizo-affective schizophrenia
E107.11 Cyclic schizophrenia
E107000 Unspeciﬁed schizo-affective schizophrenia
E107100 Subchronic schizo-affective schizophrenia
E107200 Chronic schizo-affective schizophrenia
E107300 Acute exacerbation subchronic schizo-affective schizophrenia
E107400 Acute exacerbation of chronic schizo-affective schizophrenia
E107500 Schizo-affective schizophrenia in remission
E107z00 Schizo-affective schizophrenia NOS
E10y.00 Other schizophrenia
E10y.11 Cenesthopathic schizophrenia
E10y000 Atypical schizophrenia
E10y100 Coenesthopathic schizophrenia
E10yz00 Other schizophrenia NOS
E10z.00 Schizophrenia NOS
Eu2..00 [X]Schizophrenia, schizotypal and delusional disorders
Eu20.00 [X]Schizophrenia
Eu20000 [X]Paranoid schizophrenia
Eu20011 [X]Paraphrenic schizophrenia
Eu20100 [X]Hebephrenic schizophrenia
Eu20111 [X]Disorganised schizophrenia
Eu20200 [X]Catatonic schizophrenia
Eu20211 [X]Catatonic stupor
Eu20212 [X]Schizophrenic catalepsy
Eu20213 [X]Schizophrenic catatonia
Eu20214 [X]Schizophrenic ﬂexibilatis cerea
Eu20300 [X]Undifferentiated schizophrenia
Eu20311 [X]Atypical schizophrenia
Eu20400 [X]Post-schizophrenic depression
Eu20500 [X]Residual schizophrenia
Eu20511 [X]Chronic undifferentiated schizophrenia
Eu20512 [X]Restzustand schizophrenic
Eu20600 [X]Simple schizophrenia
Eu20y00 [X]Other schizophrenia
Eu20y11 [X]Cenesthopathic schizophrenia
Eu20y12 [X]Schizophreniform disord NOS
Eu20y13 [X]Schizophrenifrm psychos NOS
Eu20z00 [X]Schizophrenia, unspeciﬁedAppendix L
Quality outcomes framework asthma Read code
list
Read code Description
H33..00 Asthma
H33..11 Bronchial asthma
H330.00 Extrinsic (atopic) asthma
H330.11 Allergic asthma
H330.12 Childhood asthma
H330.13 Hay fever with asthma
H330.14 Pollen asthma
H330000 Extrinsic asthma without status asthmaticus
H330011 Hay fever with asthma
H330100 Extrinsic asthma with status asthmaticus
H330111 Extrinsic asthma with asthma attack
H330z00 Extrinsic asthma NOS
H331.00 Intrinsic asthma
H331.11 Late onset asthma
H331000 Intrinsic asthma without status asthmaticus
H331100 Intrinsic asthma with status asthmaticus
H331111 Intrinsic asthma with asthma attack
H331z00 Intrinsic asthma NOS
H332.00 Mixed asthma
H333.00 Acute exacerbation of asthma
H334.00 Brittle asthma
H33z.00 Asthma unspeciﬁed
H33z.11 Hyperreactive airways disease
H33z000 Status asthmaticus NOS
H33z011 Severe asthma attack
H33z100 Asthma attack
H33z111 Asthma attack NOS
H33z200 Late-onset asthma
H33zz00 Asthma NOS
H33zz11 Exercise induced asthma
H33zz12 Allergic asthma NEC
H33zz13 Allergic bronchitis NECAppendix M
Quality outcomes framework chronic kidney
disease Read code list
Read code Description
1Z12.00 Chronic kidney disease stage 3
1Z13.00 Chronic kidney disease stage 4
1Z14.00 Chronic kidney disease stage 5
1Z15.00 Chronic kidney disease stage 3A
1Z16.00 Chronic kidney disease stage 3B
1Z1B.00 Chronic kidney disease stage 3 with proteinuria
1Z1B.11 CKD stage 3 with proteinuria
1Z1C.00 Chronic kidney disease stage 3 without proteinuria
1Z1C.11 CKD stage 3 without proteinuria
1Z1D.00 Chronic kidney disease stage 3A with proteinuria
1Z1D.11 CKD stage 3A with proteinuria
1Z1E.00 Chronic kidney disease stage 3A without proteinuria
1Z1E.11 CKD stage 3A without proteinuria
1Z1F.00 Chronic kidney disease stage 3B with proteinuria
1Z1F.11 CKD stage 3B with proteinuria
1Z1G.00 Chronic kidney disease stage 3B without proteinuria
1Z1G.11 CKD stage 3B without proteinuria
1Z1H.00 Chronic kidney disease stage 4 with proteinuria
1Z1H.11 CKD stage 4 with proteinuria
1Z1J.00 Chronic kidney disease stage 4 without proteinuria
1Z1J.11 CKD stage 4 without proteinuria
1Z1K.00 Chronic kidney disease stage 5 with proteinuria
1Z1K.11 CKD stage 5 with proteinuria
1Z1L.00 Chronic kidney disease stage 5 without proteinuria
1Z1L.11 CKD stage 5 without proteinuriaAppendix N
Quality outcomes framework atrial ﬁbrillation
Read code list
Read code Description
G573.00 Atrial ﬁbrillation and ﬂutter
G573000 Atrial ﬁbrillation
G573200 Paroxysmal atrial ﬁbrillation
G573300 Non-rheumatic atrial ﬁbrillation
G573400 Permanent atrial ﬁbrillation
G573500 Persistent atrial ﬁbrillation
G573z00 Atrial ﬁbrillation and ﬂutter NOSAppendix O
Respiratory infection Read code list
Read code Description
H0...00 Acute respiratory infections
H00..00 Acute nasopharyngitis
H00..11 Common cold
H00..12 Coryza - acute
H00..13 Febrile cold
H00..14 Nasal catarrh - acute
H00..15 Pyrexial cold
H00..16 Rhinitis - acute
H01..00 Acute sinusitis
H01..11 Sinusitis
H010.00 Acute maxillary sinusitis
H010.11 Antritis - acute
H011.00 Acute frontal sinusitis
H012.00 Acute ethmoidal sinusitis
H013.00 Acute sphenoidal sinusitis
H014.00 Acute rhinosinusitis
H01y.00 Other acute sinusitis
H01y000 Acute pansinusitis
H01yz00 Other acute sinusitis NOS
H01z.00 Acute sinusitis NOS
H02..00 Acute pharyngitis
H02..11 Sore throat NOS
H02..12 Viral sore throat NOS
H02..13 Throat infection - pharyngitis
H020.00 Acute gangrenous pharyngitis
H021.00 Acute phlegmonous pharyngitis
H022.00 Acute ulcerative pharyngitis
H023.00 Acute bacterial pharyngitis
H023000 Acute pneumococcal pharyngitis
H023100 Acute staphylococcal pharyngitis
H023z00 Acute bacterial pharyngitis NOS
H024.00 Acute viral pharyngitis
H025.00 Allergic pharyngitis
H02z.00 Acute pharyngitis NOS
H03..00 Acute tonsillitis
H03..11 Throat infection - tonsillitis
H03..12 Tonsillitis
H030.00 Acute erythematous tonsillitis
H031.00 Acute follicular tonsillitis
H032.00 Acute ulcerative tonsillitis
H033.00 Acute catarrhal tonsillitis
H034.00 Acute gangrenous tonsillitis
H035.00 Acute bacterial tonsillitis
H035000 Acute pneumococcal tonsillitis
H035100 Acute staphylococcal tonsillitis
H035z00 Acute bacterial tonsillitis NOS
H036.00 Acute viral tonsillitis
H037.00 Recurrent acute tonsillitis
H03z.00 Acute tonsillitis NOS
H04..00 Acute laryngitis and tracheitis
H040.00 Acute laryngitis
H040000 Acute oedematous laryngitis
H040100 Acute ulcerative laryngitis229
Read code Description
H040200 Acute catarrhal laryngitis
H040300 Acute phlegmonous laryngitis
H040400 Acute haemophilus inﬂuenzae laryngitis
H040500 Acute pneumococcal laryngitis
H040600 Acute suppurative laryngitis
H040w00 Acute viral laryngitis unspeciﬁed
H040x00 Acute bacterial laryngitis unspeciﬁed
H040z00 Acute laryngitis NOS
H041.00 Acute tracheitis
H041000 Acute tracheitis without obstruction
H041100 Acute tracheitis with obstruction
H041z00 Acute tracheitis NOS
H042.00 Acute laryngotracheitis
H042.11 Laryngotracheitis
H042000 Acute laryngotracheitis without obstruction
H042100 Acute laryngotracheitis with obstruction
H042z00 Acute laryngotracheitis NOS
H043.00 Acute epiglottitis (non strep)
H043.11 Viral epiglottitis
H043000 Acute epiglottitis without obstruction
H043100 Acute epiglottitis with obstruction
H043200 Acute obstructive laryngitis
H043211 Croup
H043z00 Acute epiglottitis NOS
H044.00 Croup
H04z.00 Acute laryngitis and tracheitis NOS
H05..00 Other acute upper respiratory infections
H050.00 Acute laryngopharyngitis
H051.00 Acute upper respiratory tract infection
H052.00 Pharyngotracheitis
H053.00 Tracheopharyngitis
H054.00 Recurrent upper respiratory tract infection
H055.00 Pharyngolaryngitis
H05y.00 Other upper respiratory infections of multiple sites
H05z.00 Upper respiratory infection NOS
H05z.11 Upper respiratory tract infection NOS
H05z.12 Viral upper respiratory tract infection NOS
H06..00 Acute bronchitis and bronchiolitis
H060.00 Acute bronchitis
H060.11 Acute wheezy bronchitis
H060000 Acute ﬁbrinous bronchitis
H060100 Acute membranous bronchitis
H060200 Acute pseudomembranous bronchitis
H060300 Acute purulent bronchitis
H060400 Acute croupous bronchitis
H060500 Acute tracheobronchitis
H060600 Acute pneumococcal bronchitis
H060700 Acute streptococcal bronchitis
H060800 Acute haemophilus inﬂuenzae bronchitis
H060900 Acute neisseria catarrhalis bronchitis
H060A00 Acute bronchitis due to mycoplasma pneumoniae
H060B00 Acute bronchitis due to coxsackievirus
H060C00 Acute bronchitis due to parainﬂuenza virus
H060D00 Acute bronchitis due to respiratory syncytial virus
H060E00 Acute bronchitis due to rhinovirus
H060F00 Acute bronchitis due to echovirus
H060v00 Subacute bronchitis unspeciﬁed
H060w00 Acute viral bronchitis unspeciﬁed
H060x00 Acute bacterial bronchitis unspeciﬁed
H060z00 Acute bronchitis NOS
H061.00 Acute bronchiolitis
H061000 Acute capillary bronchiolitis
H061100 Acute obliterating bronchiolitis
H061200 Acute bronchiolitis with bronchospasm
H061300 Acute exudative bronchiolitis
H061400 Obliterating ﬁbrous bronchiolitis
H061500 Acute bronchiolitis due to respiratory syncytial virus
H061600 Acute bronchiolitis due to other speciﬁed organisms
H061z00 Acute bronchiolitis NOS
H062.00 Acute lower respiratory tract infection
H06z.00 Acute bronchitis or bronchiolitis NOS
H06z000 Chest infection NOS
H06z011 Chest infection
H06z100 Lower resp tract infection
H06z111 Respiratory tract infection
H06z112 Acute lower respiratory tract infection
H06z200 Recurrent chest infection
H07..00 Chest cold
H0y..00 Other speciﬁed acute respiratory infections
H0z..00 Acute respiratory infection NOSAppendix P
Heavy drinker Read code list
Read code Description
1364.00 Moderate drinker - 3-6u/day
1365.00 Heavy drinker - 7-9u/day
1366.00 Very heavy drinker - ¿9u/day
136K.00 Alcohol intake above recommended sensible limits
136O.00 Moderate drinker
136P.00 Heavy drinker
136Q.00 Very heavy drinker
136R.00 Binge drinker
136T.00 Harmful alcohol use
13Y8.00 Alcoholics anonymous
14C5.00 H/O: liver disease
7L1f.00 Compensation for liver failure
7L1fy00 Other speciﬁed compensation for liver failure
7L1fz00 Compensation for liver failure NOS
9kX..00 Hepatitis status 6 months post treatment - enhanced serv adm
9kX..11 Hepatitis status 6 months post treatment
C251.11 Wernicke’s encephalopathy
C253.00 Wernicke’s encephalopathy
D307000 Deﬁciency of coagulation factor due to liver disease
E01..00 Alcoholic psychoses
E011.00 Alcohol amnestic syndrome
E011000 Korsakov’s alcoholic psychosis
E011100 Korsakov’s alcoholic psychosis with peripheral neuritis
E011200 Wernicke-Korsakov syndrome
E011z00 Alcohol amnestic syndrome NOS
E012.00 Other alcoholic dementia
E012.11 Alcoholic dementia NOS
E012000 Chronic alcoholic brain syndrome
E013.00 Alcohol withdrawal hallucinosis
E01y.00 Other alcoholic psychosis
E01y000 Alcohol withdrawal syndrome
E01yz00 Other alcoholic psychosis NOS
E01z.00 Alcoholic psychosis NOS
E23..00 Alcohol dependence syndrome
E23..11 Alcoholism
E23..12 Alcohol problem drinking
E231300 Chronic alcoholism in remission
E250.00 Nondependent alcohol abuse
E250000 Nondependent alcohol abuse, unspeciﬁed
E250200 Nondependent alcohol abuse, episodic
Eu10011 [X]Acute alcoholic drunkenness
Eu10212 [X]Chronic alcoholism
Eu10300 [X]Mental and behav dis due to use alcohol: withdrawal state
Eu10400 [X]Men and behav dis due alcohl: withdrawl state with delirium
Eu10411 [X]Delirium tremens, alcohol induced
Eu10500 [X]Mental and behav dis due to use alcohol: psychotic disorder
Eu10511 [X]Alcoholic hallucinosis
Eu10512 [X]Alcoholic jealousy
Eu10514 [X]Alcoholic psychosis NOS
Eu10611 [X]Korsakov’s psychosis, alcohol induced
Eu10700 [X]Men and behav dis due alcoh: resid and late-onset psychot dis
Eu10711 [X]Alcoholic dementia NOS231
Read code Description
Eu10712 [X]Chronic alcoholic brain syndrome
Eu10800 [X]Alcohol withdrawal-induced seizure
F11x000 Cerebral degeneration due to alcoholism
F11x011 Alcoholic encephalopathy
G852200 Oesophageal varices in cirrhosis of the liver
G852300 Oesophageal varices in alcoholic cirrhosis of the liver
J600000 Acute hepatic failure
J600011 Acute liver failure
J601000 Subacute hepatic failure
J61..00 Cirrhosis and chronic liver disease
J611.00 Acute alcoholic hepatitis
J612.00 Alcoholic cirrhosis of liver
J612.11 Florid cirrhosis
J612.12 Laennec’s cirrhosis
J612000 Alcoholic ﬁbrosis and sclerosis of liver
J613.00 Alcoholic liver damage unspeciﬁed
J613000 Alcoholic hepatic failure
J614.00 Chronic hepatitis
J614000 Chronic persistent hepatitis
J614100 Chronic active hepatitis
J614200 Chronic aggressive hepatitis
J614300 Recurrent hepatitis
J614400 Chronic lobular hepatitis
J614y00 Chronic hepatitis unspeciﬁed
J614z00 Chronic hepatitis NOS
J615.11 Portal cirrhosis
J615000 Unilobular portal cirrhosis
J615100 Multilobular portal cirrhosis
J615111 Postnecrotic cirrhosis of liver
J615200 Mixed portal cirrhosis
J615300 Diffuse nodular cirrhosis
J615400 Fatty portal cirrhosis
J615500 Hypertrophic portal cirrhosis
J615600 Capsular portal cirrhosis
J615700 Cardiac portal cirrhosis
J615711 Congestive cirrhosis
J615A00 Pipe-stem portal cirrhosis
J615B00 Toxic portal cirrhosis
J615C00 Xanthomatous portal cirrhosis
J615y00 Portal cirrhosis unspeciﬁed
J615z11 Macronodular cirrhosis of liver
J615z13 Cirrhosis of liver NOS
J615z14 Laennec’s cirrhosis, non-alcoholic
J615z15 Hepatic ﬁbrosis
J617.00 Alcoholic hepatitis
J617000 Chronic alcoholic hepatitis
J61y300 Portal ﬁbrosis without cirrhosis
J61y400 Hepatic ﬁbrosis
J61y600 Hepatic ﬁbrosis with hepatic sclerosis
J61z.00 Chronic liver disease NOS
J625.00 [X] Hepatic failure
J625.11 [X] Liver failure
J62y.00 Other sequelae of chronic liver disease
J62y.11 Hepatic failure NOS
J62y.12 Liver failure NOS
J62y.13 Hepatic failure
J633.00 Hepatitis unspeciﬁed
J633000 Toxic hepatitis
J633z00 Hepatitis unspeciﬁed NOS
J635.00 Toxic liver disease
J635000 Toxic liver disease with cholestasis
J635100 Toxic liver disease with hepatic necrosis
J635200 Toxic liver disease with acute hepatitis
J635300 Toxic liver disease with chronic persistent hepatitis
J635400 Toxic liver disease with chronic lobular hepatitis
J635500 Toxic liver disease with chronic active hepatitis
J635600 Toxic liver disease with ﬁbrosis and cirrhosis of liver
J635X00 Toxic liver disease, unspeciﬁed
J63B.00 Autoimmune hepatitis
J63X.00 Granulomatous hepatitis, not elsewhere classiﬁed
J63y100 Nonspeciﬁc reactive hepatitis
J671000 Alcohol-induced chronic pancreatitis
Jyu7000 [X]Toxic liver disease with other disorders of liver
Jyu7100 [X]Other and unspeciﬁed cirrhosis of liver
Jyu7200 [X]Other speciﬁed inﬂammatory liver diseases
Jyu7600 [X]Toxic liver disease, unspeciﬁed
Jyu7700 [X]Granulomatous hepatitis, not elsewhere classiﬁed
ZC2CH11 Dietary advice for liver diseaseAppendix Q
Total cholesterol non-response to statin treatment
for patients diagnosed with type 2 diabetes -
protocol
Q.1 Background
Patients diagnosed with type 2 diabetes areat high risk of developing cardiovascular disease (CVD). National
Institute for Clinical Excellence (NICE) recommends prescribing statins to all patients with diabetes to control
lipids and reduce CVD risk[103]. However, some patients with diabetes prescribed statins have a residual CVD
risk due to atherogenic dyslipidaemia, a blood fat disorder causing artery walls to thicken. It is characterised
by low levels of high-density lipoprotein (HDL) cholesterol and high triglycerides and low-density lipoprotein
(LDL) cholesterol, resulting in high total cholesterol values,which are associated with increased CVD risk[104].
Diabetic patients with this condition do not always respond to statins despite high-dose statin therapy[105], but it
is unclear which other factors are associated with non-response.
Many studies use CVD events to assess the performance of statins. However, CVD events may not occur for
some time, if at all, during the study period. Therefore, total cholesterol may act as a surrogate measure for CVD
risks if we assume a patients CVD risk reduces if total cholesterol decreases.
The National Institute for Clinical Excellence (NICE) identiﬁes the following health indicators for CVD in pa-
tients diagnosed with diabetes: overweight, high blood pressure, high serum albumin, smoking and high-risk lipid
proﬁle (low HDL cholesterol and high LDL cholesterol)[103] and in 2004, the Quality Outcomes Framework
(QOF)[107] was introduced to encourage regular recording of health indicators in people with chronic diseases
like diabetes. Under the scheme, practices receive points for providing good quality of care. QOF award points for
recording health indicators to monitor patients with speciﬁed diseases. For example, GPs record body mass index
(BMI), smoking status, glycosylated haemoglobin (HbA1C), blood pressure and total cholesterol measurements
for patients diagnosed with type 1 or type 2 diabetes. It is in the practices interest to gain as many QOF points as
possible, not only for ﬁnancial reward but also to ensure good management of chronic diseases in primary care.Q.2. Purpose 233
Therefore, health indicators associated with increased risk of the QOF speciﬁed diseases are more frequently
recorded following the introduction of this legislation[8, 13].
In this study, we will use primary care records of patients with type 2 diabetes and initiated statin treatment to
examine the association between sociodemographic variables and health indicators (measured before initiating
statin therapy) and the difference between total cholesterol measurements before and within the ﬁrst 6 months
after ﬁrst statin treatment. We were interested in analysing LDL cholesterol levels, but an exploratory analysis
of the data found a large percentage of patients were missing LDL cholesterol measurements. Total cholesterol
measurements were recorded more frequently than LDL cholesterol,so we chose to analyse total cholesterol
instead of LDL cholesterol. We will analyse the data using a regression model and investigate different methods
to deal with missing data using multiple imputation. We want to handle missing data appropriately so we will
compare bias and precision of different methods of handling missing data. We expect imputed data are less biased
and most precise compared to complete records analysis.
Q.2 Purpose
The aim of this study is to investigate the extent sociodemographic variables and health indicators measured
before initiating statin therapy are associated with the difference between total cholesterol measurements before
and within the ﬁrst 6 months after ﬁrst statin treatment for patients diagnosed with type 2 diabetes.
The speciﬁc objectives are, for patients diagnosed with type 2 diabetes:
1. To examine change in total cholesterol after ﬁrst statin treatment compared to before ﬁrst statin treatment.
2. To identify factors associated with lack of response to statin treatment for total cholesterol.
3. To evaluate how different methods to handle missing health indicator values impact the analysis results.
Q.3 Data source
We will extract data from The Health Improvement Network (THIN) database, a large, longitudinal, clinical
primary care database widely used in epidemiological research. Data are collected from general practices using
the Vision practice management software that have elected to join the THIN Quality Data recording scheme, ad-
ministered by Cegedim Strategic Data (CSD)[11]. Medical events are coded using the hierarchical Read system
of coding[26] and prescriptions are coded using multilex encrypted ID codes from the UK Prescription Pricing
Authority and classiﬁed according to chapters in the British National Formulary (BNF)[27].
The patient data in THIN are approximately representative of the UK population[29]. All data collected are
anonymised at source before leaving the GP system and are continually updated. THIN contains data from over
11 million patients registered with more than 500 practices. The recording of both consultations and prescriptions
are similar to national consultation and prescription statistics[30, 31]. The data provider CSD has obtained overall
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Patient information is recorded at irregular times from the point of registration with the practice to the time they
leave the practice, providing a longitudinal record of health data. Available data consists of patient characteris-
tics, medical (symptoms and diagnoses) and prescription information. THIN collects additional information on
referral to specialists, laboratory results, some lifestyle characteristics and other measurements taken in the GPs
practice. Information on area deprivation(Townsend score) is based on the patients electoral ward from the 2001
Population Census (http://www.statistics.gov.uk/census2001/census2001.asp).
Q.4 Methods
Q.4.1 Study design
This is a cohort study.
Q.4.2 Study population
We will include practices from the date the computer system is used for clinical consultations (acceptable com-
puter usage (ACU))[75],the practice has acceptable mortality recording (AMR)[74], a list size ¿ 2,000 patients
and at least 80% of patients with Townsend score quintile recorded.
We will include patients:
1. diagnosed with type 2 diabetes. This includes patients where:
 atype2diabetesReadcodeisinthepatientrecord. Wewillassumepatientswithnon-speciﬁcdiabetes
are type 2 diabetes and include them in the analysis;
 an AHD code for annual diabetes check, current diabetes status or insulin dosage;
 the data type is diabetic register, diabetic consultation or diabetes concerns; or
 they are prescribed type 2 diabetes speciﬁc medication.
2. with no previous CVD event before ﬁrst statin prescription;
3. permanently registered to the practice (patient ﬂag A or C);
4. actively registered with the practice at some time from 1 January 2004 to 31st December 2012;
5. with date of birth, gender and Townsend deprivation quintile recorded.
We will include patients 30 years or over when they enter the dataset, which occurs at the latest date of(i) ﬁrst
type 2 diabetes diagnosis; (ii) ACU date; (iii) AMR date; (iv) when the patient registered with the practice or (v)
1 January 2004.After this ﬁrst date,we will identify the ﬁrst statin prescription. To exclude prevalent cases, we
will exclude patients prescribed statins before the ﬁrst date or within 6 months of the date patients enter the study.Q.4. Methods 235
We will include patient measurements in the analysis up until the earliest date of (i) death; (ii) when the patient
transferred out of the practice; (iii) the last date the practice contributes data to THIN or (iv) 31 December 2012.
We will exclude patients if the time between ﬁrst statin prescription and last date is less than 6 months. Also,
patients must receive at least two statin prescriptions within the ﬁrst 6 month after ﬁrst statin treatment.
Q.4.3 Study variables
In this study, we will investigate the association between the difference between total cholesterol measurements
before and within the ﬁrst 6 months after ﬁrst statin treatment and the following factors measured within 6 months
before initiation of statin treatment, called baseline:
 Sociodemographic: age at ﬁrst statin prescription, gender, deprivation (quintiles of Townsend scores) and
ethnicity (white, black, South Asian or other).
 Diseases: chronic kidney disease.
 Health indicators: body mass index (BMI), systolic blood pressure, total cholesterol, HDL cholesterol,
LDL cholesterol, glycosylated haemoglobin, glomerular ﬁltration rate and smoking status.
 Statin therapy: statin type and dose.
 Other variables: Calendar year of ﬁrst statin prescription and time from diagnosis of diabetes to ﬁrst pre-
scription of statin.
To measure total cholesterol change, we deﬁne the outcome variable as the difference between the total choles-
terol measurement at baseline and the smallest total cholesterol measurement within the ﬁrst 6 months after the
ﬁrst statin treatment. Using this outcome, the constant term in the regression model is zero. We will include all
patients with a total cholesterol measurement at baseline and within the ﬁrst 6 months after ﬁrst statin prescrip-
tion.When the data are extracted, we will identify and exclude outliers using methods described previously[4].
Q.4.4 Analysis
In the baseline time block, we will include the measurement closest to the date of ﬁrst statin prescription in the
analysis if more than one measurement was recorded.
We will ﬁrst examine how total cholesterol changes from before to after ﬁrst statin treatment. We will calculate
the difference between the total cholesterol measurement at baseline and within the ﬁrst 6 months after ﬁrst statin
prescription. We will investigate if this difference is normally distributed and calculate the mean difference for
each baseline characteristic. We will also divide the difference into quintiles and produce a table of baseline
characteristics for each total cholesterol difference quintile.
We will analyse the observed data using our model of interest: a linear model with a response variable of the
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prescription. We will condition on a range of sociodeomographic factors, diseases, statin therapy and health
indicators recorded at baseline described above.
We will explore the proportions of missing data for variables at baseline. Before imputation, we will evaluate the
plausibility of the MAR assumption to assess if MI is appropriate. If the distribution of the continuous variables
with missing data is skewed, we will transform the data before imputation[47]. Next, we will impute missing
values at baseline using fully conditional speciﬁcation (FCS)[21] multiple imputation (MI) which accounts for
uncertainty due to missing data and provides unbiased estimates under the Missing At Random (MAR) assump-
tion (the reason for missing data is associated with observed data, but not the unobserved)[15, 18]. In addition to
the variables measured at baseline in the model of interest (including the outcome), we will include the following
auxiliary variables in the imputation model:
1. Patients with the following diseases diagnosed before ﬁrst statin prescription: chronic obstructive pul-
monary disease (COPD); schizophrenia, bipolar disorder and other psychoses (psychoses); asthma; and
atrial ﬁbrillation.
2. Patients prescribed following drugs during baseline:
 Anti-hypertensive drug treatment .
 Other lipid-modifying drugs dose and type bile acid sequestrants; ezetimibe; ﬁbrate; nicotinic acid
and omega 3 polyunsaturated fatty acid (PUFA) ethyl esters.
3. Respiratory infection during baseline.
4. Recognised alcohol problem (i.e. current heavy drinker).
5. Death create variable to indicate which patients die after ﬁrst statin prescription.
6. CVD event identiﬁes patients with a CVD event at any time after the ﬁrst statin prescription (separate
indicators for CHD and stroke).
Next, we will impute missing values at baseline again using multiple imputation, conditional on heath indicators
recorded before baseline. The time before baseline is divided into 6 month time blocks, excluding the earliest time
block if it is less than 6 months. We will include a maximum of 4 time blocks before baseline.If health indicators
are recorded more than once during each time block, we will select a measurement at random to include in the
analysis, except smoking status. If smoking status is recorded more than once,the most predominant category.
Time is divided into blocks to simplify imputation of missing data. We will use the two-fold FCS algorithm[1],
an extension of the FCS, to take account of the longitudinal and dynamic structure of the data. In addition to the
sociodemographic variables, health indicators (measured during each time block), outcome from the model of
interest, diseases diagnosed before ﬁrst statin prescription (described above), recognised alcohol problem, death
and CVD event, we will also include the following auxiliary variables in the imputation model:
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 Anti-hypertensive drug treatment.
 Other lipid-modifying drugs: bile acid sequestrants, ezetimibe, ﬁbrate, nicotinic acid, omega 3
polyunsaturated fatty acid (PUFA) ethyl esters.
2. Respiratory infection during each time block.
Finally, we will impute missing values at baseline using multiple imputation, conditional on heath indicators
recorded before and after baseline. The time before and after baseline is divided into 6 month time blocks, ex-
cluding the earliest or latest time block if it is less than 6 months, as select measurements during each time block
using the method described earlier. We will include a maximum of 4 time blocks before baseline and maximum
of 4 time blocks after baseline. We will impute using the same imputation model used to impute missing values
in time blocks before baseline.
After each imputation, we will ﬁt the model of interest to the observed and imputed explanatory variables at
baseline and compare to the results from the complete records analysis and the analysis of the data imputed using
baseline imputation.
We will perform all analyses using Stata SE version 12.1.
Q.5 Limitations
Our patient selection method will include some patients with type 1 diabetes in the analysis because some Read
codes do not specify the diabetes type. This could affect the results if patients with type 1 diabetes respond
differently to statin treatment compared to patients with type 2 diabetes.
We will assume all patients administer statin treatment as directed. We only know if patients were prescribed
statins, some may not administer them as directed. This can affect the results because patients who are prescribed
statins but do not administer them correctly may show a non-response because they did not take the statin.
There may be unmeasured confounding. It is not possible to adjust for all confounding because this is a cohort
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